



B.Sc (Beirut), M.Sc (Beirut)
Thesis submitted to the University of
Edinburgh for the degree of
DOCTOR OF PHILOSOPHY




who helped me finish this study
And to my family
BESSILIOS, MARY, ROSINE and my Parents,








LIST OF TABLES iii





1. PROGRESS IN TUMOR IMMUNOLOGY 1
1.1 Tumor-associated antigens 2
1.2 Tumor immunosurveillance 4
1.3 The immune system and tumor growth 7
1.4 The practical application of tumor immunology 9
2. ANTI—TUMOR ANTIBODIES 9
2.1 Circulating anti-tumor antibodies 10
2.2 In situ tumor associated-immunoglobulins 14
2.3 Practical applications of anti-tumor antibodies 21
2.4 Conclusion 22
3. NONSPECIFIC BINDING IN SITU 23




4. TUMOR SPECIFIC CELLULAR IMMUNITY 28
4.1 Tumor-specific T-cells in experimental animals 29
4.2 Tumor-specific cell-mediated immunity in immuno-
defficient experimental animals 32
4.3 Tumor-specific cell-mediated immunity in cancer patients 33
4.4 Immunodepression and cancer in Man 34
4.5 Conclusion 35
Page
5. TUMOR NONSPECIFIC CELLULAR IMMUNITY 36
5.1 Macrophages in cancer 36
5.2 Polymorphonuclear leukocytes in cancer 38
5.3 Allergy and cancer 39
5.4 Conclusion 40
6. EFFECTS OF IMMUNOSTIMULANTS IN CANCER 40
6.1 Corynebacterium parvum in experimental animals 41
6.2 C.parvum in cancer patients 43
6.3 Bacillus Calmette Guerin 45
6.4 Other immunostimulants 47
6.5 Conclusion 48
7. PROSPECTS OF TUMOR IMMUNOLOGY 49
7.1 Tumor immunodiagnosis 49
7.2 Tumor immunotherapy 51
8. PURPOSE OF STUDY 53
9. APPROACH USED 54
9.1 Development of an indirect radio-immune antiglobulin
test (RIAT) 54
9.2 Application of the indirect RIAT 56
9.3 Development of the direct RIAT 57
9.4 Application of the direct RIAT 58
9.5 Subclass studies 59






2. TISSUE CULTURE 61
3. TUMOR CELL PREPARATION FOR IN VIVO TUMOR PROPAGATION .... 61
4. TUMOR CELL PREPARATION FOR THE ANTIGLOBULIN ASSAY 62
5. ANTISERA 63
a) Rabbit anti-mouse immunoglobulin 63
b) Normal rabbit serum 64
c) Goat anti-rabbit immunoglobulin 64
6. IODINATION 66
7. PREPARATION AND IODINATION OF IMMUNE RAM-Ig 67
8. THE INDIRECT PLATE RIAT 68
9. THE INDIRECT TUBE RIAT 68
10. THE DIRECT TUBE RIAT 69
11. EVALUATION OF RESULTS 69
Page
RESULTS
1. THE-DEVELOPMENT OF THE INDIRECT ANTIGLOBULIN TEST 71
a) The effect of enzyme treatment 72
b) A comparison of plate and tube methods 73
c) A comparison of precoating techniques 73
d) An examination of cell recovery 74
e) The variation of reagent concentration 75
f) The variation of cell number 76
g) The variation of incubation time . 76
h) The effect of human aggregated IgG pretreatment 77
i) Nonspecific binding to dead cells 78
j) The effect of FCS in cell washings 78
k) Summary 79
2. THE APPLICATION OF THE INDIRECT ANTIGLOBULIN TECHNIQUE.. 81
a) The response to CCH1 in nontreated and C.parvum
treated mice 81
b) The response to T3 in nontreated and C.parvum
treated mice 83
c) The response to CCH1 and T3 tumors 84
d) The response to excised and cultured tumor cells .... 85
e) The response to different de.ses of CCH1 tumor cells.. 85
f) The response to pronase prepared and mechanically
prepared CCH1 cells 86
g) Summary 86
3. THE DEVELOPMENT OF THE DIRECT RADIO-IMMUNE ANTIGLOBULIN
TEST 88
a) Effect of tube precoating 89
b) Specificity of the RAM Ig 89
c) Effect of enzyme treatment 90
d) Influence of reagent concentration 92
e) Effect of incubation time and temperature 93
f) Effect of cell concentration 94
g) Assessment of NRIg binding 95
h) Non-specific binding to dead cells 95
i) A study of F(al5)2 binding 95
j) Summary 96
4* APPLICATION OF THE DIRECT RIAT 98
a) The response to CCH1 and T3 tumors in different mice. 98
b) The response to CCH1 tumors in C.parvum treated and
nontreated mice 99
* c) The response to excised and cultured CCH1 tumor cells 99
d) The response to CCH1 injected into opposite limbs
in the same mouse 99
e) The response to CCH1 and T3 tumors in the same mouse. 100
f) The response to freshly excised and cultured CCH1
tumors in the same mouse 101
g) The response to different doses of CCH1 tumor cells
in the same mouse 101
h) Additional C.parvum studies 103
i) Summary 104
Page
5. IMMUNOSUPPRESSIVE STUDIES 105
6. SUBCLASS STUDIES 107
DISCUSSION
1. SUMMARY OF THE RESULTS 108
a) The development of the direct and indirect RIAT 108
b) The application of the direct and indirect RIAT 109
2. RELEVANCE OF THE RADIO-IMMUNE ANTIGLOBULIN TEST TO THE
STUDY OF TUMOR-ASSOCIATED IMMUNOGLOBULINS, AND ITS
POTENTIAL Ill
3. RELATIONSHIP OF THE IMMUNOGENICITY AND DOSE OF TUMOR
CELLS TO THE IN VIVO BINDING OF TAIg 115
4. IN VIVO KINETICS OF TAIgs 119
5. INFLUENCE OF C.PARVUM ON THE IN VIVO BINDING OF TAIgs 122
6. MECHANISMS OF IN VIVO TAIg BINDING 125
a) The effect of T-cell deprivation 125
b) The effect of gold salt treatment 125
c) The effect of sublethal irradiation 126
d) The effect of immunostimulation 126
e) The nature of TAIgs 128







A direct and indirect radio-immune antiglobulin tests (RIAT)
were developed and used 'to study tumor-associated immunoglobulin (TAIg)
levels in transplanted freshly excised solid tumors. The studies were
performed on 8-12 week old inbred CBA mice. The tumors investigated were
grown from freshly excised and cultured CCH1 and T3 fibrosarcoma tumor
cells.
The RIATs developed were based on isotopic antiglobulin tests
which had been used in this department to determine circulating anti¬
tumor antibodies in tumor-bearing mice. They were modified and improved
in order to be used to detect in vivo bound TAIgs in solid tumors. The
indirect RIAT developed was used in both quantitative and qualitative
TAIg studies. The more sensitive direct RIAT was used solely in quantitative
studies on TAIgs.
In order to optimize the test a number of variableswere investigated.
These included the method of tumor cell preparation and the influence of
reagent concentration, tumor cell number, and the period of incubation.
Furthermore, attempts were made to reduce nonspecific binding of reagents
by precoating the plastic plates and tubes with various protein containing
media. As a result of these investigations, techniques were developed
which were sufficiently sensitive for semi-quantitative and semi-qualitative
studies.
In vivo bound TAIgs in solid tumors and its variation with age and
size of tumors was assessed by both the direct and indirect RIATs. The
more immunogenic CCH1 tumors were found to possSss higher levels of TAIgs
than the less immunogenic T3 tumors. Moreover, tumors produced by the
injection of tumor cells contaminated with host cells were found to possess
higher levels of TAIgs than tumors produced by cultured tumor cells which
are devoid of host cells. Similarly, tumor cells prepared in different
ways(enzyme vs mechanical) were found to produce tumors of different TAIg
content. In addition, the in vivo binding of TAIgs was found in general
to vary positively with the age and size of the tumors. The injection
of 1-5 million tumor cells was found to produce larger tumors ?of higher
TAIg content than the injection of 0.1-0.5 million tumor cells. Similar
effects were noted whether the tumors were compared in different mice
or on opposite limbs of the same mouse. Comparative results were also
obtained by a double radio—immunoassay test which was carried out in
parallel with the RIATs. The amount of in vivo bound TAIg in solid tumors
was thus found to be dependent on immunogenicity, method of maintenance
(ie. in vivo or in vitro), and the method or preparation of the tumor cell
inoculum.
The cellular basis of TAIgs was studied in immuno-stimulated and
immuno-deficient mice. Intraperitoneal G.parvum (CP) administration
resulted in an increase of TAIgs in both CCK1 and T3 tumor models, though
this effect was more marked in the former. Moreover, additional studies
revealed that CP treated CCH1 tumors had higher levels of cell-surface
bound IgA, IgG2b, and IgG3 than non-treated CCH1 tumors. Parallel
qualitative studies on CCH1 tumor extracts showed that CP treated tumors
also had more IgGl, IgA and IgM.
Studies were also performed in thymectomized and nude mice in order
to assess the effect of T-cell deprivation on the in vivo binding of TAIgs.
The TAIg content in tumors grown in T-cell deficient mice was shown not to
differ from tumors grown in normal mice. Preliminary experiments were also
conducted on mice treated with gold salts in order to determine the influence
of macrophages in TAIg binding. No significant difference was obtained
between tumors grown in gold-salt treated mice and nontreated mice. Moreover,
whole body irradiation (400 rads) 24 hrs, before the injection of tumor cells
was not found to appreciably effect the in vivo binding of TAIg.
The significance of these results and their relevance to tumor immunodiagnosis
and immunotherapy are discussed.
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PREFACE
In the early part of this century, the eventual immunological
control of cancer seemed possible since experiments with outbred
animals showed that tumor cells could be rejected when transferred
into various animals. However, studies on inbred animals in the
1930's indicated that these early hopes were premature. For the
rejection of tumor cells was found to be due to normal transplantation
antigens present on these cells. It was only after two decades \tfhen
the existence of tumor-specific transplantation antigens was demonstrated
that immunology gradually became an integral part of cancer research.
INTRODUCTION
1. PROGRESS IN TUMOR IMMUNOLOGY
Extensive research in tumor immunology during the 1970's
must have brought little comfort to those immunologists who began
the decade with great hopes for the immunological control of cancer.
The accumulated experimental and clinical data in tumor immunology
unravelled a field of immense complexity, to the extent that more
questions were raised than answered. Immunologists began the last
decade by asking the question, "does the immune system prevent tumor
growth?" (Burnet, 1970), and ended the decade with the question,
"does the immune system enhance tumor growth?"; a question which
was inspired by the immuno-stimulation theory (Prehn, 1977). In addition,
certain anti-tumor antibodies, immune-complexes, and suppressor T cells
were demonstrated to inhibit the cytotoxic action of host immunocompetent
cells against tumors.
However, in so far as the obtained data indicated the complexity
of tumor immunology, it also revealed a significant relationship between
the immune system and tumor growth. Tumor associated antigens were shown
to exist in many chemically and virally induced tumors; macrophages,
T cells, and certain tumor specific antibodies were found to inhibit
tumor growth; and various immunostimulants were shown to improve the
prognosis of cancer patients.
One can envisage that during the 1980's research in tumor immunology
will concentrate on the elucidation of the immunological mechanisms
that promote or inhibit tumor growth. Although a great deal
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of time and work might precede the understanding of these mechanisms,
the ultimate contribution of tumor immunology in the prevention and
control of cancer remains in little doubt.
1.1 Tumor-associated antigens
The "raison d'etre" of tumor immunology is the existence of
tumor-associated antigens. Without the latter, research in tumor
immunology could hardly be expected to achieve its practical
aspirations, which include immunotherapy and immunodiagnosis. Since
tumor-associated antigens were shown to exist on chemically and
virally induced tumors, as well as on some spontaneous tumors
(Shimkin, 1977), the significance of tumor immunity in these tumors
has been in little doubt. On the other hand, the unequivocal
demonstration of tumor-associated antigens where it is of primary '
concern, i.e. in human and spontaneous animal tumors, has been
unsuccessful so far (Weiss, 1977). One of the reasons behind the
latter is believed to be due to the presence of the antigens on
such tumors in cryptic form. This possibility has been reinforced
by recent results which have shown the conversion of non-antigenic
tumor cells to antigenic tumor cells by enzymatic treatment (Bekesi
and Holland, 1976). However, not all cell-surface manipulations
have been found to produce this effect. In one study, protein cross-
linking on the surface of tumor cells was found to inhibit the
i
immunogenecity of the tumor cells (Price et.al., 1979). It is
interesting that although the latter cells lost their immunogenecity,
their antigenicity was maintained. This revealed the important role
the structure of cell-surface antigens played in eliciting the immune
response.
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Another reason behind the absence of antigens on
spontaneous tumors could be the rapid shedding of antigens
from the surface of tumor cells. A third reason could be
that antigens are too weak to be detected by conventional
techniques. These hypotheses give credence to the attempts that
are presently being made to expose, isolate, and purify tumor-
associated antigens on spontaneous experimental and human tumors.
Antigens on experimental tumors consist of three types,
tumor specific antigens (TSA), tumor associated antigens (TAA),
and tumor associated transplantation antigens (TATA) (Moore, 1973).
At present, the existence of TSA cannot be stated with certainty.
However, TAA have been demonstrated and they include foetal antigens,
like carcinoembryonic and alpha-foeto protein, and cell surface
antigens, induced by onco-RNA viruses. TATA, which occur on the
tumor cell-surface, are capable of eliciting in vivo transplantation
rejection to autochthonous tumor cells.
1.1.1 Chemically induced tumors : Methylcholanthrene, dimethylbenz (a)
anthracene, ethyl carbamate and benzpyrene are examples of the chemicals
that can induce tumors in animals. Whereas their mechanism of tumor
induction and period of latency may vary, they all share the capacity
to induce tumors which possess distinct TATA. Even different tumors
induced in the same animal by the same chemical exhibit antigenic
differences. However, antigenic cross-reactivity may be demonstrated
and this could be attributed to "passenger virus" or "antigenic
conversion" (Moore, 1978). In addition, serological studies have
shown chemically induced tumors to possess surface TAA as well.
—•4—
1.1.2 Virally induced tumors : Certain DNA and RNA viruses are
knovm to induce tumors in animals. Examples of the former are
simian papova-virus (SV40) and herpes simplex; and examples of the
latter are murine leukemia virus (MuLV) and mouse mammary tumor
virus. Unlike chemically induced tumors, common antigens do exist
on different tumors induced by the same virus. Tumor antigens
associated with DNA viruses include nuclear and cytoplasmic
antigens, and cell-surface antigens; while tumor antigens associated
with RNA viruses include diverse virion and virus induced antigens
(Witz et.al., 1976 and Moore, 1973).
1.2 Tumor immunosurveillance
The discovery of transplantation antigens and their ability
to elicit cellular immunity, and the demonstration of tumoroussociated
antigens in experimental tumors led to the emergence of the immuno¬
surveillance theory. Introduced by Burnet in 1970, it stated that
tumors were continuously arising in the human body, but that the
majority of them were eliminated at the initial stages by the immune
system. In other words, the immunosurveillance theory predicted an
increase of tumor incidence in immunosuppressed individuals, and
the improvement of prognosis by immunostimulants. After a decade of
intensive research in tumor immunology, the immunosurveillance theory
still has its advocates and opponents.
The opponents of the immunosurveillance theory base their
argument on three main points: monoclonality of tumors, absence of
major differences in antigenic strength between in vivo and in vitro
induced tumors, and lack of significant increases of tumor incidence
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in immunosuppressed animals. Moller and Moller (1978) argue that the
monoclonality of tumors in neoplasia casts doubt upon the immuno-
surveillance theory, for if the latter was true then the failure of
the immune system should give rise to polyclonal tumors. Moreover,
according to the immunosurveillance theory, only weakly antigenic
tumor-cells would escape the immune system suggesting, therefore,
that tumors induced spontaneously in vitro would be antigenically
stronger. However, no significant differences in antigenic strength
between in vivo and in vitro induced tumors have been observed (Evans
et. al., 197$ and Moller and Moller, 1976).
Apart from DNA viral tumors, no significant increase of tumor
incidence has been noted in immunosuppressed animals (Stutman, 1975).
Although a similar assessment of tumor incidence in Man remains to be
made, the latter observation gives weight to the arguments put forward
by the opponents of the immunosurveillance theory. Moreover, a further
set-back to the immunosurveillance theory has come from the emergence
of the immunostimulation theory which predicts that, far from inhibiting
tumors, the immune system might actually contribute to the growth of
tumors (Prelin, 1976).
Advocates of the immunosurveillance theory base their arguments
on the following : the immunosuppressive properties of oncogenic
viruses; the apparent increase of tumor incidence in immunosuppressed
patients; improved prognosis of cancer patients undergoing immunotherapy;
and non-T cell surveillance against tumors in nude mice. Friedman and
Ceglowski (1973) postulated that immunosuppression by viruses was
responsible for many of the tumors they produce. The role of immuno¬
suppressive factors in the etiology of cancer was expounded further
by Kamo and Friedman (1977) who stressed the importance of the immune
-6-
system in the host-parasite relationship that exists during the
development and progression of the malignant process. The apparent
increase of tumor incidence in immunosuppressed patients, especially
those who have undergone organ transplantation (Videback, 1973 and
Penn and Starzl, 1973), has helped to reinforce the argument of the
advocates of the immunosurveillance theory.
The significance of the immune system in cancer was further
revealed by various immunotherapeutic trials. The administration
of immunostimulants such as Coj^oebacterium parvum and Bacillus-
Calmette Guerin together with chemotherapy, Jrradiation and/or surgery
has been found in some cases to improve the prognosis of cancer patients
(Mastrangelo et. al., 1976). Finally, nude mice, whose lack of increase
in tumor incidence has strongly supported the opponents of the immuno¬
surveillance theory, have been shown to possess strong non-T cell
mediated surveillance mechanisms (Kiessling et. al., 1975; Herberman
et.al., 1975; Kiessling et. al., 1976 and Klein ana Klein 1977). The
possible implication of non-immunological factors in the defence of
newborn mice against tumors was also shown by Zinzar et. al., (1976 and
1978).
In conclusion, the immunosurveillance theory appears to be
lingering on in spite of the doubt cast upon it by substantial contra-
indicative experimental data. Ultimately, the relevance or irrelevance
of the immunosurveillance theory might be revealed, but only after
sufficient research has been conducted into human cancer. Meanwhile,
the importance of the immune system in the progression of tumor growth
continues to be suppoted by experimental evidence.
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1.3 The immune system and tumor growth
When one considers the various types of tumors, the different
species of experimental animals, and the diverse methods of immuno¬
assays that have been used, the delay in the achievement of conclusive
results in tumor immunology becomes understandable. However, this delay
does not imply that the efforts of tumor immunologists have been in
vain. On the contrary, their intensive research has shown the
importance of both specific and non-specific humoral and cellular
immunity in tumor growth. Anti-tumor antibodies were shown to exist
in the sera of tumor-bearing animals and cancer patients (Jose and
Skvaril, 1974; Ran et. al., 1976; Lewis et« al., 1976; Heimen and
Klein 1976; Haskill et. al. , 1977; and Gupta et. al. , 1979) and within iheirtuinor!
(Vanky et. al., 1975; Dorval et. al. 1976; Witz 1977; Gersth et. al.,
1977; Witz and Moav, 1978; Moav et. al., 1978; Ehrlich and Witz, 1979
McCoy et. al., 1979 and James et. al., 1979).
Similarly, specific cellular immunity against tumors was shown
to exist in the peripheral blood of tumor bearing animals (Bruce et. al.,
1976; Plata et. al., 1976 and Holden et. al., 1976) and cancer patients
(Hellstrom et. al., 1971 and Jondal et. al., 1975), and within the -tumors
of experimental animals (Holden et. al., 1976 and Russell et. al., 1976a & b).
It must be stated, however, that the association of specific cellular
immunity in cancer patients has been less apparant than that observed in
experimental animals (Takasugi et. al. 1973 and Bean et. al. 1975).
Macrophages too were shown to play an important role in tumor growth
inhibition (James et, al., 1977; Miller and Feldman, 1977; Haskill, 1977;
Lohmann-Mathes et. al., 1979 and Domzig and Lohmann-Mathes, 1979).
Although the diverse data produced by the different experimental
systems has hindered progress towards the elucidation of the
mechanisms involved in tumor immunology, the results have shown
the relationship between the immune system and tumor growth to
be two sided. On the one hand, tumor growth was shown to be
enhanced by the immune system and conversely, it was shown to be
inhibited by the immune system. The types of immune cells or
immunoglobulin classes associated with either effect have not
been clearly determined so far. However, results in general
have indicated that immunoglobulins and antigen-antibody
complexes tend to enhance tumor growth, while T cells and
macrophages tend to inhibit tumor growth (Klein, 1972; James
et. al., 1975; James et. al., 1976; Fiedman, 1976; Baldwin and
Price, 1976; Price and Baldwin, 1977; Johnson et. al., 1977;
Witz, 1977;Shearer and Fink, 1977; Hofken et.al., 1978a; Hofken
et.al., 1978b; Hofken et. al., 1978c; Shin et.al., 1973; and
Price et. al., 1979).
It can be stated that, while the association of the immune
system with tumor growth has been shown, only a glimpse of the
mechanisms involved in tumor immunology has been obtained.
Continued research in tumor immunology will, it is believed,
elucidate these mechanisms and enable them to be utilized in the
prevention and cure of cancer. The possibility of such an
achievement is especially boosted by the encouraging results
attained in the practical applications of tumor immunology.
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1.4 The practical application of tumor immunology
Although tumor immunology has barely progressed beyond its
preliminary stage, attempts have already been made to apply it in
tumor immunodiagnosis and immunotherapy. In immunodiagnosis,
anti-tumor antibodies have been utilized to forecast malignant
growth (Ting, 1976), and to locate occult neoplasia (Terman et.al.,
1975).
In immunotherapy, various immunostimulants have been used
to improve the prognosis of cancer patients (James et. al., 1975;
Mastrangelo et. al., 1976; Israel, 1976; Torisu et. al. 1976 and
Gutterman et. al., 1976). Although not all trials have succeeded
in extending the period of remission or preventing the regrowth
of tumors, some trials have achieved very encouraging results.
Moreover, anti-tumor antibodies have been used to enhance the
specificity of anti-tumor drugs (Ghose and Blair, 1973).
The relevance of immunology to tumor growth is further
expounded in the following sections. It will become apparent
that the available data have paved the -way for significant advances
to be made in tumor immunology.
2. AMTI-TUMOR ANTIBODIES
The study of anti-tumor antibodies was first
restricted to humoral antibodies in the sera of tumor bearing
animals and cancer patients. Although circulating anti—tumor anti¬
bodies were demonstrated in the sera of tumor bearers, hardly any
concrete correlation was found between tumor growth in vivo
and circulating anti-tumor antibodies. Consequently, research
has been extended to anti-tumor antibodies found within the
tumor, where TAIgs were found to exist on tumor cells and host
cells. Some of these anti-tumor antibodies have been isolated
and their behaviour studied both in vitro and in vivo. Although
greater insight has been gained into the association of anti-tumor
antibodies with tumor growth, and the practical benefits that can
be accrued from them in tumor diagnosis and drug-guidance in
chemotherapy, the precise role of anti-tumor antibodies has not
yet been fully elaborated.
2.1 Circulating anti-tumor antibodies
Initial research on circulating anti-tumor antibodies
produced contradictory results. On the one hand, they were found
to block the anti-tumor action of host cells and enhance tumor
growth (Bansal et. al., 1972), while on the other hand, they were
found to cooperate with host cells and inhibit tumor growth
(Johnson et. al. 1977). What made the anti-tumor antibodies
behave in one way or the other appeared to depend on the type of
tumor, extent of tumor growth and the immunological state of the
host. Moreover, it has become clear that anti-tumor antibodies
are seldom in themselves responsible for the "blocking effect"
(Price and Robins, 1973). For instance, although anti-tumor
antibodies persist in the sera of mice after the excision of
their tumors, post-surgical sera rarely exhibit a blocking effect.
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Also, immune sera which bind to effector cells in vitro ana block
their subsequent action on tumor cells, are nonetheless capable
of rejecting tumor growth in vivo. Therefore, factors other than
anti-tumor antibodies appear to be responsible for the blocking
effect, such as soluble tumor antigens, antigen antibody
complexes (Coggin et. al., 1974) and other tumor cell products
(Dauphine et. al., 1974; Keisari and V/itz, 1975 and Lev/is et. al. , 1976)
2.1.1 Circulating anti-tumor antibodies in experimental animals.
Although the role of circulating anti-tumor antibodies in
tumor rejection or enhancement remains unclear, their existence in the
sera of tumor-bearing animals has been well documented. In one study
by Ran et. al. (1976), cytotoxic anti-tumor antibodies in mice appeared
on the second week after the injection of tumor cells and remained high
thereafter. In a similar study by Ting (1976), kinetics of the antibody
response and its specificity was found to vary between different tumors.
Mice with progressive tumors were found to have higher levels of
circulating anti-tumor antibodies than mice with regressing tumors or
no tumors at all. In the sera of mice bearing a methyl-cholanthrene induced
sarcoma, significant levels of circulating anti-tumor antibodies
appeared after excision (Harder and McKhann 1968).
Noncytolytic circulating anti-tumor antibodies were among the
antibodies found in the sera of DBA/2j mice hyperimmunized against
L-513-tumor cells (Goldstein et. al., 1973). Haskill et. al. (1977)
were able to demonstrate the presence of IgGl, IgG2a, IgG2b, IgA and
IgM antibodies in the sera of DBA/2 mice bearing T1699 tumors. IgE
has also been associated with tumors (Rosenbaum and Dwyer, 1977).
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Robins (1975) showed the presence of circulating anti-tumor
antibodies in the sera of mice bearing both ascitic and solid
tumors. However, once the tumors in the latter became palpable,
the antibodies disappeared from the corresponding sera. Similar
results were noted in a review by Coggin et. al. (1974).
2.1.2 Circulating anti-tumor .antibodies in pa-hi pnfg
Circulating anti-tumor antibodies have also been demonstrated
in the sera of cancer patients, although their anti-tumor specificity
remains less clear than the circulating anti-tumour antibodies in
experimental animals. In most studies, the association of circulating
antibodies with the tumor was observed by the ability of these
antibodies to block the anti-tumor action of host cells. Steel et.al
(1975) were able to decrease the blocking effect in the sera of
patients after absorbing these sera with S.aureus protein A which is
known to bind to certain IgG subclasses. Similarly, IgGl and IgG3
were found to be associated with the blocking effect in the sera of
children with neuroblastoma (Jose and Skvaril, 1974). Heimen and
Klein (1976) were able to demonstrate immune complexes in the sera
of patients with Burkitt's lymphoma and nasopharyngeal carcinoma,
where IgG was found to be a principal component. Lewis et.al. (1976)
asserted that anti-antibodies were an integral part of tumor associated
antibodies. These anti-antibodies were thought to have both beneficial
effects, when directed against blocking circulating anti-tumor
antibodies and detrimental effects, when directed against cytolytic
circulating anti-tumor antibodies.
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2.1.3 In vivo and in vitro effects of circulating anti-tumor antibodies
As mentioned earlier, the in vivo and in vitro effects of
circulating anti-tumor antibodies have been shown to correlate with
tumor growth enhancement, on the one hand, and tumor growth inhibition,
on the other. Bansal et.al. (1972) showed that the injection of sera
obtained from rats carrying a progressively growing polyoma tumor into
polyoma isografted rats enhanced the growth of the tumor. Tamerius et.al.
(1975) found that the blocking factor in the sera of multiparous mice
was associated with IgG2a and IgG2b. In contrast, Karris et.al. (1978)
showed that .isolated anti-tumor IgGl antibody enhanced tumor growth
in vivo, while whole antisera rarely did so. In another study, it was
demonstrated that anti-SV 40 antisera which were positive in the in vitro
antibody-dependent-cell-cytotoxicity, were not able to protect aganst
SV40 tumor cell challenge (Prather et.al. 1979). In some instances,
antibodies to normal cells have been found to enhance tumor growth.
Heidrick et.al. (1973) found that a certain dilution of antibodies to
normal skin cells which were cytotoxic to malignant cells in vitro,
became tumor growth enhancers at a greater dilution.
There is ample evidence too for tumor growth suppressive
properties of circulating anti-tumor antibodies. Johnson et.al. (1977a & b)
demonstrated that allogeneic IgGl anti-tumor antibody cooperated with
macrophages and blood platelets to supress tumor growth in vivo. Miller
and Feldman (1977), working with another tumor system, made similar
observations; however, the suppressor antibody that cooperated with
macrophages was found to be IgG2b. IgG2a, with or without macrophages,
enhanced tumor growth. Farram et.al.(1973) showed that antitumor
antibodies inhibited the growth of Meth.A tumors both in vitro and
in vivo, probably through a complement dependent lysis of the tumor cells.
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Cantrell et.al. (1976) further demonstrated that complement dependent
cytotoxic anti-tumor antibodies which were produced after chemotherapy
and immunotherapy, correlated well with improved prognosis.
In conclusion, it can be said that while research on
circulating anti-tumor antibodies has been successful in associating
these antibodies with the tumor, it has failed so far to elucidate
the in vivo mechanisms involved, be it in tumor growth enhancement
or inhibition.
2.2 In situ tumor-associated immunoglobulins
The failure to demonstrate a clear relationship between the
role of circulating anti-tumor antibodies and tumor growth in animal
models or cancer patients, prompted researchers to study in situ tumor-
associated immunoglobulins (TAIgs). It was realized that the essential
problem was not whether anti-tumor antibodies existed in the sera of
mice and cancer patients, but whether such antibodies reached the
tumor site at all and what happened thereafter in the tumor micro-
environment .
One of the difficult tasks that confronted pioneer workers in
this field was the development of sensitive techniques to detect
immunoglobulins on the surface of freshly excised tumor cells. The
routine preparation of tumor cells by enzyme digestion could not be used
as the latter was known to remove surface bound TAIgs. The indirect
antiglobulin test was one technique which had been used to study tumor
cell surface antigens. Sparks et.al. (1969) developed the isotopic
antiglobulin test introduced by Harder and McKhann (1963) to study
humoral antibodies directed against tumor and histocompatibility antigens.
Burdick et.al. (1973) improved the radioimmune antiglobulin test (RIAT)
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and rendered it more sensitive for the detection of cell-surface
bound antibodies. Consequently, Goldstein et,al. (1973) used the
RIAT to demonstrate specific anti-tumor antibodies in the sera of lymphoma
bearing mice. However, none of these methods were applied for the
study of in situ TA.Igs.
Some researchers have used protein A from S>aureus bacteria
strain Cowan I, which could bind to mouse IgG2a, IgG2b, and IgG3 as
well as human IgGl, IgG2 and IgG4 globulins passively bound to the
surface of cells (Kronvall et.al. 1970). Brown et.al. (1977) employed
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I-labelled protein A to study anti-tumor antibodies bound to cell-
surface antigens. Although the latter was found to be more sensitive
than the RIAT, it had the inherent disadvantage of only detecting certain
immunoglobulin subclasses. The RIAT is now a widely used method for
the study of in vivo bound TAIgs (V/itz, 1977 and James et. al. 1979)
However, other methods such as mixed hemadsorption, hemagglutination,
and immunofluorescence have also been used (Irie et.al. 1975; Witz 1977
and Haskill et.al. 1977).
Although sufficient evidence nov; exists indicating the in situ
association of immunoglobulins with the tumor, the immunological role
of these immunoglobulins and their proportional distribution on the
different cells within the tumor remains to be established.
2.2.1 Tumor-associated immunoglobulins in experimental animals
The association of immunoglobulins with experimental tumors
in vivo is now well documented (V/itz 1977). Although some of these
TAIgs have been shown to be 'tumor specific, others have been found to
be either natural immunoglobulins or non-tumor related antibodies.
For example, mice treated with bovine serum albumin (BSA) prior to
the injection of tumor cells were found to have anti-BSA antibodies
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on their ascitic tumor cells (Witz, 1977).
Haskill et.al. (1977), using an indirect immunofluorescence
test, were able to detect XgG2a and IgG2b on tumor cells. The
latter were found not to be saturated with immunoglobulins, as
they absorbed additional anti-tumor antibodies. Further studies
indicated that the production of these TAIgs greatly depended on
thymus derived cells for all Ig classes and subclasses except IgG2b.
Dorval et.al (1976) showed that various in vivo grown tumors were
able to fix protein A. Tonder et.al (1976) determined the amount
0
of IgG on 10 tumor cells and showed it to vary from less than
100 ng to approximately 600 ng. Only a minority of the latter was
found to be bound to Fc-receptor cells within the tumor.
In another study, Ouchterlony analysis revealed the presence
of antiviral IgG2a and IgGl in tumor eluates (Goldroson and Dent, 1977).
The former was detectable at all tumor growth stages studied, while
the latter was only detected on tumors that were in situ for more
than 60 days. IgA and IgM were also found but their presence was not
correlated with tumor age. Robins (1975) was also able to detect
tumor specific antibodies on an ascitic variant of rat hepatoma.
In general, current research into TAIgs in situ centers around
the following: identification of the cell types within the tumor
which possess or produce TAIgs; elucidation of TAIg kinetics; and
determination of the in vivo and in vitro effects of TAIgs on tumor
cells and on host cells.
In some tumor systems, like melanoma, the immunoglobulins
have been found to be exclusively associated with the host cells
(Witz, 1977). In most of the other systems, however, TAIgs have
been associated with both tumor cells and host cells, some of the
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latter consisting of Fc-receptor host cells (Tonder et.al., 1976
and Witz, 1977).
In vitro studies on TAIg binding kinetics showed that the
surface bound immunoglobulins were in active equilibrium with the
culture medium. Yeenof et.al (1976), investigating membrane bound
7S IgM on Daudi cells, discovered that within 10 hrs of adding
125
I-anti IgM, more than 80% of the cell bound radioactivity was
shed from the cells. This took place concurrently with the loss
of IgM molecules from the surface of tumor cells, probably due
to internalization. Although the shed antibodies could rebind
to fresh Daudi cells, some of them were found to be in the form of
immune-complexes. Caspi et.al. (1976') obtained similar results
with MDAYmurine tumor cells. Freshly explanted MDAY cells which
were sensitive to complement mediated lysis lost this sensitivity
upon short term culture at 37°C. Witz and Moav (1978) detected
IgG2a on SEYF-a cells, a polyoma virus-induced ascites tumor cells.
The specific cytotoxic activity of tumor eluates which was highest
in 11-15 day old tumor cells, decreased with the propagation time
of the tumor. This could have been due to the binding of noncytotoxic
antibodies or to the emergence of molecules capable of inhibiting such
activity. Moreover, the tumor eluates were found to have higher
binding constants than antitumor antibodies obtained from the sera of
tumor bearing mice. In an extension of these studies, Moav et.al. (1978)
determined two distinct populations of molecules in tumor eluates:
one with high binding constant to the tumor cells, and another with
a much lower binding constant to these cells. It was suggested that
the former consisted mainly of antibodies to surface antigens of tumor
cells.
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Ran et.al (1973) showed that antilymphocyte cytotoxic antibodies
were amongst the eluates of SSYF-a tumor cells. Since the titer
of these antibodies in the sera of tumor bearing mice was lower
than that of the tumor eluates, it was suspected that tumor cells
selectively absorbed the lymphocytotoxic antibodies from the serum.
Rittenhouse et.al.(1978) also demonstrated the spontaneous
release of high-molecular-weight aggregate containing IgG from the
surface of Ehrlich ascites tumor cells during incubation for 1 hr in
cold isotonic buffer. Wolosin and Greenberg (1979), in a competitive
radio-immunoassay study, showed that several tumor lines acquired
Ig rapidly between 3-18 hrs after intra-peritoneal implantation into
normal syngeneic mice. The in vivo acquisition of these TAIgs was
found to be a T-independent phenomenon. Moreover, since the kinetics
of normal syngeneic serum binding to tumor cells in vitro matched that
of TAIg in vivo, the authors deduced that the latter was due to in vivo
binding of natural antibodies to tumor cells. The in vivo and in vitro
effects of TAIgs are elaborated in section 2.2.3.
2.2.2 Tumor-associated immunoglobulins in cancer patients
TAIgs have also been discerned in human neoplasia (I'/itz, 1977).
Dorsett et.al. (1975) \\rere able to isolate tumor specific antibodies
from effusions of ovarian carcinomas. Vanky et.al. (1975) found TAIgs
in 18 of 44 cell suspensions (41%) prepared from surgical specimens
of human tumors. Only tumor cells without TAIgs were capable of
stimulating autologous lymphocytes. Infiltrating lymphoid cells were
not thought to be the carriers of the TAIgs as lymphnode cells, spleen
cells, and bone marrow cells seldom exhibited surface bound Igs as much
as the amount found on tumor cells. Similarly, Gerstl et.al.(1977)
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found membranous and cytoplasmic IgG in surgical specimens of human
lung carcinoma. IgA and IgM were also detected but less frequently
than IgG. Examination of Fc-receptor host cells within the tumor
showed that the latter cells v/ere unlikely carriers of the TAIg,
especially that only 10% of IgA are monomeric while none of the IgM Igs
have Fc-portions available for reaction. Irie et.al. (1975), using
mixed hemadsorption technique, demonstrated TAIg and complement on the
cell surface of human biopsies and autopsies. Gupta and Morton (1975)
found specific anti-tumor antibodies in eluates of human melanoma cells which
contained more IgG than IgA.
2.2.3 In vivo and in vitro effects of tumor-associated immunoglobulins
The in vivo and in vitro effects of TAIgs fluctuate between
tumor growth enhancement and tumor growth inhibition (Witz, 1977).
Tumor lysosomal extracts are thought to be responsible for cleaving
the Fc-portion of surface-bound antibodies rendering them incapable
of complement mediated lysis but capable of retaining their blocking
effect (Dauphine et.al., 1974 and Keisari and Witz, 1975). Moreover,
antigens released from tumor cells are capable of deterring the action
of tumor specific antibodies by the formation of immune-complexes
(Baldwin and Price, 1976).
The in vivo acquisition of Igs by tumor cells have been found to
/*i
be inhibited by IV or IP injection of tumor antigens (Wolosin and
Greenberg, 1979).
TAIgs in human tumor biopsies were not found to stimulate auto¬
logous lymphocytes, unlike biopsies that were free of TAIgs and which
did stimulate lymphocytes (Vanity et. al, 1975). Moreover, TAIgs in
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eluates of SEYF-a tumor cells were found to mediate complement
dependent cytotoxicity of normal lymphnode cells (Ran et.al. 1978)
On the other hand, TAIgs have also been found to be tumor inhibitory.
A study of T-1699 murine adenocarcinoma suggested that IgG2a were
active in macrophage mediated cytotoxic reactions and IgG2b in the
immediate hypersensitivity reaction to T-1699 cells (Haskill st.al. 1977).
Johnson, et.al. (1977c) determined that between 70,000 and 130,000
surface bound IgGl anti-tumor antibody molecules were sufficient to
cause 50% suppression of tumor growth in mice inoculated with 50,000
lymphoma tumor cells. TAIgs obtained from tumor eluates of SV40 tumors
did not block in vitro lymphocyte dependent microcytotoxicity of immune
lymphocytes against cultured SV40 tumor cells (Goldrosen and Dent, 1977).
The antibodies in the latter eluates, however, were antiviral antibodies.
TAIgs eluted from tumor cells at low pH were incapable of rebinding
o
to cultured cells, unlike those eluted by prolonged incubation at 37 C
which retained their binding capacity (Witz, 3977). An analysis of acid eluted
TAIgs revealed that they consisted of free Igs, antigen-antibody immune
complexes, and degraded Igs. Tumor cells maintained in culture for 1 hr
became insensitive to complement action even though 70-80% of the TAIgs
were still cell-associated (Witz, 1977). It was suggested that the TAIgs
were interiorized.
In conclusion, although TAIgs exist in experimental and human
tumors, their distribution oh the different cells within the tumor
and their role in tumor inhibition or enhancement remains to be elucidated.
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2.3 Practical applications of anti-tumor antibodies
Like most other fields of tumor immunology, the field of
practical applications of anti-tumor antibodies has only recently
emerged. Some progress has already been achieved, especially in
the realm of chemotherapy and tumor diagnosis. In chemotherapy,
attempts have been made to use anti-tumor antibodies as drug
carriers in order to restrict damage to tumor cells and spare
the normal cells. In diagnosis, anti-tumor antibodies have been
used to detect both original tumors and tumor metastases.
The problems residing in the use of anti-tumor antibodies
in chemotherapy included the following: the availability of biochemical
sites for linking the drug to the antibody without effecting the
activity of either; the binding of therapeutically effective amounts
of the drug to the antibody; the delivery of the drug in active form
to the tumor site; emergence of host reactions to the protein; and
the emergence of resistant tumor cells (Ghose and Blair, 1978).
Ghose et.al. (1976) were able to demonstrate preferential localization
of chlorambucil-linked anti-tumor antibodies in the mice tumors. Mice
injected with drug-linked anti-tumor antibodies exhibited a higher
survival time than mice injected with either the drug or the antibody
alone. These studies were extended in include 24 patients with
progressive metastatic malignant melanoma, where encouraging results
were also obtained. Furthermore, the preferential localization of
131
I-linked anti-tumor antibodies in the tumors of 2 cancer patients
was demonstrated.
To date, anti-tumor antibodies have been used in attempts to
improve the therapeutic effects of the following agents (Ghose and
Blair, 1978): chlorambucil and Trenimon (alkylating agents);
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daunorubicin, adriamycin and bleomycin (antibiotics); methotrexate
(antimetabolite); phospholipases and microbial toxins (cell surface
agents); and diptheria toxin and toxic plant proteins (protein-
synthesis inhibitors). Although minor improvements in the
specificity of these anti-tumor agents have been noted, the practical
application of drug-linked anti-tumor antibodies remains very limited.
The unavailability of sufficient amounts of alio or iso-anti-tumor
antibodies has greatly contributed to this limitation.
Anti-tumor antibodies have also been utilized in the detection
of tumor growth. Ting (1976) was able to detect anti-tumor antibodies
in the sera of tumor-bearing mice at a relatively early stage.
Consequently, the presence of such antibodies in human sera could be
used as an early warning system of tumor growth. In another study,
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I-labelled tumor-specific antibodies, isolated from mice with
neuroblastoma, were found to localize preferentially in the tumor
when reinjected into tumor bearing mice (Terman et.al. 1975).
These labelled anti-tumor antibodies could be utilized in the detection
of occult neoplasia in vivo.
2.4 Conclusion
It is apparent from what have been stated above that, while
considerable progress has been made in the detection and isolation of
anti-tumor antibodies, a great deal remains to be understood before
they may be utilized in tumor monitoring and eradication. Progress
has been and still appears to be complicated bj/- the number of experimental
tumor systems, and the various types of human cancer that exist. Whereas
in one system tumor-associated Igs inhibit tumor growth, in another system
they enhance it. While in one system in situ TAIgs is wholly associated
with tumor, in another system they are associated with both, host and
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tumor cells. Moreover, work on drug-linked anti-tumor antibodies
has been hampered by the lack of sufficient amounts of antibodies
and the instability of such complexes.
As mentioned, however, all classes and subclasses of anti¬
bodies have been associated with tumors, both in the sera of tumor-
bearing animals and patients, and within their tumors. Current
research on antitumor antibodies centres around the elution of
in vivo bound TAIgs from the tumor cells; tie determination of
their type and specificity; the identification of the cells within
the tumor; the elucidation of the in vivo mechanisms by which TAIgs
enhance or inhibit growth; and more efficient utilization of anti¬
tumor antibodies in chemotherapy and tumor diagnosis.
3. NONSPECIFIC BINDING IN SITU
It is probable that a significant proportion of the tumor-
associated-immunoglobulins are comprised of nonspecific antibodies,
natural antibodies and/or immune-complexes, trapped in the tumor
during their circulation through it. Certain of these non-tumor
related immunoglobulins and immune complexes may bind to tumor cells
and host cells inside the tumor through Fc-receptors found on these
cells. Similarly, certain complement components have been detected
on in vivo growing tumors. However, the in vivo role of complement
in tumor immunity is only slightly understood.
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3.1 Non-specifically associated antibodies and immune complexes
It is assumed that non-tumor related immunoglobulins and
immune-complexes are bound to Fc-receptor bearing cells within the
tumor. The existence of such cells with Fc-receptors in tumors is
well documented (V/itz, 1977). Kerbel et.al. (1975) exhibited a
high proportion of Fc-receptor bearing cells in a variety of in vivo
growing tumors. Many of these cells were found to be actively
phagocytic and some were found to be of T-cell origin. Moreover,
there were indications that the majority of these cells were of host
origin. Tumor cells cultured in vitro over long periods of time were
devoid of such cells. Similarly, Szymaniec and James (1976) showed
the presence of Fc-receptor bearing cells in methyl-cholanthrene
induced fibrosarcomas. The existence of these cells in tumors and
their in vivo kinetics was also reported by Pross and Kerbel (1976).
Before presenting evidence on the presence of immune-complexes
or non-specifically bound immunoglobulins in tumors grown in vivo,
their relationship to tumor growth is briefly expounded. Immune-
complexes have been found to play a significant role in blocking the
anti-tumor effect of host cells (Price and Robins, 1978). Circulating
immune-complexes have also been detected in the progressor sera of
patients with neuroblastoma (Jose and Seshadri, 1974). The greatest
blocking effect of these immune complexes was manifested at antigen-
antibody equivalence. Tamerius et.al. (1975) postulated that the
blocking factor noted in the sera of multiparous mice consisted largely
of immune-complexes between emhyonic antigens and IgG2a and IgG2b.
Immune complexes were also isolated from effusions of ovarian carcinomas
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(Dorsett et.al., 1975). Bowen et.al. (1975)showed that sera obtained
from animals bearing small tumors (7-14 day old) were free of
immune-complexes, in contrast to sera obtained from animals
bearing large tumors (24-28 day old). The latter were capable of
blocking the cytotoxicity of syngeneic lymphnode cells against
cultured tumor cells. It is probable, therefore, that immune-
complexes contribute to the escape of the tumor from cellular
immune destruction.
In addition to the evidence showing the existence of Fc-
receptor bearing cells in tumors and the presence of immune-complexes
in the sera of tumor bearers, it is now becoming clear that immune-
complexes actually bind to these cells in vivo thus probably blocking
the destruction of the tumor by host cells. Braslawsky et.al. (1976a)
injected mice with bovine serum albumin (BSA) or ovalbumin (OA) prior
to the injection of tumor cells. Examination of the 7-9 day old
ascitic tumors revealed that BSA or OA treated mice contained anti-BSA
or anti-OA antibodies respectively on the freshly prepared tumor cells.
The removal of phagocytic and adherent cells from the tumor cells
population did not completely eliminate the in vitro binding of antibody-
complexed BSA or OA to the tumor cells, indicating that tumor cells per se
might be capable of binding immune-complexes. However, experiments
with hybrid mice did show that the binding of immune-complexes was
mostly limited to infiltrating host cells.
The in vivo binding of immune-complexes to ascitic tumors was
shown to increase with time (Braslawsky et.al., 1976b). In contrast
in vivo bound antibodies lost their cytotoxicity with time. Consequently,
it was postulated that tumor antigens and receptors for immune-complexes
-26-
were in close proximity on the tumor cell surface, thus enabling the
immune-complexes to inhibit the binding of specific cytotoxic antibodies
to the antigens on tumor cells. In a later study, however, it was shown
that the treatment of tumor cells by specific anti-tumor antibodies
inhibited the fixation of immune-complexes by these cells (Braslawsky
et.al. 1976c). It may be deduced, therefore, that should there
initially be a large influx of anti-tumor antibodies into the tumor
in vivo, then these antibodies could inhibit the subsequent binding of
immune-complexes and prevent their detrimental blocking of cell mediated
immunity. Unfortunately, spontaneous tumors do not appear to possess
antigens that could evoke the early production of appreciable amounts
of specific antibodies.
The nature of Fc-receptors on tumor cells per se needs to be
elucidated, although there are indications that they might be produced
by viruses in some tumors. Herpes simplex virus have been found to
produce Fc-receptors on infected cells in vitro which could bind IgG
molecules of several species (Westmoreland and Watkins, 1974).
Cytomegalovirus infected fibroblasts were also found to develope Fc-
receptors for IgG but not IgM or IgA, molecules (Keller et, al. 1976).
It is possible, therefore, that in addition to binding to Fc-receptor
bearing host cells within the tumor, immune complexes and non-tumor
related immunoglobulins bind to some tumor cells via Fc-receptors
produced by viruses.
3.2. Complement
Although little is known about the in vivo role of complement
in tumor immunity, its association with tumor growth has been observed.
Nishioka et. al. (1976) showed high levels of complement in the sera of
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lung cancer patients. Further studies led these researchers to propose
that the levels of complement increased in these patients in order to
compensate for the decline of cell mediated immunity. Complement
component (C3)las been detected on freshly prepared human tumor cells
(Irie et. al. 1974; and Irie et, al., 1975), and on Erlich ascites tumor
cells (Rittenhouse et. al., 1978). Experiments by Segerling et. al. (1976)
on guinea pig hepatoma ascitic tumor cells suggested that the in vivo binding
of complement components (C3 and C4) increased with time.
Like anti-tumor antibodies, complement may be present in the vicinity
of the tumor cell membrane, but fail for one reason or another to exert
its cytotoxic effect. The latter appears to depend on the growth cycle of
the tumor cells, the production of anti-complementary factors and/or the
secretion of extracellular enzymes by the tumor cells. Cooper et. al.
(1974) showed that the complement-mediated lysis of virally induced
lymphoma cells was limited to the G1 phase of the cell cycle. Complement
lysis did not occur during the other phases of the cell cycle even though
complement components (C5-C8) were bound throughout these phases resulting
in the characteristic plasma membrane lesions. In another study, it was
indicated that tumor cells might produce extra-cellular enzymes that
could cleave the Fc-portion of surface-bound antibodies thus destroying
their ability to bind complement (Keisari and Witz, 1975). Fridman et. al.
(1974) demonstrated that sensitized lymphnode cells produced an immuno¬
globulin binding factor which could protect IgG sensitized erythrocytes,
but not IgM sensitized erythrocytes, from complement mediated lysis. This
iramunoglobulin-binding-factor was shown to be distinct from other known
lymphokines. It is probable, therefore, that factors produced either by tumor
cells or host cells could prevent tumor-associated-immunoglobulins from
binding complement and causing the lysis of tumor cells.
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3.3 Conclusion
In conclusion, therefore, humoral factors including non¬
specific immunoglobulins, immune-complexes, and complement, could
be amongst the elements present within the tumor microenvironment.
Non-specifically associated immunoglobulins and immune-complexes
appear to bind to Fc-receptor bearing cells thereby blocking, on
the one hand, the anti-tumor action of host cells, and on the other
hand, preventing anti-tumor antibodies from exerting their effect.
The action of complement appears to be hindered by agents binding
to or cLeaving the surface-bound anti-tumor antibodies, and by phases
of the cell cycle. It is hoped that further research will result
in the control of these humoral factors and lead to the prevention
of their detrimental effects.
4. TUMOR SPECIFIC CELLULAR IMMUNITY
Since cell-mediated immunity was found to be responsible for
allograft rejections and since immunodeficient and thymectomized
animals exhibited increased incidence of certain tumors, it therefore
followed that cell-mediated immunity could be important in the prevention
of tumor growth (immunosurveillance theory). Hov/ever logical the
concept of immunosurveillance may have seemed, facts do not wholly support
it yet. Apart from DNA viral tumors, cellular immunity has not yet been
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found to be necessary for the prevention of experimental spontaneous
or virally (RNA) and chemically induced tumors. Moreover, some
researchers have related the increase of lymphoreticular tumors in
immunodeficient animals to the lack of T-cell defense against
oncogenic viruses and not against tumors.
On the other hand, the association of T cells with
certain transplantable and human tumors has been demonstrated.
The methods employed for T-effector cell studies have varied from
colony-inhibition and microcytotoxicity to tests with IUDR and Cr
labelled tumor cell targets (Beverley, 1978). With most of these
assays, clear evidence for T-cell involvement has been obtained
with murine sarcoma virus tumors, TI699 mammary adenocarcinoma,
human Burkitt's lymphoma and other tumors.
4.1 Tumor-specific T-cells in experimental animals
The existence of specific anti-tumor T cells in experimental
tumor-bearing animals has been frequently reported (Beverly, 1978).
Viral antigens were found to be the target of T cells in some of
the experimental tumors. When lymphocytes, which have been primed
in vivo with MuLV-G leukaemia cells, were stimulated with disrupted
MuLV in culture, effector cells with high cytotoxicity against
leukaemic cells were generated (Bruce et.al. 197S). Plata et.al.
(1976) identified T cells as the cytolytic agents in a secondary
mixed-leukocyte-tumor cell culture. Spleen cells obtained from
regressor mice that had rejected murine sarcoma-virus induced tumors
were cultured with syngeneic RBI-5 tumor cells. During 22 days of
culture, T cells appeared to change from small cells to large cells
and then revert back to small cells, simulating in vivo blastogenesis
and maturation. The cytotoxicity of these T cells was found to be
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independent of macrophages and non T-cells. A comparison of these T cells with
T—cells obtained from allogeneic mixed-leukocyte-culture indicated that
the underriding mechanism could be cell-mediated immunity against the
tumor.
Holden et.al. (1976), using a Cr release assay (CRA) and growth
inhibition assay (GIA) in primary murine sarcoma-virus (MSV) induced
tumors, found small T cells to be active in CRA and macrophages to
be active in GIA. An examination of the host-cell content of the tumors
showed that 30%-40% were T cells, 50% were macrophages, and 5% were B
cells. Moreover, the T cells were found to be tumor-specific, unlike
the macrophages which were found to react against non cross reacting
antigens. No T cells were observed in progressing MSV tumors.
Similarly, in a comparison between regressing and progressing Moloney-
sarcomas, Russel et. al. (1976 a & b) found more T lymphocytes in the
former on all days tested post-tumor-cell injection. On day 6 of tumor
growth in regressing tumors, the T cells were found to be large in size
which led these researchers to propose that these cells might be
indispensable for tumor regression due to their homing and direct
cytotoxic properties. Moreover, inflammatory cells in progressing tumors
were found to be limited to the periphery of the tumors, unlike regressing
tumors whereby the inflammatory cells were found to have infiltrated the
tumor mass.
Small and Trainin (1976) showed lymphocytes to be significant in a
benzpyrene-induced fibrosarcoma and a spontaneously occuring carcinoma
of C57BL mice, and in an MCA-induced fibrosarcoma of C3H mice. Both
in vivo and in vitro experiments indicated that sensitized spleen cells
consisted of two subpopulations. One comprised of large cells which
enhanced tumor growth and another comprised of small cells which inhibited
I
tumor growth. The growth enhancing lymphocytes were always dominant
when the two subpopulations of the cells were injected together. It
was not clear at the time whether the two types represented different
kinds of lymphocytes or the same kind but with varied degrees of
maturity. In support of the latter study, Fujimote et.al. (1976a)
demonstrated that immunosuppressor T cells were a significant con¬
stituent of T cells in mice bearing an MC-induced sarcoma. The i.v.
transfer of washed thymus or spleen cells from tumor-bearing animals
to immune animals was found to significantly weaken their capability
to reject the syngeneic tumor. Moreover, splenectomy of tumor-bearing
mice or the treatment of normal syngeneic mice with anti-lymphocyte
serum after tumor-cell inoculation resulted in the suppression of
tumor growth. Further studies showed that these immunosuppressor
T cells appeared within 24 hours after the inoculation of tumor cells
and lasted until 5 days after the excision of the tumor (Fujimoto, 1976b).
Although the immunosuppressor cells were observed in the thymuses,
Spleens, draining lymphnodes, and the bone marrow of tumor-bearing
mice, they were not detected in the peripheral blood. As for the
nature of these immunosuppressor T cells, they were shown to be mature
cells of relatively small size. The relationship between the immuno¬
suppressor T cells and other T cells such as effector and helper T cells
remains to be established.
Haskill et.al. (1976) postulated that T cells were important
in regressing TI699 mammary adenocarcinoma since the tumors became
m, •
progressing after treating the mice with anti-lymphocyre-serum. Their
experiments suggested that T-cells elicited a delayed hypersensitivity
reaction which led to the influx of macrophages into the tumor.
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4.2 Tumor-specific cell-mediated immunity in immunodeficient
experimental animals
Studies on T cells in immunodeficient animals were carried out
in order to establish the role of T cells in the prevention of
spontaneous tumor growth and hence to examine the validity of the
immunosurveillance theory. These studies indicated that while T cells
were important in the prevention of DNA viral tumors, like polyoma
tumors, they were hardly necessary for the prevention of other types
of tumors (Stutman, 1975).
Although increased lymphoreticular neoplasma were found in nude
mice, the incidence of these tumors were related more to the lack of
T cell protection against viruses than tumors per se (Holland et.al., 1978)
Indeed, a reduced risk of solid tumors was observed in these nude mice,
thoughv this could have been due to their short life span. Moreover,
in a study of 15,700 nude mice corresponding to 5,600 mouse years, not
a single incidence of a spontaneous tumor was reported (Rygaard and
Povlsen, 1976). The latter authors argued convincingly that irfectious
disease rather than somatic mutation was the reason behind the evolution
of T cells and its raison d'etre. The impotence of T cells against viral
oncogenesis was also emphasized by Allison et.al. (1974). However, nude
mice treated with anti - lymphocyte serum in the latter study developed
dcin tumors earlier than nude mice that remained untreated. This led to
the suggestion that a second surveillance mechanism independent of T
lymphocytes might exist. Evidence for the latter has also come from
other studies (Kiessling et.al. 1975; Hetberman et.al. 1975; and Kiessling
et.al. 1976).
Norbury and Kripke (1978) studied ultraviolet carcinogenesis in
T-cell depleted mice. Although tumors were found to develop earliest
in the latter mice, they grew most rapidly in mice T-cell depleted but
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restored with thymus grafts. Therefore, contrary to the immuno-
surveillance theory, the presence of T cells proved to be stimulatory
to tumor growth. In fact, it appears that the immunosurveillance
theory is being replaced by the immunostimulation theory, which
predicts that the growth of tumors may be due to a reduced immune
response (Prehn, 1976).
4.3 Tumor-specific cell-mediated immunity in cancer patients
The role of cell-mediated tumor immunity in Man remains far
from being clear. Reports indicating the presence of tumor-specific
T cells in cancer patients have been contradicted by opposite reports.
The confusion has been largely blamed on the absence of proper controls
and lack of uniformity of assay systems used (Bean et.al. 1375).
Jondal, et. al. (1975) demonstrated the presence of tumor specific
T cells in a Burkitt's lymphoma (BL) biopsy. Killer T cells from
patients with infectious mononucleosis (IM) were able to recognize
tumor cells recovered from the biopsy. These results led tie researchers
to propose that patients with BL exhibit a cell-mediated immunity
and that this immunity could be strengthened by the transfer of killer
cells from patients with IM. Similarly, cell-mediated anti-tumor immunity
was demonstrated in the majority of 373 cancer patients (Hellstrom et.al.
1971). The observed anti-tumor effect of lymphocytes isolated from
cancer patients was shown to be specific since they did not exert any
effect on tumor cells obtained from different neoplasms. In contrast
to these studies, Takasugi et. al. (197$ showed that lymphocytes isolated
from normal individuals were as cytotoxic, if not more, as lymphocytes
from cancer patients against cultured tumor cells from 7 established
lines and 12 short-term cultures. The only specific cell-mediated
tumor immunity observed was that by lymphocytes obtained from bladder
cancer patients.
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A workshop on cell-mediated cytotoxicity for bladder carcinoma
carried out in 1974 at the Sloan-Kettering Institute, New York, revealed
the complexities involved in the evaluation of cell-mediated immunity
in cancer patients (Bean et.al. 1975). It was concluded that only a
continued cooperation among the different laboratories based on uniform
assays, uniform patient-control selections, and uniform statistical
analyses would result in the understanding of tumor cell-mediated immunity.
The intricacies of tumor cellular immunity were also discussed by Baldwin
(1975) who stressed the importance of characterization and standardization
of target tumor cells, tumor-associated antigens, effector cells, and
microcytotoxicity assays.
4.4 Immunodepression and cancer in Han
Although increases in the incidence of certain tumors have
been shown in immunodepressed patients, it is not clear yet whether
immunodepression is the cause or the result of this increase in tumor
growth. In a long and detailed report on immunodepression and cancer
in Man and animals, Stutman (1975) demonstrated that immunodeficient
individuals exhibited increased lymphoreticular malignancies and that
organ transplant recipients usually developed lymphomas. On the other
hand, incidence of cancer among patients with myasthenia gravis was
shown to decrease after thymectomy. Cessation of immunosuppression
in organ transplant patients, was found to inhibit tumor appearance
(Penn and Starzl, 1973). Moreover, thirty patients with noncancerous
diseases who were treated with immunosuppressives developed cancer.
Depletion of lymphocytoses has been associated with advanced
Hodgkin's disease and its poorer prognosis (Hansen and Good, 1974).
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Furthermore, although T-cell deficiencies were noted in chronic
lymphatic leukaemia, T cells isolated and concentrated from these patients
exhibited normal phytohemagglutinin responses.
4.5 Conclusion
Although evidence exists for tumor specific cell-mediated immunity in
experimental animals, evidence for specific cellular immunity in cancer
patients remain, to be established. As mentioned above, the task for
determining the significance of tumor-specific cell-mediated immunity
in cancer patients appears to be tedious and long, depending largely on
the collaboration among the different laboratories.
Both tumor-suppressor T cells and tumor-enhancer T cells have been
shown to exist in tumor-bearing experimental animals. The various mechanisms
involved are not yet fully understood and may be complicated by the fact
that T cells isolated from peripheral blood may not necessarily be the
same as those obtained from the tumor. Haskill et.al. (1976) demonstrated
that host cells isolated from the tumor were very active in colony-
inhibition tests, unlike the cells isolated from spleen, lymphnodes,
peyer's patches, or blood. It was suggested that the active host cells
were either sequestered by the tumor, or that these cells were produced
within the tumor.
The immunosurveillance theory has been shown to be restricted
to DNA viral tumors in experimental animals. In Man, hov/ever, the validity
of the theory has been inconclusive. Its examination has been hampered by
tie combination of different kinds of immunode ficiencies at different
ages under the single title of 'primary immunodeficiency', by sampling
procedures and by inaccurate tumor diagnoses (Stutman, 1975).
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5* TUMOR NONSPECIFIC CELLULAR IMMUNITY
Although considerable research has been carried out on the
relationship between macrophages and cancer, the study of other
immunologically active cells like the polymorphonuclear leukocytes
(PMN) and K cells, have been relatively neglected (Sadler and Castro,
1978). Macrophages have been found to react against tumors and inhibit
its growth. However, the mechanisms by which non-specific cellular
immunity operates in tumor-bearers remain unknown.
5.1 Macrophages in cancer
Macrophages have been widely studdgd in cancer where sufficient
data has been produced to indicate the association of macrophages with
tumors, and its importance in tumor growth inhibition (see e.g. 'The
Macrophage anc Cancer1, James et.al. 1977). In general, macrophages,
unlike certain types of T cells, have been found to act against the
tumor rather than facilitate its growth. However, overproduction of
macrophages has > been shown to suppress lymphocyte production and thus
possibly enhance tumor growth (Rhodes, 1977).
Miller and Feldman (1977), working with rat molonev sarcoma,
demonstrated that macrophages together with antibodies could inhibit
tumor growth in vivo. However, this macrophage-antibody cooperation
was found to be restricted to IgG2b, while IgM and IgGl were found to
be ineffective, and IgG2a was found to intensify tumor ganwth. Moreover,
hyperimmune peritoneal exudate macrophages were found to inhibit, ana
in some cases eliminate, tumor growth even without the involvement of
antibodies.
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Lohmann-Mathes et.al. (1979) ascribed tumor growth inhibition
to macrophages which had been allowed to mature from bone marrow cells
in culture. In contrast to the latter, peritoneal and spleen
macrophages were found to be ineffective against tumor cells. In an
extension of this work, the lytic cells were identified as non-adherent
non-phagocytic promonocytes, which if permitted to mature in vitro to
phagocytic macrophages, retained their lytic activity at 1:1 phagocyte
target cell ratio (Domzig and Lohmann-Mathes, 1979). Similarly,
nonphagocytic ADCC effector cells obtained from mammary adenocarcinoma
T1699 were found to be related to macrophages (Haskill, 1977). These
cells became phagocytic after an overnight incubation.
In some instances the macrophage content of the tumor has been
found to be as high as 50% of the host infiltrating cells (Holden, 1976;
and Russell, 1976). Macrophages were shown to be tumor inhibitors as
long as the tumor-cell number did not exceed a certain threshold
(Norman, 1978). Once the latter was surpassed, a complete suppression
of macrophages possibly by the tumor cells, ensued. In the same study,
macrophages were found to be susceptible to the ascitic fluid obtained
from the tumor-bearing mice.
In conclusion, although the significance of macrophages in tumor
growth inhibition is well documented, the mechanisms are not clear at
the present time. However, the following mechanisms can be envisaged
(Van Furth, 1977 and Shin et. al. 1978):
a) inhibition of the tumor by complement components, lymphotoxins
or lysosomes that are released through bridges between the
macrophage and the tumor cell.
b) suppression of tumor cells by macrophages through soluble
mediators.
c) cytolosis of the tumor cells by membrane fractions of macrophages
d) release of factor-increasing-monocytcPoieses(FIN) by macrophage-
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tumor interaction. FIM could fail to reach the tumor due
to a defect in chemotaxis.
Whatever the mechanisms involved, macrophage proliferation and
its functions against the tumor seem to be dependent on tumor cell type
and number (VanFurth, 1977).
5.2 Polymorphonuclear leukocytes in Cancer
Studies on the role of PMN in cancer have been hindered by the
fragility of these cells and by the preoccupation of research workers
with lymphocytes and macrophages. In general, however, the activity
of PMN in cancer patients have been found to be depressed.
McRipley et. al. (1967) studied the phagocytic activity of
peripheral blood leukocytes against E, coli, P. auriginc-sa and S. albus
in patients v/ith various malignant diseases. PMN from most of these
patients exhibited impaired bactericidal activity and this imparment
was not correlated with gammaglobulin levels. In contrast, Kalinske
and Hoeprich (1969) did not find depressed activity of PMN in patients
v/ith chromic myelocytic leukaemia or patients v/ith chronic lymphocytic
leukaemia. It was argued that this discrepancy may have been due to the
fact that, in the latter study, patient—control tesis v/ere carried out
simultaneously and that metamyelocytes and myelocytes, which are predominant
in such patients, v/ere considered among the PMN. Strauss et. al. (1970)
demonstrated decreased phagocytic and bactericidal activity of PMN in
children with acute leukaemia. Moreover, although PMN from patients
in remission had normal phagocytic activity, they continued to exhibit
decreased bactericidal activity. In a modified technique using
autoradiography, Cline (1973) also showed PMN defects in patients
with acute myelocytic leukaemia.
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However, PMN have been found to respond to tumor tissue. Basophil-
associated-mononuclear cells in patients with breast cancer were
found to respond to autologous cancer tissue (Black and Leis, 1971).
This response, together with basophil counts, was increased after
4
mastectomy.
Hexose-monophosphate-shunt activity and nitroblue tetrazolium
reduction were amongst the biochemical reactions which were incorporated
in later PMN studies. Using such methods, decreased number and
functional capability of PMN were found in patients with acute lymphocytic
leukaemia, acute myeloblastic leukaemia, and chronic myelocytic leukaemia
(Skeel et.al., 1971 and Tan et.al. 1973). However, results had to be
considered carefully, as false positive and false negative reactions
were observed in a study carried out by Ashburn et,al. (1973).
The cause of depressed PMN in cancer patients and its relationship
to tumor growth remains unclear. Bactericidal defect of PMN in children
with acute lymphocytic leukaemia was found to be due to carniospinal
irradiation (Baehner et.al., 1973). In another study, PMN defects in
malignant patients was observed to be independent of the cancer type,
the mode of chemotherapy, or the type of infection (Pickering et.al. 1975).
5.3 Allergy and cancer
Attempts have been made to study the relationship of allergy to
cancer. Ure (1969) studied 140 patients in the gynaecology wards of
a large hospital and found the incidence of allergy and cancer among
the patients to be mutually exclusive. Similarly, a study by Meers
(1973) indicated that persons who did not have allergy were three times
more likely to develop cancer than allergic persons. In contrast,
Shapiro et. al. (1971) failed to observe any negative correlation between
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allergy and cancer. However, they argued that the number of patients
employed in such studies was too small to produce significant relation¬
ships of allergy with cancer.
Since IgE and pharmacologically active cells are important in
allergy, their relationship to cancer have also been studied.
Circulating IgE levels were found to be depressed in cancer patients
(Jacobs et.al., 1972). Rosenbaum and Dwyer (1977) reported on the
involvement of IgE and its related pharmacologically active cells in
cancer. Although the overall data remained confusing, they concluded
that IgE and pharmacologically active cells could be important in
tumor growth inhibition and therefore deserved more attention from
researchers.
5.4 Conclusion
In general, the study of tumor-nonspecific cellular immunity has
been overshadowed by the study of T cells and antitumor antibodies.
However, considerable data has been produced indicating the importance
of macrophages in tumor growth inhibition. Reports of the other cell
types including PMN, remain relatively scarce and their relationship
to cancer still remains to be clarified.
6. EFFECTS OF IMIUNOSTIMULANTS IN CANCER
It is arguable that one of the most practical benefits in tumor
immunology has accrued from the study of immunostimulants. Not only have
they been found to prevent or inhibit immunogenic experimental tumors
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(reviewed by Bast and Rapp, 1976), but encouraging results have also
been obtained in certain spontaneous experimental tumors and human
cancer (reviewed by Mastrangelo et. al., 1976; and Baldwin, 1978).
Many parameters have been found to influence the effect of immuno-
stimulants; these include : their mode of preparation, schedule of
application, route of injection and dose. Overall optimal conditions
for the application of any particular immunostimulant have not been
obtained since their efficacy varies according to the tumor-system
or experimental animal used. However, with respect to spontaneous
tumors, the most effective results have been obtained when the immuno¬
stimulant has been either injected together with the tumor cells or
injected into an already established tumor (Baldwin, 1978).
Among the immunostimulants used to date have been Coryne-
bacterium parvum (C. parvum), Bacillus Calmette Guerin (BCG), methanol
extraction residue of tubercle bacillus (HER), Staphylococcus aureus
and Bordetella pertusis. There are indications that in certain cases
the mode of anti-tumor action of these immunostimulants is macrophage
mediated and is independent of T cells.
6.1 Corynebacterium parvum in experimental animals
In 1966, Woodruff and Boak demonstrated that the growth of a
mammary adenocarcinoma tumor was inhibited when C.parvum was injected
iv on days 8 and 12 after tumor-cell injection. Since then the effects
of C. parvum on tumor growth in experimental animals have been widely
studied and its effects on cancer patients examined. These studies
have, in general,confirmed the inhibitory effects of C. parvum on
experimental tumors and have suggested its therapeutic benefits in
cancer patients whose tumors have been treated ;^ith surgery, chemotherapy
and/or irradiation.
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Sorne of the recent work on C. parvum included a study carried
out by Pimm and Baldwin (1977) on the therapeutic effects of C. parvum
in various rat tumors. The best therapeutic effect was obtained when
C. parvum was injected SC together with the tumor cells. In some cases,
the latter treatment not only prevented the growth of the tumor, but also
evoked concomitant immunity against tumor cells injected at the same
time into another part of the animal. Macrophage depletion with silica
was found to abrogate the preventive action of C.parvum. Similarly,
results obtained by Likhite (1974a) had shown that C. parvum was most
effective in Fischer rats when injected into growing subcutaneous
tumors. The inhibited tumors were found to be infiltrated mainly by
macrophages. Moreover, rats which have rejected their tumors, acquired
permanent specific immunity against the syngeneic tumors.
The tumor-inhibitory action of C. parvum has not been consistent
because, as mentioned above, its effectiveness depended upon the tumor
system or the experimental animal used. For example, successful
inhibition of tumor growth by the injection of C. parvum via a certain
route and at a certain time in one animal system did not necessarily
imply that the result would be reproduced in another animal system. Indeed,
contradictory results might be obtained in different animal systems.
In one study, the administration of C, parvum was found to lead to
immunological enhancement of leukaemia L120 in allogeneic mice (Herd
and Mitchell, 1976). This enhancement was again found to be macrophage
mediated, as the reduction of macrophages caused the reversal of tumor
growth. Moreover, complement-dependent cytotoxic antibodies were found
to be appreciably suppressed in mice pretreated with C. parvum. In
another study, the antitumor affect of C. parvum was found to differ
markedly depending on the route of its injection and the anatomical
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location of the tumor (Conley and Remington, 1978). Iv or ip C. parvum
treatment failed to protect mice against ependyblastoma injected
intracerebrally or subcutaneously, but protected the mice against
tumor-cells injected intraperitoneally.
Attempts have been made to study the serological effects of
C, parvum treatment. James et.al. (1976) demonstrated that C. parvum
injection into normal and tumor bearing mice resulted in the increase of
certain immunoglobulin levels, especially IgG2b. The latter was found
to be dependent upon the dose of C. parvum and its route of injection.
Moreover, these serological changes were suppressed by the administration
of gold salts which are known to inhibit macrophage function. The increase
in immunoglobulin levels by C, parvum treatment was found to be rather
nonspecific and, in some instances, very heterogenous (James et. al. 1977a)•
There is substantial evidence to suggest that C. parvum exerts
its effect by stimulating macrophages (James et. al. 1976 and Pimm and
Baldwin, 1977). However, the involvement of T cells, B cells and mast
cells cannot be ruled out (James et.al., 1977b; and Likhite, 1974a).
6.2. C. parvum in cancer patients
Progress towards the application of C♦ parvum in cancer has been
hindered by the lack of controlled studies and by contradictory results
obtained with the animal model, where in some cases C. parvum was found
to enhance tumor growth. Nevertheless, the therapeutic significance
of C. parvum has been indicated in some of the trials that have been
carried out.
Israel (1976) studied the therapeutic effects of C. parvum in
patients v/ith various types of cancer including disseminated breast
cancer, disseminated epidermoid bronchogenic carcinoma, and oat cell
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bronchogenic carcinoma. In the majority of cases, C. parvum administration
was found to act synergistically with chemotherapy, resulting in improved
prognosis. Although C. parvum treated and nontreated patients received
the same overall dosage of drugs, those on immunotherapy were able to
receive the drugs less frequently but at a higher dose each time.
Consequently, it was not possible to conclude whether the improved prognosis
was due to the latter differences in chemotherapy regimes or to immunological
effects.
I
James et.-al, (1975) studied the serological changes in cancer patients
treated with C. parvum, where an overall increase of immunoglobulin levels,
especially IgG, was obtained. It was postulated that the administration
of C. parvum could inhibit the action of blocking antibodies by enhancing
the production of complement-fixing antibodies.
Hirshaut et. al. (1976) attempted to evaluate the immunological
capacity of C. parvum by investigating its route of injection, dose, schedule
and toxicity. Their preliminary results showed that subcutaneous C. parvum
administration was the least toxic.
The mechanisms behind C. parvum action in cancer are still far from
clear. However, as in the animal model, the beneficial role of macrophages
is suspected. It is thought that C. parvum could activate macrophages which
would recognize cells that have lost their contact inhibition properties
(Israel, 1976). Further support for the involvement of macrophages, as
well as cytotoxic antibodies, is indicated by the results of Biran et. al.
(1976) which show that C. parvum administration results in increased
complement consumption. Moreover, C. oaryum might decrease drug metabolism
thus modifying the functions of chemotherapy (Soyka et. al. 1975) The
enhancement or inhibition of chemotherapy by the latter cmld depend on the
time of C. parvum administration.
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6.3 Bacillus Calmette Guerin
With respect to BCG, considerable advance has been made in
immunotherapeutic research. Its effects in cancer patients have
been thoroughly investigated where BCG, either alone or with chemo¬
therapy, was found to produce improved prognosis (Mastrangelo et. al
1976).
The immunotherapeutic effects of BCG have been observed in
experimental tumors (Bast and Rapp, 1976). Like C. parvum, the
action of BCG has been found to vary with the experimental tumor system
used, which has hindered efforts to determine the optimal conditions
for its administration. In some spontaneous tumors, however,
optimal results with BCG have been obtained when it was administered
together with the tumor cells (contact therapy) (Baldwin et. al. 1976).
An intact immune system was not found to be necessary in order
for the BCG to exert this effect, as similar results were obtained
in nude mice. The therapeutic effects of contact therapy with BCG
were also demonstrated by Sparks et. al. (1974). Preoperative intra-
tumor injection of BCG or its postoperative SC injection was found to
improve the prognosis of tumor bearing mice, and in some cases, even
cure them.
There are indications that the mechanisms of anti-tumor action
of BCG are similar to those of C. parvum. Boyle et. al. (1976)
detected complement dependent cytotoxic anti-tumor antibodies in the
sera of guinea pigs cured of their tumors by BCG treatment. Preston
et. al. (1971) found that in vitro stimulation of lymphocytes with
tuberculin resulted in the production of macrophage aggregating or
migration inhibiting factors. It is therefore assumed that BCG functions
-46-
by stimulating lymphocytes which then activate macrophages or enhance
the production of cytotoxic anti-tumor antibodies through lymphoKines
and B cell - T cell cooperation respectively.
Many trials have been carried out with BCG in cancer patients where
some encouraging results have been obtained. One such trial was conducted
by Torisu et. al. (1976) who studied the effects of active immunotherapy
with living BCG in 98 cancer patients with various types of cancer.
A strong correlation was found between intradermal BCG administration and
improved prognosis. Moreover, their results supported an immunological
basis for the latter, as the effectiveness of BCG was found to be
related to immune-responsiveness. Immunocompetent patients -were found
to respond much better to BCG therapy than patients with suppressed immunity.
The effectiveness of BCG therapy was also demonstrated by Gutterman
et. al. (1976) in patients with malignant melanoma, colorectal carcinoma,
and disseminated breast cancer. BCG administration by scarification was
found to improve survival in melanoma patients when applied alone, and in
patients with breast cancer and colorectal carcinoma when applied with
chemotherapy. However, the significance of the results obtained in this
study was limited by the fact that controls consisted of historical cases.
In another study, postoperative lung cancer patients treated with intra¬
pleural BCG exhibited improved recovery (McKneally et. al., 1976).
However, this effectiveness of BCG was found to be limited to patients who
have had a limited tumor burden. Cn the other hand, no positive effects
of BCG were obtained in a study carried out by Pinsky et. al. (1976) on
patients with stage II melanoma. This result was explained by some as
being due to improper application of BCG vis a vis the amount administered
and its anatomical location.
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In conclusion, it can be said that the fulfilment : of the
following requirements might lead to a better response to BCG therapy
(Bast et. al. 1974):
a - the injection of the proper number of organisms
b - the utilization of the proper substrain
c - the achievement of close proximity with tumor cells
d - the ability of the host to develop an immune response
to tumor antigens.
6.4 Other inununostimulants
Some of the other immunostimulants that were studied include
MER, S.aureus, statolon, and B. pertusis. Weiss et. al. (1976) studied
the effect of the MER fraction of tubercle bacilli on the in vitro
cytotoxicity of the RES against neoplastic cells. The ip injection of
MER into mice onpe or twice before the injection of turner cells was found
to stimulate the lymphoid cells both specifically and nonspecifically
against the tumor cells. It was postulated that there was more to the
mechanism of the stimulation than just an occasional cross-reactivity
between MER and the tumor cells, or the destruction of tumor cells as
bystanders. In an extension of these studies, results by Kedar et. al
(1978) demonstrated similar effects of MER when administered to lymphoid
cells in vitro. However, as occasionally obtained in the in vivo
experiment, this effect was found to be dose dependent since higher
quantities of KER produced suppression of lymphoid cells. Fractionation
studies showed that cells stimulated by MER belonged to the non-adherent
cell population.
Chirigos and Theodore (1976) studied the effect of S. aureus
membranes (SAM) on leukaemia in mice. The id administration of SAM after
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the initiation of chemotherapy was found to markedly improve the
recovery of the mice. SAM application was thought to reverse the
immunosuppression caused by chemotherapy and thus enable the immune
system to eradicate the residual tumor cells. The interesting result
obtained in this study was that the effects of SAM were independent of
the dose used or its time of administration.
The immunostimulatory effects of double stranded RNA (dsRNA)
obtained from statolon, which is a lyophilized medium from cultures
of mycophage infected P. stoloniferum, was studied by Marx and Wheelock
(1976). Leukemogenesis was suppressed in 50% of mice treated with the
dsRNA iv on day 3 after Friend Leukaemia virus injection.
A study by Likhite (1974b) showed that the SC injection of
killed B. pertusis mixed with tumor cells produced a specific and a
lasting rejection of tumor growth. Ip injection of the killed organisms
either alone or mixed with killed tumor cells conferred no such
protection on the mice.
6.5 Conclusion
The therapeutic implications of immunostimulants in cancer appear
to be promising. Considerable evidence suggests an immunological basis
for the anti-tumor function of these immunostimulants, which if understood
could lead to the cure and even the prevention of cancer. Therefore,
consistent research on the mechanisms of action of the above mentioned
and other immunostimulants seems to be warranted.
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7. PROSPECTS OF TUI-iOR IMMUNOLOGY
It is apparent from what has been mentioned so far that considerable
data has been produced over the past two decades to justify continued research
in tumor immunology. The association of host cells and anti-tumor antibodies
with tumor growth has been proved and the influence of immunostimulants on
this association has been demonstrated. Further research ought to be carried
out in order to obtain a greater understanding of this tumor-host association.
Moreover, methods have to be devised in order to utilize tumor-growth
suppressor host cells and antibodies, and eliminate tumor-growth enhancer
host cells and antibodies. It is arguable that research in tumor immunology
will contribute a great deal towards not only the ultimate prevention
and control of tumor growth, but also towards a greater comprehension of
normal and pathological immune mechanisms. In the near future, however, two
main avenues appear to be open for the practical application of tumor immunology;
namely, immuno-diagnosis and immunotherapy.
7.1 Tumor immunodiagnosis
The aim of tumor immunodiagnosis has been the utilization of cellular
and humoral anti-tumor immunity for the early detection of tumor growth and
for the assessment of post-operative and post-chemotherapy prognosis.
Preliminary work in immunodiagnosis involved the use of in vitro cell-
mediated cytotoxicity in the evaluation of patients' cell-mediated immunity
against the tumor. However, progress in the latter was hampered by the
inconsistent and nonspecific behaviour of lymphocytes against tumor cells
in vitro. Moreover, this was further complicated by the fact that the anti¬
genic expression of a particular tumor differed according to whether it was
obtained from a short term cultured, long term cultured, or an in vivo grown
tumor. It became clear, therefore, that for greater specificity in cancer
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immunodiagnosis, a technique had to be devised which could assess the reactivity
of host cells against tumor antigens. The latter could be extracted and stored,
and thus supply a source of constant antigenicity.
Extensive work is being conducted cn the characterization and utilization
of carcinoembryonic and alphafoetoprotein antigens (Shuster et. al. 1978).
Although the use of these two tumor-associated antigens is hindered by their
presence in the sera of some normal individuals, their purification and
identification could contribute appreciably to the early detection of tumor
growth. On the other hand, efforts are being made to extract antigens from the
surface of tumor cells and use them in tumor immunodiagnosis.
An assay that could specifically detect anti-tumor immunity has been
the leucocyte adherence inhibition (LAI) test (Maluish and Halliday, 1974;
and Marti and Thomson, 1976). It was based on the observations that normal
leucocytes adhere to glass and that this adherence is inhibited if sensitized
leucocytes are exposed to the autologous antigens. The LAI assay has been
declared by some investigators to be sufficiently sensitive to differentiate
between various tumors and to assess the progress of tumor growth (Rutherford
et. al. 1977; and Flores et. al., 1977). It was concluded by Flores et. al. (1977)
that the inhibition of leucocyte adherence was caused through cytophylic anti¬
tumor antibodies attached to the leucocytes. However, this should have been
supported by demonstrating consistent LAI of normal leucocytes to which anti¬
tumor IgG had been bound. Moreover, the effect of antibody elution from the
surface of sensitized leucocytes on LAI test was not investigated. Nevertheless,
the LAI has been considerably improved and the prospects for its continued use
in immunodiagnosis appear encouraging (Shuster et. al. 1978)•
Other methods for tumor immunodiagnosis have included skin sensitization
to iumor antigens. Char et. al. (1974) studied cutaneous delayed hypersensitivity
responses to a soluble melanoma antigen in thirty—two patients with ocular melanoma.
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It was found that this assay was capable of assisting in the diagnosis
of ocular melanoma. Kopersztych et. al. (1976) examined cell mediated
immunity in patients with carcinoma by using skin tests with ubiquitous
antigens, by determining the T & 3 cell numbers in peripheral blood and
by the response of lymphocytes to phytoheamaglutinin. By these three
criteria they were able to distinguish disseminated disease from
localized disease.
Anti-tumor antibodies have also been used in tumor immunodiagnosis
(Ting, 1976; and Terman et. al., 1975). However, efficient utilization
of this approach awaits the development of more refined techniques and
a greater understanding of the in vivo mechanisms of anti-tumor antibodies.
7.2 Tumor immunotherapy
Knowledge obtained from tumor immunology research can also be
practically applied in the field of cancer immunotherapy. Indeed, attempts
at immunotherapy in cancer have been made for many years. Although some
of these attempts have been successful, the practice of tumor immuno¬
therapy remains largely empirical.
The rationale behind tumor-immunotherapy has been the demonstration
of the existence of tumor antigens, the correlation of immunodefficiency
with poor prognosis, and the relative improvement of prognosis by
immunostimulation(Gutterman et. al. 1978). Tumor immunotherapy has consisted
of six approaches; namely; systemic active nonspecific immunotherapy;
systemic active specific immunotherapy; adoptive immunotherapy; passive
immunotherapy; local immunotherapy and combined immunotherapy (immuno¬
therapy plus surgery, chemotherapy and/or irradiation). Of these, loeal
and combined immunotherapy have been the most successful (especially
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TABLE 1 SOME POSSIBLE EFFECTS QE ANTI-TUMOR ANTIBODIES IN VIVO
A - OF ADVANTAGE TO THE HOST
1. Direct cytotoxic effect on tumor cells.
2. Coat tumor cells rendering them susceptible to phagocytosis
or K cell cytolysis.
3. Activation of the complement system resulting in the generation
of
a) Kinins and anaPhylatoxins which increase vascular
permeability and infiltration of PMN.
b) C3b and C4b which promote localization of various host
effector cells.
B - OF ADVANTAGE TO THE TUMOR
1. Coat tumor cells rendering them resistant to attack by macrophages,
K cells or antibody.
2. Modulate tumor antigens so rendering tumor less susceptible to
antibody or cell mediated lysis.
3. Interact with soluble tumor antigens to form soluble complexes
which inhibit attack by macrophages, K cells and T cells.
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when administered in conjunction with immunostimulants). Active immunotherapy
' by Vibrio cholera neuraminidase treated tumor cells was found to produce tumor
regression in mice when combined with surgery (Eios and Simmons, 1976).
Treatment of tumor-bearing mice with V. chdera neuraminidase treated cells
and BCG after chemotherapy was found to improve the survival of the mice
(Cantrell et. al. 1976). Progress of immunotherapy in human cancer has also
been noted in leukaemia and solid tumors (Freeman, 1978; and Gutterman et. al
1978). A potential goal of leukaemia-immunotherapy includes the in vitro
sensitization of lymphocytes obtained from patients in remission, with the
aim of reinjecting these cells to the same patients on relapse.
Carter (1976) outlined the difficulties encountered in immunotherapy
and expressed the dire need for meticulous classification of the cancer type
under study and the proper randomization of patients. Immunologists were
advised to follow the consecutive phases applied in the evaluation of new
drugs. These included an assessment of toxicity in phase I, a limited
examination of clinical activity in phase II, and, if relevant, a large scale
clinical investigation in phase III. Passive humoral immunotherapy was
discouraged because of fears of tumour growth enhancement.
In conclusion, it is agreed that the practical prospects of tumor
immunotherapy for the near future lie in the combined modality approach.
Extensive efforts are needed to evaluate the significance of the other above
mentioned approaches, as well as other immunotherapeutic modalities. The
latter include the utilization of transfer-factor, immune RNA, thymic hormones,
and the ultimate use of immunoprophylaxis with specific tumor antigens. Finally,
increased used of antitumor antibodies in cancer chemotherapy can be envisaged.
Such antibody-conjugated drugs have been shown to be more efficient in cc moating
tumors than antibody or drug alone (Ghose and Blair, 1978; and Hurwitz et. al. 1979)
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8. PURPOSE OF STUDY
As stated previously, extensive research on tumor bearing
animals and cancer patients has shown that circulating anti-tumor
antibodies behave in two ways. On the one hand, circulating anti¬
tumor antibodies have been found to produce in vitro and in vivo
blocking of anti-tumor action of host cells (Tamerius et. al. 1975;
Harris et. al. 1973; and Heidrick et. al. 1978), and on the other hand,
they have been found to mediate or assist the anti-tumor action of host
cells (Johnson et. al., 1977 a & b; and Miller and Feldman, 1977).
The extent to which each class or subclass of anti-tumor antibodies
contributed to tumor growth enhancement or inhibition varied with the
animal strain, type of tumor, and the extent of tumor growth. Moreover,
the quality and quantity of anti-tumor antibodies has been shown to be
influenced by various treatments such as BCG or C. parvum administration
(James et. al., 1975, 1975 and 1977a; and Boyle et. al., 1973), and T-cell
deprivation (James et. al., 1977b). The extensive work on circulating
anti-tumor antibodies revealed their importance in the tumor-host relation¬
ship and paved the way for further studies, especially in the use of these
antibodies in chemotherapy and diagnosis. The bisided effects of anti¬
bodies in tumor-bearing hosts are summarized in Table 1.
Although research on circulating anti-tumor antibodies is continuing,
appreciable attention has lately been diverted towards the study of in situ
tumor associated immunoglobulins (TAIgs). It was realized that the study
of TAIgs would result in a greater understanding of the role of anti-tumor
antibodies in vivo. Initial studies on TAIgs were concentrated almost
entirely on experimental ascitic tumors, principally because of the
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relative ease by which these cells could be recovered from the anima]
host. These studies showed that TAIgs existed on the surface of in vivo
grown tumor cells and that the quantity and quality of these TAIgs varied
with the type of tumor, age of the tumor, and the immunological state of
the host (Witz, 1977). Similar studies on solid tumors were less frequent
because relevant assays to recover the tumor cells and examine their TAIg
content were not available.
In view of the significant role that in situ TAIgs might play in
solid tumors, it was the purpose of this study to develop sensitive techniques
for the detection of TAIgs in solid tumors and its utilization in various
studies on in vivo bound TAIgs. The latter were to include the following :
a - a comparison of TAIg binding in different types of tumors
b - a study of the kinetics of TAIg binding.
c - an assessment of the influence of C. parvura on the quantity
and quality of TAIg
d - an examination of the mechanisms involved in TAIg binding.
9. APPROACH USED
9.1 Development of an indirect radio-immune-antiglobulin test (RIAT)
An indirect radio-immune-antiglobulin test which had been used for
the study of circulating anti-tumor antibodies in this laboratory, was
modified and adopted for the study of TAIgs on freshly excised tumor
cells. It consisted of the following steps: incubating the tumor cells
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prepared from a freshly excised tumor with rabbit-anti mouse
immunoglobulin, in the wells of a plastic plate for an hour; washing the
125
cells several times with 5-10% FCS ; incubating the cells with I-
goat-anti-rabbit IgG; washing the cells again for several times,
and determining the counts.
One of the difficulties which had to be overcome was the pre¬
paration of tumor-cell suspensions without the use of enzymes, since the
latter were known to remove surface bound immunoglobulins. This "was
achieved by the mechanical preparation of tumor cells which involved
gently teasing tumor pieces with a pair of sterile syringe needles. Although
the viability of tumor cells prepared in this manner was low, the physical
shape of the cells remained intact and later studies showed that the presence
of surface bound TAIgs bore no relationship to the viability of the cells.
Another factor which had to be considered was the possible elution
of TAIgs from the surface of tumor cells. This was avoided by performing
the assay immediately after tumor excision, and at a temperature of between
0 to 4 degrees centigrade.
Nonspecific binding of reagents to plastic was a third problem which
had to be solved before the optimum conditions of the assay could be determined.
A series of precoating experiments showed that foetal calf serum was most
suitable for inhibiting the nonspecific binding to plastic, though this
could not be prevented entirely.
Binding of reagents to tumor cells had been found to vary positively
with reagent concentration and incubation time (Sparks et. al., 1969
Burdick et. al., 1973; and Brown et. al. 1977). Although an optimum
incubation time could not be obtained, 80% of the reagent was shown to bind
within one hour of incubation. Similarly, reagent binding in our assay
was found to vary positively with reagent concentration and incubation time.
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The indirect plate method proved to be sufficiently sensitive to
detect TAIgs on freshly excised cells. However, it was decided to
develop a tube method which could facilitate the technical aspect of
the assay and improve its specificity. Therefore, a series of comparative
experiments between the plate and tube methods were conducted. Similar
results were obtained by both methods; however, the tube method was
chosen for the application of the indirect RIAT because of its technical
feasibility,
9.2 Application of the indirect RIAT
9.2.1 The response to CCKl in nontreated and C. parvum treated mice;
Preliminary studies on TAI and its in vivo kinetics were carried out on
a chemically induced tumor (CCHl) which was known to be strongly immuno¬
genic (James et. al., 1979). The variation of in vivo TAIg binding
with age and size of CCHl tumors was studied. Moreover, since C. parvum
had been found to influence the humoral immune response of tumor bearing
animals, its effect on in vivo TAIg binding to CCHl tumors was also studied.
9.2.2 The response to T3 in nontreated and C. parvum treated mice: In order
to determine whether or not in vivo TAIg binding depended on the 'type
of tumor, the response to T3 ( a less immunogenic tumor than CCHl;
was studied. The variation of in vivo TAIg binding with age and size
of T3 tumors was examined, and the influence of C. parvun on this
variation was evaluated.
9.2.3 The response to CCHl and T3 tumors: Although the response to
T3 tumors was found to be weaker than the response observed against CCHl
tumors, further experiments were conducted in order to evaluate the
significance of this difference in response. Hence, the variation of
in vivo TAIg binding with age and size of both tumors were examined
simultaneously.
9.2.4 The response to CCK1 excised and cultured tumor cells : There
have been reports of different immunological responses to tumors induced
by freshly excised and cultured tumor cells (Moore, 1977; Pross et. al., 1976
and James et. al. 1979). In order to determine whether the two forms of
tumor cells would elicit different in vivo TAIg binding, the response to
CCKl excised and cultured tumor cells was compared.
9.2.5 The response to different doses of CCHl tumor cells, and to
pronase prepared versus mechanically prepared CCHl tumor cells : During
the preliminary studies, it was observed that in vivo TAIg binding in
nontreated tumor-bearing mice tended to increase with size of tumors.
Consequently, the response to different doses of tumor cells was compared
in order to determine whether TAIg binding was related to the size of
tumors. Moreover, in order to evaluate further the kinetics of TAIg
binding, the response to pronase prepared cells and mechanically prepared
cells was compared. It was known that the two forms of tumor cells would
differ in their host cell content and thus could elicit different responses.
9.3 Development of the direct RIAT
The indirect RIAT, though able to detect differences in in vivo
TAIg binding among various tumors, lacked sufficient sensitivity and was
laborious. Therefore, a direct RIAT was developed which could provide a
better assessment of the kinetics of TAIg binding and its in vivo mechanisms.
The parameters which were specified in section 9.1, were again
examined for the development cf the direct RIAT. Similar to the indirect
RIAT, reagent binding to tumor cells in the direct RIAT was found to vary
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airectly with reagent concentration, incubation time, and number
of tumor cells. The specificity of the RAIIIg binding to tumor cells and its
binding to the latter via its Fc-portion were also assessed.
9.4 The application of the direct RIAT
9.4.1 The response to various types of tumor cells: In order to
confirm earlier results obtained by the indirect RIAT, comparative
studies between CCHl and T3 tumors and between CCH.1 excised and
cultured tumor cells were repeated. The differences observed between
these tumors using the indirect method were again noted using the
direct RIAT.
9.4.2 The response to tumor cells injected into opposite limbs in
the same mouse: Tumors grown on opposite limbs of the same mouse were
compared in order to establish whether the response observed in
different mice would be reproduced in the same mouse. The different
responses to different types of tumors noted previously were again
observed in the same mouse.
9.4.3 The influence of C. parvum on the response to CCI-I tumors:
Additional studies were carried out to examine the effect of C. parvum
on the in vivo TAIg binding to CCHl tumor cells. While ip injection
of C. parvum on day 3 after tumor cell injection was found to increase
TAIg binding, no effects were observed when C.parvum was injected SC
on day 3, or intratumor on day 8 after tumor cell injection. It should
be mentioned, however, that the former experiment was conducted on
tumors grown in different mice, while the latter two experiments were
conducted on tumors grown in the same mouse.
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9.5 Subclass studies
The studies mentioned above provided a quantitative assessment
of TAIg in solid tumors. However, a more thorough understanding of TAIgs
in solid tumors required a qualitative assessment of the surface bound
TAIgs. This was deemed to be necessary especially when it was noted that
C, parvum treated tumors, although smaller in size than nontreated tumors,
possessed higher quantities of TAIgs. It was postulated that the latter
two types of tumors could differ in their quality of TAIg in addition
to their observed quantity differences. Preliminary studies were initiated
to study cell-surface bound IgGl, IgG2a, IgG2b, IgG3, IgA and IgM, in
C.parvum treated and nontreated CCK1 tumors.
9.6 Studies on the mechanism of in vivo TAIg binding
Finally, an investigation was made into the mechanism of TAIg
binding. The studies included the effects of T-cell deprivation
(in thymectomized mice and nude mice), whole body irradiation, and
gold salts administration. Antibody responses in B mice have been shown
to be considerably reduced (Haskill et. al., 1977). Sublethal irradiation
of mice has been found to reduce the in vivo coating of tumor cells
(Dorval et. al., 1976). Similarly, administration of gold salts have
been observed to influence serological changes in tumor bearing mice
(James et. al., 1976).
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H ATERIALS AND Li E T H 0 D S
1. ANIMALS
a) MICE
Male and female mice, 3-12 weeks old, of the inbred C3A strain
were used. They were bred in our department from stock mice originally
obtained from the MRC Laboratory Animal Centre, Carshalton, England.
The mice were housed in plastic boxes (5-10 a box) lined with 'wood
shavings. A constant temperature of 22°C was maintained in the room
with a continuous air exchange to ensure adequate ventilation. Mice
were fed with mouse cake ad libitum (McGregor & Co (Leith) Ltd.,
Edinburgh).
Nude mice and their litter-mates were obtained from Moredun
Institute, Edinburgh and maintained in germ free conditions. Details
on the precise origin of these mice was not available but some of then had
recently been mated with CBA mice.
B mice consisted of thymec tomized and X-irradiated CBA mice.
They were thymectomised at the age of 4-6 weeks, followed ten days later
by whole body X-irradiation (850 rad) with thorax shielding. The mice
were then allowed to recover over a period of several weeks. Controls
included non-treated aid sham-thymectomized mice. T cell deprivation was
assessed by the visual examination of the absence of the thymus and by
the antibody response to SRBC.
b) RABBITS
Adult New feland white female rabbits were used. They were kept




They were maintained under standard conditions at the University
Centre for Laboratory Animals (The Bush, Willow Bridge, Midlothian)
2. TISSUE CULTURE
CCHl 21 tissue culture cells were maintained in RPMI-1640 medium
buffered with 20mM HEPES and supplemented with 10% heat-inactivated foetal
calf serum (FCS), 2 ml glutamine, lOOu/ml penicillin and 100 Mg/ml
streptomycin.
The CCrP- tumor cells were originally induced in 8-10 week old CBA
mice in our laboratory by the intramuscular (IM) injection of methyl-
cholanthrene (0.5 mg) in trioctanoin(0.2 ml). They were propagated
in vivo by SO injection into the limbs of mice and in vitro by tissue
culture. Their passage number varied from 21-27. T3 tumors have been
obtained after injection of CBA mice with syngeneic embryo cells which
had undergone spontaneous transformation in vitro. Information regarding
the immunogenicity and TD50 a the tumor cells is listed in table 2.
3. TUMOR CELL PREPARATION FOR in vivo TUMOR PROPAGATION
Tumor growth v/as produced by transplanting 1 x 10° tumor cells SO
into the limbs of syngeneic mice. The tumor cells used were obtained
in the following manner
A tumor v/as asceptically excised and put in a sterile universal tube
containing a few mis. of Dulbo;co saline placed on ice. After cutting
the tumor into small pieces using a pair of sterile syringe needles,
it was ir abated with 10 mis of prona.se (pH 7,2, 2.5 mg/ml in Dulbecco
RpIH buffer) at 37og for y2 hour with occasional gentle shaking. The
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supernatant was decanted, the tumor further cut into smaller pieces
and reincubated with 10 mis pronase, 0.5 ml DNA ase (20%^) Sir 5
V
minutes with occasional shaking. The cellular suspension was then
collected in another sterile universal tube through a sterile metal
gauze screen filter and left on ice. The process of incubation and
the collection of the cellular suspension was repeated twice or
more, depending on the number of cells required. The cells were then
washed three times with Dulbecco saline (224 g, 7.5 min.; MSE, England),
6
counted, and diluted to 1 x 10 cells/ml.
4. TUMOR CELL PREPARATION FOR THE ANTIGLOBULIN ASSAY
On the day of the test, 3-5 mice/group were sacrificed by ether
inhalation. Their tumor sizes were measured(average of 2 perpendicular
diameters), excised, and collected in universal tubes containing Dulbecco
saline. The tumors were then cut into smaller pieces using a pair of
sterile syringe needles and slowly stirred in a beaker containing
complete RPMI for about 10 min. The supernatant was then transferred
into a test tube and the debris allowed to settle. The clear cellular
suspension was then transferred by a pasteur pipette into a universal
centrifuge tube, washed three times with Dulbecco saline (224 g, 7.5 min.;
MSE, England), resuspended in 1 ml complete RPMI, counted and diluted to
5 x 105 cells/ml. The viability of the cells, as assessed by trypan blue
dye exclusion, varied from 10-50% with no apparent change in the morphology
of dead cells. 31ood was also collected from the mice and the sera
o o
separated and stored at -20 C. All procedures were carried out at 4 C.
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5. ■ ANTISERA
a') RAB3IT-AHTI-MOUSE EMUNOGLOEULIN (RAM-Ig)
(1) RAM—Ig^j : This antiserum was used in the initial experiments
for the development of the indirect radioimmune-antiglobulin test
(RIAT). It was prepared by the IM injection of mouse IgG (lmg/ml)
plus 1 ml of freund's complete adjuvant (FCA) into rabbits on day 0,
followed by a similar injection on day 22 and a third intra¬
peritoneal (IP) injection with alum on day 42. 50 ml bleeds were
obtained when required from day 50 onwards, the final bleed being
on day 125. The mouse IgG used had been obtained by precipitating
7g fraction of normal mouse serum twice with 28% Na^SO^, dissolving
in lOmM P0^ buffer (PH 7.9), and then dialyzing overnight against
PBS.
(2) RAM-Ig^ : This antiserum was used in the remaining indirect
RIAT assays and was obtained as follows: On day 0, 5 ml of
rabbit blood was collected ana the erythrocytes (R3C) separated
O
and washed three times with PBS. 3.0 x 10° RBC were injected ip
into 12 CBA mice. Six mice were sacrificed on day 6 and bled out.
The serum was separated and inactivated by incubation at 56°C for
30 mins. The pooled serum from the 6 mice was incubated for 30 mins
v/ith freshly prepared rabbit RBC at 37°C (approximately 3 ml of
serum with 1 ml packed RBC). The RBC's were then washed, mixed
with 1 ml FCA and injected back to the rabbits IP (for anti-IgM
response). The same procedure as day 6 was carried out on day 12
on the remaining 6 mice (for anti-I# response). Six more mice were
injected with fresh RBC on day 21 and on day 28 the same procedure
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as day 6 was again carried out (for boosting). On day 60, the
rabbits were bled out after the presence of an adequate anti-mouse
Ig response had been confirmed by immunoelectrophoretic and gel
diffusion plates.
(3) RAM-Ig^gj : This antiserum was purchased from Dako-Patts, Denmark
and was used in the direct RIAT.
(4) RAM-IgG^, G2a, G2b, G^, A and M were purchased from Bionetics,
Kensington, Md.
(b) NORMAL RABBIT SERUM (NRS)
(1) NRS^^: The normal rabbit serum, used in the initial experiments
with the indirect RIAT, was a prebleed from the rabbit in which the
RAH—Ig(^) was raised-
(2) MRS2^ : Likewise this NRS was a prebleed from the rabbits in which
the RAM-Ig^2^ was raised.
(c) GOAT-ANTI-RABBIT Ig (GAR-Ig)
(1) GAR—Ig^^ : GAR-Ig^j had been prepared earlier by injecting goat
v/ith HOrng of a rabbit IgG preparation in complete FCA once a month
for a total of 4 consecutive months, followed by a fifth injection
given 2 months after the fourth. The rabbit IgG had been prepared
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by the Batch chromatography on DEAE 52 cellulose of 50 ml of MRS.
The goat bleeds were pooled and the IgG prepared by NagSO salt
precipitation and Batch DEAE 52 separation. The final concentration
was 1 gram per cent.
(2) GAR-Ig^ : This antirabbit antiserum consisted of acid-eluted
GAR-Ig prepared by the following: lg of gel (Sepharose, Pharmacia
Fine Chemicals, England) was swollen for 15 minutes at room temperature
in 20Cml of 0.00111 Hcl, filtered through a sintered glass filter and
washed with the same amount of 0.001M Hcl. Rabbit IgG (lOmg/gel) was
dissolved in 0.1M borate buffer containing 1M MaCl, PH 8, added to
the gel and the contents mixed by slow stirring for 2 hours at RT.
The unbound protein was removed by washing the gel on a sintered glass
filter with the borate buffer. The remaining active groups on the gel
was blocked by reacting for 2 hours wiih 1M ethanolamine at PH 8,
(approximately 2 gel volumes of ethanolamine were used and the gel
was stirred slowly throughout the blocking procedure). The gel was
then washed in turn with 0.1M acetate buffer PH 4 containing 1M NaCl
and 0.1M borate buffer PH 8 containing 1M NaCl and poured into a 10ml
syringe barrel. The GAR antiserum was dialyzed against the borate
buffer and applied to the column at 4°C and allowed to remain in contact
with it for at least Vz hour. The unbound protein was eluted with the
above borate by washing with 2 or more column volumes. The specifically
absorbed antibody was eluted with 0.2M glycine HCL buffer, PH 2.8,
containing 0.5M NaCl. The PH of the effluent was adjusted to 7 by
collecting 3 ml fractions in 1 ml of 2M Tris HC1 buffer, PH 7.8.
The protein containing fractions were pooled, dialyzed and concentrated.
The strengths and concentrations of the GAR-Ig thus prepared are listed
in Table 3.
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TABLE 3 THE STRENGTHS AND CONCENTRATIONS OF
THE GAR Is; ACID ELUATES
Source Final conc. Strength
GAR Ig
A/S 2/4 0.43 g % Fairly strong
line to 1:8
Dil NRS + NRIgG
As above 0.32 g % V4 dil
GAR Ig
prep. 238
0.42 0/g /O 1/8 dil
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(3) Swine anti-rabbit Ig was purchased from DAKO immunoglobulins, Denmark.
6. IODINATION
RAM-Ig^ : To 0.5ml-lml of the protein (6mg/ml), 100 jal of 0.5M
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phosphate buffer, PH7.6 was added followed by ImCi of I (Amersham,
England), and 100jil of chloramine-T (BDH, England), with the amount
of Chloramine-T being ^5 that of the protein. After 2 minutes stirring,
the reaction was halted by the gentle addition of 100 jul of Na,-,S„0_2 2 d
(BDH, England) with the amount of Na„S 0 being twice that of the
2 2 5
Chlor. T. The labelled protein was then passed through Sephadex-G25
(column dimensions: 15 cm long of approx 1.5 cm diameter), (Pharmacia
Fine Chemicals, England), and collected in glass tubes in 3ml amounts.
4 ji1 amounts from each of the latter tubes were counted and the tubes
correlating with the first peak utilized. The protein solution v/as
ultracentrifuged (76,000 g, 4°C, 1 hour. MSE, England), diluted to the
desired concentration and stabilized with BSA, lOmg/ml (Miles Laboratories,
USA), prior to being aliquoted and stored at -20°C.
GAR—Ig : The same method as that of the RAM-Ig^. iadination v/as used
except that in some cases, the unbound iodine v/as removed by dialysis
as follows: the labelled protein v/as transferred to a dialysis tube
placed in a beaker containing 20ml 10% KI and 1 litre PES, and left
stirring at 4°C for 72 hours during which the beaker contents were
twice replaced with PBS buffer.
Before use, lml amounts of all antisera were always preabsorbed
6 o
with 20-40 x 10 CCH1 and/or T^ cells (4 C, 1-2 hours), ultra-
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centrifuged (76,000 g, 1 hour, 4°C, USE, England), and stored in
aliquots at -20°C.
51 5
Cr LABELLING OF THE CELLS : To 5 x 10 cells/ml in Dulbecco saline
51
2.5mCi of Cr was added (Amersham, England). The cellular suspension
/ ■—'
was incubated at 37°C for /£ hour shaking gently every 5 minutes. The
cells were then washed three times with 20 ml 5% FCS-Dulbecco, the
cells being recovered each time by centrifugation at 224 g, 4°C for
5 minutes, (USE, England). The cells were left at 4°C for Vz hour to
allow release of isotope from the cells, which were then again washed
twice as above and resuspended into original volume in Dulbecco saline.
7. PREPARATION AND I0DINATI0N OF IMMUNE RAM—Ie
• i ■ i — ■ ■ ■ ■ ... ■■ , -ii — .I.II—i ■ — ■ — — HiJ
Mouse Ig was prepared by precipitation with (NH4)2S04. After dialysis
against coupling buffer, it was conjugated to CNBr activated sepharose
(around 23 mg/g). 10 mis of RAM Ig(2) was applied to the sepharose column
and unbound protein washed off with PBS. The specific antibody was acid
eluted into the PBS buffer at PR 8.0. Approximately 5 mg of antibody was
recovered. This was concentrated by vacuum dialysis to around 7S0 jugm/ml
in saline and then aliquoted in 1 ml amounts.
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1 ml of this reagent was iodinated with 1 mCi I using standard
conditions. After purification on G-25 followed by ultracentrifugation in
order to remove aggregates, the regant was diluted to 10jugm/ml in complete
RPMI containing 10 mg/ml BSA at PH 7.2.
NRS Ig was iodinated under identical conditions. It was observed
that the antibody iodinated less readily than the normal IgG. The concentration
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of each reagent was measured by single radial immunodiffusion after
separation from free iodine by gel filtration. The concentration of
each was found to be approximately the same.
8. THE INDIRECT PLATS RIAT
0
freshly excised or cultured tumor cells (5 x 10 /ml) were distributed
in a plastic plate (Sterlin, Middlesex, England). 100/jal/well and centrifuged
for 8 minutes at 224 g {MSE, England). 50 jal/well of RAM or NRS (1 jug/well)
were added, left on ice for half an hour and the cells then washed three
times with 10% FCS-MEM, being recovered after each washing by centrifugation
— "I Qp-
at 224 g for 2 minutes at 4 C (MSE, England). 50 jal of I-GAR (10 jug/well)
was then added and the plate incubated at 4°C for another Vz hour. The cells
were then washed three times with 5-10% FCS-PBS and transferred into a new
plastic plate and left to dry overnight. The next day, the plate was cut
into individual wells and counted. Individual tumors were tested in triple
or quadruple wells.
9. THE INDIRECT TUBE RIAT
5
100 jal of freshly excised or cultured tumor cells (5 x 10 /ml) were
distributed in polyesterone tubes (Sterilin, U.K.) whichfed been precoated
with 5% FCS by incubation overnight at 4°C, mixed with an equal volume of
RAM (1 /ig/100 jal) or NRS (3 ;ug/100 jb.1) and incubated on ice for one hour.
The cells were then washed three times with 10% FCS MEM (4 ml/tub3) and incubated
125
with 100yul of I-GAR (10 jag/100 ,ul) for a further one hour on ice. The
cells were then washed four times with 5—10% FCS—PBS (4ml/tube) before being
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counted. Individual tumors were studied in quadruple tubes.
10. THE DIRECT TUBE RIAT
5
100jul of freshly excised or cultured tumor cells (5 x 10 /ml) were
distributed in 5% FCS precoated polyesterene tubes, mixed with an equal
125
volume of I-RAM (4 jug/100 jul) and incubated on ice for 1-2 hours. The
cells were then washed four times with 5% FCS-PB5 (4ml/tube), the cells
being recovered after each wash by centrifugation at 224 g for 2-5 minutes at
4°C CMSE, England), and counted in Wallac gamma counter. Individual tumors
were studied in quadruple tubes.
11. EVALUATION OF RESULTS
The GAR Ig bound to the cells in the indirect RIAT was determined
in the following manner :
Counts/5 minutes/sample x 10,000 ng
125
amount of I-GAR Ig bound =
-*
125
Counts/5 minutes of 100>ul of ~ I-GAR Ig
The RAH Ig bound to the cells in the direct method was similarly
determined as follows :
Counts/5 minutes/sample x 4000 ng
125
amount of I-RAM Ig bound =
Counts/5 minutes of 100 jal of 125 *
I-RAH Ig
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* The RAM Ig and GAR Ig were the TCA precipitates of the respective
100jul radioiodinated reagents. The precipitates were obtained by
adding 0.1 ml FCS and 4 mis 20% TCA to 0.1 ml of the iodinated reagent,
and centrifuging the mixture at 1,133 g^4°C, for 15 min. (I-ISE, England).
The antiglobulin bound represents the amount bound to freshly




THE DEVELOPMENT OF THE INDIRECT ANTIGLOBULIN TEST
The indirect radio-immune antiglobulin test (EIAT) extensively-
used in our department to study circulating antitumor antibodies was
developed for the study of in vivo bound tumor associated immunoglobulins
(TAIg). The development of the technique involved the following :
a) An assessment of the effect of enzyme treatments used in the preparation
of tumor cell suspensions from freshly excised tumors. This was carried
out in view of the ability of enzymes to remove surface bound TAIg.
b) A comparison between tube and plate methods in the indirect RIAT.
The use of the tube method would have been preferred if it proved to
be as sensitive as the plate method.
c) The effect of precoating the plates or the tubes with different sera
on the inhibition of reagent binding to plastic.
d) The variation of reagent concentration, cell concentration and incubation
time in order to determine the optimum conditions for TAIg studies.
e) Cell recovery studies in order to determine whether cell loss throughout
the assay was correlated with the low radioactive counts obtained at the
end of the RIAT.
f) An assessment of the influence of FCS in cell washings. This was carried
out in view of the inhibition of non-specific binding attributed to FCS.
g) An investigation of nonspecific reagent binding to dead cells since
low viability was a characteristic of the mechanically prepared cells.
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h) A study of human aggregated IgG pretreatment of the cells to investigate
reagent binding to infiltrating Fc-receptor host cells which may have
been present in the excised tumor.
THE EFFECT OF ENZYME TREATMENT
Enzymes such as trypsin, pronase, and others are extensively
used in the preparation of tumor cell suspension from freshly excised
tumors. Certain enzymes are known to remove antigens and immunoglobulins
from the surface of the cells (Hynes, 1976).
In order to determine whether enzyme treatment of the cells removed
any TAIg that might be present on their surfaces, mechanically prepared
cells were compared to those prepared by enzymes. In all the cases studied,
enzyme prepared cells exhibited lower TAIg (Fig. 1).
In the first experiment, mechanically prepared CCH'l tumor cells
were compared to cells prepared by pronase digestion. Mechanical preparation
of the cells involved gentle teasing of tumor tissue and washing the cells in
Dulbecco saline (see Materials and Methods). In contrast, enzyme preparation
consisted of incubating the tumor pieces with the enzyme for 30 minutes at
37°C, then discarding the supernatant, followed by a further two or three 5
minute incubations where the supernatants were collected and the cells washed.
As can be observed from Figure 1, pronase prepared cells exhibited a much
lower TAIg level than mechanically prepared cells.
In the second experiment, in which mechanically prepared W54
"spontaneous" tumor cells were compared to those prepared by pronase, the
latter once again shov/ed lower TAIg levels. In both experiments 1 and 2,
the enzyme concentration was 2.5 mg/ml.
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In the third experiment, mechanically prepared CCH1 cells were
compared to cells prepared by pronase and trypsin. As in the two previous
experiments, enzyme prepared cells again showed lower levels of TAIg.
The trypsin concentration was 2.5 mg/ml.
A COMPARISON OF PLATE AND TUBS METHODS
The plate method was compared to the tube method in order to
determine which of the two methods was the more feasible for TAIg
studies. The number of cells tested and the amounts of reagents used
were the same in both methods. However, the volumes of the reagents used
in the tube method were about twice as high. This facilitated cell washings
and prevented excessive cell loss.
No significant difference in nonspecific binding was observed
between the two methods (Fig. 2). However, in all experiments, the tube
method consistently proved to be the more sensitive than the plate method.
A COMPARISON OF PRECOATING TECHNIQUES
High nonspecific binding of the reagents to the plastic was observed.
In order to block or reduce this nonspecific binding, the plate was precoated
with three different sera. The procedure consisted of precoating the wells
of the plate with human, calf and horse sera (1 in 10 v/v) overnight at 4°C
and removing the sera before carrying out the RIAT.
Calf serum precoating was found to considerably reduce the nonspecific
binding of the reagent to plastic (Fig. 3). In contrast, however, the
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reagents were found to cross react with the horse and human sera,
thus leading to an increase of the nonspecific binding.
In a second experiment, precoating with 5% foetal calf serum
(FCS) was found to substantially reduce the nonspecific binding of the
reagent to plastic (Fig. 8).
Since precoating with FCS reduced nonspecific binding, it was
adopted as a standard procedure for the application of RIAT in TAIg
studies.
AN EXAMINATION OF CELL RECOVERY
125
The I GAR counts obtained were relatively low. One reason
behind this could have been the loss of cells throughout the RIAT.
In order to examine this probability, Crr1 labelling was used.51
The Crr1 labelling procedure has been mentioned in the materials51
5
and methods section. Briefly, 5 x 10 cells/ml were labelled with
2-3 mCi Cr_.. sodium chromate for 30 minutes at 37°C, washed 3 times,
51
left at 4°C for %, hour and then washed again 2 times. The RIAT was
then carried out as mentioned earlier. The process consisted of
incubating the cells with RAM and MRS for hour on ice, washing
125
the cells three times, then incubating the cells with ~ I-GAR for
a further % an hour. The cells were then transferred to a new plate
after washing them 3 times. Untransferred cells were also studied.
In the first experiment, CCKl 20 tumor cells were studied and
a general reduction of counts v/as observed throughout the RIAT.
The trend obtained was as follows in decreasing order : untreated
cells, cells washed 3 times, cells incubated twice and washed 6 times
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(untransferred), cells incubated twice and washed 6 times (transferred
to new wells). As can be observed, similar counts were obtained in the
presence of the three reagents NRS, RAM, GAR (Fig. 4).
In the second experiment, cultured cells were studied. Since
the cells had a higher viability than the mechanically prepared CCH1
cells, they produced relatively higher counts. The general trend, however,
remained very similar to that of the previous experiment (Fig. 5).
Although these results might suggest loss of cells throughout
the RIAT, it is more likely due to spontaneous release of Cr. .
51
THE VARIATION OF REAGENT CONCENTRATION
Six experiments were carried out to study the variations of reagent
concentration. In all cases a positive correlation of reagent concentration
with its binding to the cells was obtained.
125
The concentration of I GAR Ig, was studied in the first experiment
where dilutions of 25, 50, 75 and 100^ig/ml concentrations were used.
Almost a direct relationship of reagent concentration to its binding
to the cells was obtained between 25 and 75jug/ml. However, the slope
of the variation became less acute as the concentration was increased
to 100>ig/ml (Fig. 6).
In the second experiment, binding of the GAR Ig to the cells was
once again found to vary directly with its concentration in both the
plate and tube methods (Fig. 7). Unlike the previous experiment,
however, the slope of the variation remained stfcep even though high
concentrations of the reagent were used.
In the remaining four experiments, the variation of RAM Ig and



























FIG 1 A COMPARISON BETWEEN MECHANICAL AND ENZYME PREPARATIONS OF TUT TOR CELLS
Mechanical preparation consisted of teasing the tumor tissue with a
sterile syringe needle at 0-4°C. Enzyme preparation included the
routine enzyme procedure outlined in the 'Materials and Methods' section.
The figure depicts the results of 3 experiments carried out on freshly
excised CCIil and V/54 'spontaneous' tumor cells by the indirect plate
radioimmune antiglobulin test. Note that enzyme treated tumor cells

























IG 2 A COMPARISON BETUEEN THE PLATE AND TUBE INDIRECT RADIO-IMMUNE ANTIGLOBULIN
Equal amounts of reagents and number of tumor cells were used in both
the plate and tube methods. However, the volume of the medium in which
the cells and reagents were suspended in the tube method we% about 3
times more than that of the plate method. Moreover, the tube method
enabled the use of larger volumes of washing media. It can be observed
that the specificity of RAM Ig binding towards freshly excised
tumor cells (CCH^) is increased in the tube method. Note that reagent
binding to cultured tumor cells (TC) hardly exceeds background (Nil)
















Pre coating human calf horse nil human calf horse nil human calf horse nil
serum.
Reagent RAMIg NRS Ig Medium
FIG 3 THE EFFECT OF PRECOATING PLATES 17ITH VARIOUS PROTEINS ON THE
NONSPECIFIC BINDING OF REAGENTS
The wells in the plastic plate were precoated with human, calf and
horse sera overnight at 4 C. The sera were then decanted and the
standard, indirect radio—immune antiglobulin test carried out on
freshly excised CCH1 tumor cells and controls (-cells). It can be
observed that human and horse sera, enhanced the nonspecific binding
of EAI-I Ig in contrast to calf serum which inhibited this nonspecific
binding (compare precoated nil wells with nonprecoated nil wells).
125
Similarly, nonspecific binding of NF.S Ig and ° I—GAR Ig (medium) was
most inhibited by calf serum. NRS Ig binding to iumor cells may be














4 AN EXAMINATION OF CELL RECOVERY
51,
Freshly excised CCIil tumor cells were prelabelled with Cr and their
progress through the standard indirect plate radio-immune antiglobulin
test was assessed. It can be observed that the counts decrease as the
assay progresses: a. untreated cells; b. cells after the first incubation
and 3 washes; c. cells after the second incubation and. S washes; d. cells
after the final transfer to new wells. Note that similar counts were
observed with cells incubated with NRS Ig or medium; e. cells after the
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Tissue Culture Cells
FIG 5 AN EXAMINATION OF CELL RECOVERY
51Cultured CCH'l tumor cells were prelabelled with Cr and their progress
through the standard indirect plate radio-immune antiglobulin test was
assessed. It can be observed that the counts decrease as the assay
progresses: a. untreated cells; b. cells after the first incubation and
3 washes; c. cells after the second incubation and 6 washes; d. cells
after the final transfer into new wells. Note that similar counts were
observed with cells incubated v/ith NRS Ig or medium; e. cells after the
second incubation and six washes; f & g cells after the final transfer
to new wells.
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the results of the first experiment exhibited an optimum value of 1 in 50,
although the probability of an artifact could not be excluded.
In the second experiment, where RAM and NRS dilutions of 1,
0.5 and 0.25 jag/lOOjul concentrations were studied, a direct correlation
of reagent binding to cells with reagent concentration was observed in
both the plate and tube methods. Although higher binding was obtained with
the tube method, the general trend of the variation was similar to that
observed with the plate method (Fig. 9).
In the third experiment, RAM and MRS dilutions of 5 and lyug/lOOjul
concentrations were studied. Once again a direct relationship of binding
with reagent concentration was noted (Fig. 10).
Finally, in the fourth experiment, RAM and NRS amounts of 100 and
10 jug were studied. As can be observed from Figure 11, reagent binding
to cells varied positively with its concentration.
THE VARIATION OF CELL NUMBER
The standard number of cells used in our assay was 5 x 10°/ml.
However, in order to determine whether reagent binding was dependent
on cell number, the amount of binding to tiro different cell numbers of
5 3
5 x 10 /ml and 5 x 10 /ml was studied. The binding of the reagent to
the cells was found to be directly proportional to the cell number
(Fig. 11).
THE VARIATION OF INCUBATION TIME
The indirect RIAT involved tiro incubation periods (See Material
and Methods). In the first incubation period RAM and NRS reacted with
the cells and in the second incubation period the GAR Ig reacted with the
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cells. In both cases the reagent binding was found to increase as
the incubation time was prolonged.
The incubation time of RAM and MRS with the cells -was studied in
the first experiment where incubation periods of 15, 30, 30 and 120
minutes were used. In both the plate and tube methods, reagent binding
to the cells was found to increase as the incubation time was prolonged
(Fig. 12). The drop observed at 60 minutes with the plate method
could have been an artifact.
In the second experiment the incubation time variation of GAR Ig
with the cells was studied. Again binding increased as the incubation
time was prolonged (Fig. 13).
THE EFFECT OF HUMAN AGGREGATE IgG PRETREATMENT
Fc-receptor host cells have been found to be present within tumors
and tumor cell suspensions (Szymaniec and James, 1976). In order to find
out whether our reagents were binding to the Fc-receptors of host cells,
two experiments were carried out in which excised and cultured CCIIl cells
were pretreated with aggregated human IgG for % hour at 4°C. This pre-
treatment was expected to block the Fc-receptors of the cells and thus
prevent the Fc-portion of the RAM and/or GAR Ig from binding to these
receptors. The RAM and MRS had been absorbed with the aggregated IgG.
In the two experiments that were carried out to examine reagent
binding to Fc-receptors, no significant difference between aggregated
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125.FIG 6 DETERMINATION OF THE OPTIMUM CONCENTRATION OF I-GAR Ig IN THE
INDIRECT PLATE RADIO-IMMUNE ANTIGLOBULIN TEST
In this experiment, the concentration of GAR Ig was varied while RAH Ig
and NRS Ig concentrations were kept constant. Note that the binding
125
of I-GAR Ig to the freshly excised CCM tumor cells incubated with
RAM Ig, NRS Ig, or medium, usually increases with the concentration of























Plate method Tube method
125,
MEG. 1 DETERMINATION OF THE OPTIMUM CONCENTRATION 0? I-GAP. lg III THE
INDIRECT PLATE AND TUBE RADIQ-IKMUHE ANTIGLOBULIN TESTS.
In this experiment, the concentration of GAR Ig was varied while the
RAM Ig concentration was kept constant. It can be observed that the
125
binding of I-GAR Ig to freshly excised tumor cells increases with
its concentration. Note that reagent binding to cultured tumor cells
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DETERMINATION OF THE OPTIMUM DILUTIONS OF RAH Ig and NRS Ig IN THE
INDIRECT TUBE RADIO-IMMUNE ANTIGLOBULIN TEST
In this experiment, the dilutions of RAM Ig and NRS Ig were varied
while the GAR Ig concentration was kept constant. Both nonprecoated
tubes and tubes precoated with 5?i-FCS-P3S were used. In this experiment,
the optimum RAM Ig dilution was found to be 1:50. Note that precoating
inhibited the nonspecific binding of reagents to plastic (no cells).
































INDIRECT PLATE AND TUBE RADIO IMMUNE ANTIGLOBULIN TESTS
In this experiment, the amounts of RAM Ig and MRS Ig were varied
while the GAR Ig concentration was kept constant. In both the plate
and tube methods GAR Ig binding to the freshly excised cells increases
with the amount of RAM Ig. Note that reagent binding to cultured


































FIG 10 DETERMINATION OF THE OPTIMUM AMOUNTS OF RAH Ig and MRS Ig IN THE
INDIRECT TUBE RADIO IMMUNE ANTIGLOBULIN TEST, ANT) THE EFFECT OF
TREATMENT WITH AGGREGATED HUMAN IgC-
In this experiment, the amounts of RAM Ig and NRS Ig were varied while
the GAR Ig amount was kept constant. Moreover, the freshly excised and
cultured CCHI tumor cells were incubated with either medium or aggregated
human IgG before being tested in the radio immune antiglobulin test. It
can be observed that GAR Ig binding to cells increases with the amounts of
RAM Ig and NRS Ig. Note that pretreatment with aggregated human IgG did
not decrease reagent binding to the cells. This suggests that the reagent
binding is not due to cytcphyllic Fc-interactions. It does not, however,
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FIG 11 DETERMINATION OF THE OPTIMUM AMOUNTS OF RAM Ig and NRS Ig IN THE
INDIRECT TUBS RADIO IMMUNE ANTIGLOBULIN TEST AT TWO DIFFERENT CELL NUMBERS
In this experiment, the amounts of RAM Ig and NRS Ig were varied while
the GAR Ig amount was kept constant. Moreover, the effect of cell number
was assessed. It can be observed that GAR Ig binding to cells increases
with the amounts of RAM Ig and NRS Ig. Note that reagent binding also























FIG 12 DBTEPUHATIOH OF IKS OPTIITULI FIRST INCUBATION TINS IN THE INDIRECT
PLATE AND TUBE RADIO IIETJNS ANTIGLOBULIN TESTS
In this • experiment, the reagent concentrations were kept constant
while the time of the first incubation period was varied. In both
the plate and tube methods, reagent binding to freshly excised CChj.
tumor cells gradually increased with incubation time. Note that






















FIG 13 DETERMINATION OF THE OPTIMUM SECOND INCUBATION TIIIE IN THE INDIRECT
TUBS RADI0 IMMUNE ANTIGLOBULIN TEST
In this experiment, the reagent concentrations were kept constant
while the time of the second incubation period was varied. It can be
observed that the reagent binding to freshly excised CCIil tumor cells
gradually increased with incubation time. Note that reagent binding
























FIG 14 THE EFFECT OF TREATMENT WITH AGGREGATED HUMAN IgG ON REAGENT BINDING
IN THE INDIRECT PLATE RADIO IMMUNE ANTIGLOBULIN TEST
Freshly excised and cultured CCH1 tumor cells were pretreated with
aggregated human IgG for half an hour at 4°C, separated from the
aggregated IgG by centrifugation, and then compared to nontreated
cells in the indirect plate radio immune antiglobulin test. Note
that no significant difference was observed between treated and non-
treated cells.
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NONSPCCIFIC BINDING TO DEAD CELLS
Since the mechanically prepared cells had low viability, the
possibility ox nonspecific binding to dead cells was investigated.
Binding to both killed excised and cultured tumor cells was studied.
Mechanically prepared cells were divided into two groups,
one of which was stored at 4°C for 2 hours while the other group
was incubated at 48°C for 2 hours. At the end of the 2 hours, the
viability of the first group remained 40% whereas the viability of
the second group was reduced to 15%. As can be observed from Figure
15, no significant difference of binding was obtained between the two
groups.
In the second experiment, dead and live tissue culture cells
(TC) were compared. The live cells were killed by a two hour incubation
period at 48°C which reduced their viability from 100% to 12%, No
significant difference of reagent binding between live and dead TC
was obtained (Fig. 16).
THE EFFECT OF FCS IN CELL WASHINGS
Since FCS was found to inhibit nonspecific binding to plastic,
its role in cell washings was examined. As previously mentioned, the
indirect P.IAT involved two groups of washings: one group after the
first incubation period which consisted of three washings with 10%
FCS—MEM (4ml/tube), and another group after the second incubation
period which consisted of four washings with 10% FCS-PBS (4ml/tube).
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A comparison of 5% PCS medium with 10% PCS medium was carried
out in the first experiment. The medium which contained 10% PCS was
found to produce less nonspecific binding than the medium which contained
5% PCS (Pig. 17).
Media containing 10% FCS, 5% FCS and no PCS were compared in the
second group of washings. No significant difference in nonspecific binding
was obtained between media containing 10% FCS or 5% FCS (Pig. 18).
Based on these results, it was therefore agreed to use media
containing 10% FCS in the first group of washes, and media containing 5%
FCS in the second group of washes.
SUMMARY
Studies were undertaken to determine the optimal experimental
conditions for measuring tumor associated Ig by the indirect RIA.T.
Preliminary studies revealed as expected the unfeasibility of
using enzymes for tumor cell preparation as they were found to remove the
surface bound TAIg. Consequently, the enzyme procedure was replaced by
mechanical preparation of the cells.
A comparison of plate and tube methods showed the tube method to
be a more sensitive and iea.sible method for the study of TAIg.
Precoating the tubes with 5% FCS was found to appreciably inhibit
the nonspecific binding of reagents to the plastic.
Reagent binding to cells was found to be directly correlated with
reagent concentration, cell number and incubation time. The following
conditions were found to give satisfactory results :
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a) GAR Ig concentration of 10 jag/100 jj.1
b) RAM Ig concentration of 1 p.g/100 jal
A
c) cell number of 5 :c 10 /100 ^ul
a) incubation time of 1 hour
Cell recovery studied appeared to suggest spontaneous Cr
51
release and/or cell death throughout the RIAT.
A study of cell washing media showed 10% FCS-MEM and 5% FCS-PBS to
be the most effective media.
Dead cells were found not to bind the reagents nonspecifically.
The high binding to mechanically prepared cells could not therefore
be attributed to nonspecific binding to dead cells.
Finally, reagent binding to Fc-receptor host cells within the





















REG 15 THE EFFECT OF DEAD CELLS ON REAGENT BINDING
Freshly excised CCHl tumor cells were divided into 2 tubes, one of which
was left at 4°C for 2 hrs, while the other was incubated in a 48°C water
bath for 2 hrs. The viability of the cells incubated at 4°c was 40% and
they were denoted as 'live cells'. The viability of the cells incubated
o
at 48 C v/as 15% and they were denoted as 'dead cells'. The indirect
plate ra.dio immune antiglobulin test was carried out on the 'dead'and
'live' cells. It can be observed that at the various final stages of
the radio immune antiglobulin test, there was no increased binding of
reagents to 'dead' cells: (a) and (b); cells incubated with RAH Ig
before and after transfer into new wells respectively, (c) and (d); cells
incubated with MRS Ig before and after transfer into new wells respectively
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Cultured CCH1 cells
FIG 16 THE EFFECT OF DEAD CELLS On REAGENT BINDING
Cultured CCH1 tumor cellswere divided into 2 tubes, one of which was
left at 4°C for 2 hrs, while the other was incubated in a 4G°C water
bath for 2 hrs. The viability of the cells incubated at 4S°C dropped
from lOO/o to 12?o. The indirect plate ratio-immune antiglobulin test
was carried out on the live and dead cells. It can be observed that
at the various final stages of the uadio immune antiglobulin test, there
was no increased binding of reagents to dead cells: (a) and (b); cells
incubated with RAM Ig before and after transfer into new wells respectively
(c) and (d); cells incubated with MRS Ig before and after transfer
into new wells respectively (e); cells incubated with medium after


















?IG 17 THE EFFECT OF FCS IN WASHING MEDIA IN THE INDIRECT TUBE RADIO I-MHUNE
ANTIGLOBULIN TEST
In this experiment, all conditions were kept constant while the FCS
content in the washing media used after the first incubation period
was varied. Although no significant differences were noted between
the use of the different media, it can be observed that washing with
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FIG 13 THE EFFECT OF FCS IK \7ASHINC- MEDIA IN THE INDIRECT TUBE RADIO IMMUNE
ANTIGLOBULIN TEST
In this experiment, all concentrations were kept constant while the
FCS content in the washing media used after the second incubation
period was varied. It can be observed that washing with FCS containing
media slightly reduced the nonspecific binding of reagents to control
tubes (TC)
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APPLICATION OF THE INDIRECT
ANTIGLOBULIN TECHNIQUE
THE RESPONSE TO CCH1 IN NONTRSATED AND C. PARVUM TREATED MICE
Four experiments were carried out in order to study the variation
of in vivo bound tumor associated Ig (TAIg) to cells with time and
size of tumors in nontreated and C. parvum (cp) treated mice. The
treated mice included those which had been injected with 0.2 ml (1.4 mg/ml)
cp (Wellcome Research Laboratories, England) intraperitoneally 3 days
after the injection of tumor cells.
In the first experiment, tumor cells from nontreated mice showed
a slight increase of TAIg binding on the third week, while those of cp
treated mice showed a substantial increase on week three, followed by
a decrease on week four. However, the standard deviation (SD) remained
high in both groups.
The results of the second experiment showed a different pattern.
The tumors from nontreated mice exhibited a slight decrease of TAIg on
week 3, while those of cp treated mice showed a continual increase
with time. Nevertheless, the SD in both groups still remained high.
In experiment 3, tumors from nontreated mice showed a different
pattern from cp treated mice. Whereas in the former the TAIg increased
on week 3 and decreased on week 4, in the latter the TAIg decreased and
increased on weeks 3 and 4 respectively (Fig. 19).
The results of the last experiment showed an increase of TAIg with
time in both groups (Fig. 20). The degree of this increase however
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varied between the two groups.
All the results from the experiments carried out on nontreated
and cp treated mice are combined in Figures 21 and 22. As can be
observed, 6 out of 7 experiments with nontreated mice show an increase
of TAIg on week 3, whereas only one out of 3 show an increase on week 4.
With cp treated mice, 3 out of 4 experiments show an increase of TAIg
on weeks 3 and 4.
Figures 23 and 24 include the combined results obtained with
nontreated and cp treated mice, presented in the form of mean TAIg binding
versus time. While nontreated mice exhibit a fluctuating pattern, cp
treated mice show a slow but consistent increase of TAIg binding with
time. The variation of tumor size with time in nontreated and cp
treated mice together with the variation of TAIg binding is also shown
in Figures 23 and 24.
Figure 25 shows the combined results obtained with nontreated
and cp treated mice, presented in the form of TAIg binding with size.
Tumor sizes ^15 mm in nontreated mice and^ 15 mm in cp treated mice
are considered since the majority of their respective tumors lie
within these boundaries. Whereas only 52% of nontreated mice show a
TAIg value above 2.5 ng, 80% of cp treated mice do. Moreover, the
in vivo bound TAIg in botil groups is positively correlated with size.
Figure 26 depicts the variation of TAIg with size in nontreated tumors.
A linear relationship can be observed between TAIg binding and size.
It was observed that normal rabbit serum (MRS) bound to the cells
obtained from the tumor, though to a much lesser extent than rabbit
anti-mouse serum (RAM). However, the variation of MRS binding with time
































rIG 19 THE VARIATION OF TAIg BIifSING WITH THIS IN CCHi TUT TORS AND THE EFFECT
OF C.PARVUI1 ON THIS VARIATION
C3A mice were injected s.c. on Day 0 with 10° viable CCHi tumor cells.
Half of these were treated ip with 1.4 mg of C, parvum on Day 3. At
various times thereafter, the amount of host Ig associated with the
4
surface of 5 x 10 cells from individual tumors was assessed by the indireci
radio immune antiglobulin test. It can be observed that TAIg binding
increases and decreases during weeks 3 and 4 respectively in nontreated
mice. In contrast, TAIg binding decreases and increases during weeks 3
and 4 respectively in C.parvum treated mice. Note that TAIg amounts in
C. parvum treated mice are appreciably higher than TAIg amounts in non-





























FIG 20 THE VARIATION OF TAIg BINDING WITH TIT-IE IN CChl TUMORS, AND THE
EFFECT OF C.PARVUSCN THIS VARIATION
~ 6
CBA mice were injected s.c. on Day 0 with 10 viable CCHl tumor cells
Half of these mice were treated ip with 1.4ms of C ■ pa.rvum on Dac»r 3.
At various times thereafter the amount of host Ig associated with the
4
surface of 5 x 10 cells from individual tumors was assessed by the
indirect radio immune antiglobulin test. It can be observed that in
both C. parvum treated and nontreated mice TAIg binding increases
during week 3 of tumor growth. However, while TAIg binding remains
the same on day 27 in nontreated mice, it continues to increase in
C. narvum treated mice. Note that TAIg amounts on days 13 and 27 in





FIG 21 THE VARIATION OF TAIg BINDING WITH TII1E IN NON TREATED CCH1 TTJT-IOR—
BEARING MEGS
CBA mice were injected s.c. on Day 0 with 10° viable CCH1 tumor cells.
The figure depicts mean TAIg amounts obtained at various time intervals
in 7 experiments. Note that in 6 out of the 7 experiments, TAIg binding
increases during the 3rd week of tumor growth. In only 3 experiments
did the mice survive long enough for their tumors to be studied on the
fourth week. Of these 3 experiments two experiments show a drop of
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THS VARIATION OF TAIg BINDING WITH TINE IN C. PARVUM TREATED CCHl
TUIIQR—BEARING IIICE
6
CBA mice were injected s.c. on Day 0 with 10 viable CCHl tumor cells.
On day 3, the mice were injected in with 1.4 rng of C. parvum. The
figure depicts mean TAIg amounts obtained at various time intervals
in 4 experiments. Note that in 3 out of the 4 experiments, TAIg binding
increases during the 3rd week of tumor growth. Moreover, in contrast to
the observation made with nontreated mice (see Fig 21), TAIg binding
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23 THE VARIATION OF TAIy BINDING AMD TUMOR SIZE V/ITH TIME IN NON-TREATED
CCH1 TUMOR BEARING LUCE
CBA mice were injected s.c. on Day 0 with 10° viable CCHl tumor cells
The figure depicts mean TAIg amounts and tumor sizes obtained
at various time intervals of tumor growth in different experiments.
Note that there is consistent increase of TAIg binding and tumor size
during the 3rd week of tumor growth. However, while tumor size
continues to increase until day 24, TAIg binding appears to fluctuate
Thereafter, tumor size and TAIg binding once again vary similarly






FIG 24 THE VARIATION OF TAIg BINDING ATE) TUMOR SIZE WITH TIME IN G.PARVUM
TREATED CCH1 TUHOR BEARING MICE
0
CBA mice were injected s.c. on Day 0 with 10 viable CCFl tumor cells.
On day 3, the mice were injected ip with 1.4 mg of C. parvum. The
figure depicts mean TAIg amounts and tumor sizes obtained at various
time intervals of tumor growth in different experiments. Note that
the:® is consistent increase of TAIg binding with time. In contrast,
tumor size remains small and begins to increase only during the 4th
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FIG 25 THE VARIATION OF TAIg BINDING WITH TUMOR SIZE IN C. PARVUIi TREATED
Size
(mm)
AND NONTREATED CCKl TUNQR 3EARING MICE
Q
C3A mice were injected s.c. on Day 0 with 10 viable CCHl tumor cells.
On Day 3, half of the mice were injected ip with 1.4 mg of C. parvum _
The figure depicts tumor size and the amount of host Ig associated
4
with the surface of 5 x 10 cells from the corresponding tumors in
the four experiments carried out on C. parvum treated and nontreated
mice. It can be observed that while the slope of variation of TAIg
binding with respect to tumor size does net differ between 0. parvu
treated and nontreated mice, the former exhibit markedly higher levels















I O-^-CJ)-—O pO—O |




FIG 26 THE VARIATION OF TAIg BINDING WITH SIZE IN NOHTREATED CCH1 TUIIOR
BEARING MICE
0
CBA .nice were injected s.c. on Day 0 with 10 viable CCHI tumor cells.
The figure depicts tumor size and the amount of host Ig associated
4
with the surface of 5 x 10 cells from the corresponding tumor in
all the experiments carried out on CCHI tumor bearing mice. It can
be observed that there is a significant positive correlation betrueen
TAIg binding and 'tumor size.
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THS RESPONSE TO T3 IN UONTREATED A?TO CP TREATED MICE
The in vivo bound TAIg and its variation with time and size of
the T3 tumors in nontreated and cp treated mice was compared in 3
experiments. In general, cp treated mice exhibited higher in vivo
bound TAIg levels, although the pattern of response in relation to time
between the 2 groups remained similar.
In the first experiment nontreated mice showed hardly any
increase of TAIg on the 3rd week of tumor growth. Cp treated mice,
on the other hand, not only showed an increase of TAIg on week 3 but
the levels were also higher than those of nontreated mice.
125
Different batches of I GAR were used on week 2 as opposed
to weeks 3 and 4 in experiment 2. Whereas nontreated and cp treated
mice could be compared on week 2, their TAIg levels could not be compared
with those obtained on weeks 3 and 4. On week 2, cp treated mice showed once
again higher levels of TAIg compared to nontreated mice. Unlike the case
in experiment 1, however, no difference was exhibited bet-ween the 2 groups
on week 3. The tumors in this experiment were grown from cultured T3
tumor cells.
The results of experiment 3 were similar to those obtained from the
previous two experiments in that cp treated mice again consistently showed
higher levels of TAIg. However, a slightly different pattern of response
was obtained between the 2 groups with relation to time. "Chile nontreated
mice showed a decrease of TAIg on week 3 and no variation on week 4, cp
treated mice showed a decrease and an increase on weeks 3 and 4 respectively
(Fig. 27). The standard deviation in this experiment was less than those
observed in the previous 2 experiments.
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Figures 28 and 29 combine the results of the 3 experiments in
the form of mean in vivo bound TAIg variation with time. Although
differences in the pattern of response between the 2 groups is not
as apparent as observed with CCH-i tumors, cp treated mice nevertheless
show a more acute variation of TAIg with time compared to nontreated
mice. Moreover, tumors obtained from cp treated mice show almost
consistently higher amounts of TAIg.
THE RESPONSE TO CCH1 AND T3 TUMORS
The results of the two experiments that were carried out in this
group showed the CCH1 cells to be more immunogenic. The latter exhibited
higher levels of in vivo bound TAIg in most cases.
Cultured T3 tumor cells were used in the first experiment in order
to produce the T3 tumors. The CCHl tumors were grown from freshly excised
CCHl tumor cells. As can be observed from Figure 30, the CCHl tumors
had higher levels of TAIg on day 13. By the second week of tumor growth
however, the TAIg levels in T3 tumors had increased to the same levels
of those of CCK1 tumors. In both tumors the in vivo bound TAIg
increased with time.
T3 tumors were grown from freshly excised T3 tumor cells in the
second experiment where again they exhibited lower TAIg levels than CCHL
tumors which, unlike the first experiment, did not increase with time
(Fig. 31).
In general, T3 tumors consistently showed lower levels of TAIg































FIG 27 THE VARIATION OF TAIg BINDING WITH TIME IN T3TUI10RS, AND THE EFFECT
OF C. PARVUH ON THIS VARIATION.
6
CBA mice v/ere injected s.c. on Day 0 with 10 viable T3 tumor cells.
On day 3, half of these mice were injected ip with 1.4 mg of C. parvum .
At various times thereafter the amount of host Ig associated with
/I
the surface of 5 x 10*"* cells- from individual tumors 'was assessed
by the indirect radio immune antiglobulin test. It can be observed
that TAIg binding decreases after the 3rd week in nontreated mice.
In contrast, after an initial drop during the 3rd week, TAIg binding
increases in C.parvum treated mice. In addition, tumors from C. parvum
treated mice exhibit higher amounts of TAIg than tumors from nontreated







FIG 28 THE VARIATION OF TAIg BINDING Arm TUMOR SIZE 17ITH TINE IN NCNTREATED
T3 TUMOR BEARING MCE
C3A mice were injected s.c. on Day 0 with 10° viable T3 tumor cells.
The figure depicts mean TAIg amounts and tumor sizes obtained
at various time intervals of tumor growth in different experiments.
Note that while there is a consistent rapid increase of tumor size
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FIG 29 THE VARIATION OF TAIg BINDING AND TUNOR SIZE VJITH Til IE IN C. FARVULI
TREATED T3 TUMOR BEARING MICE
0
C3A mice were injected s.c. on Day 0 with 10 viable T3 tumor cells.
On day 3, the mice were injected ip with 1.4 mg of C. parvum. The
figure depicts mean TAIg amounts and tumor sizes obtained at various
time intervals of tumor growth in different experiments. Note that
the fluctuating variation of TAIg binding with time obtained in
nontreated mice (see Fig 28) is again observed with C.oarvan treated
mice. However, the amounts of TAIg in C. parvum treated mice are
appreciably higher than nontreated mice. Note also that tumor growth






















FIG 30 THE VARIATION OF TAIg 3IMPING V.'ITK TINE III CCH1 AND T3 TUMOR
BEARING MICE
Equal numbers of CBA mice were injected s.c. on Day 0 with 10°
viable CCH1 or T3 tumor cells. At various times thereafter the
,/7
amount of host Ig associated with 5 x 10 cells from individual
tumors v/as assessed by the indirect radio immune antiglobulin test.
It can be observed that TAIg increases during the 3rd week in both
0CH1 and T3 tumors. However, the amount of TAIg on day 13 is
lower in T3 tumors than CCHl tumors. Note that there is no increase



























•IG 31 THE VARIATION OF TAIg BINDING WITH TIME IN COM. AND T3 TUMOR
BEARING MICE
Equal numbers of CBA mice were injected s.c on Day 0 with 10^
viable CCH1 or T3 tumor cells. On days 13 and 20 of tumor growth
4
the amount of host Ig associated with 5 x 10 cells from individual
tumors was assessed by the indirect radio immune antiglobulin test.
No variation of TAIg binding with time was observed in both CCITL
and T3 tumor bearing mice.
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THS RESPONSE TO CCM1 EXCISED AMD CULTURED TUI-IOR CELLS
Two experiments were carried out to study the in vivo bound TAIg
variations with age and size of tumors induced by excised and cultured
CCli.l cells. Tumors induced by cultured cells exhibited lower levels of
TAIg and smaller tumor sizes.
In the first experiment, on days 16 and 23 of tumor growth,
iumor produced by excised CCHl cells showed higher levels of TAIg than
those produced by cultured cells. Moreover, the TAIg in tumors produced
by excised CCHl cells increased in the third week, while those of tumors
produced by cultured CCHl cells remained constant on the 3rd week,
increasing substantially only in the 4th week.
The results obtained in the 2nd experiment were consistent with
those of the first experiment with respect to TAIg levels. Tumors
produced by excised CCHl cells again showed higher TAIg levels than
those produced by cultured cells. However, the TAIg level in this experiment
decreased in the 4th week of tumor growth (Fig. 32).
Tumors produced by cultured cells were not only smaller in size,
but also the great majority of them had TAIg levels lower than 2 ng.
Conversely, tumors produced by excised CCHl cells had larger sizes
as well as higher TAIg levels.
THE RESPONSE TO DIFFERENT DOSES OF CCHl TUMOR CELLS
The response to 2 different doses of 0.5 end 5 x 10 /ml CCHl
cells was studied in one experiment. Tumors produced by the larger
dose showed higher levels of TAIg and were of larger sizes (rig. 33).
-86-
The TAIg levels in both groups increased with time. Moreover, 60%
of tumors produced by the larger dose exhibited levels of TAIg above
2 ng, compared to only 10% of those produced by the smaller dose.
THE RESPONSE TO PR0NAS5 PREPARED AT ID MECHANICALLY PREPARED CCH1 CELLS
Mice were injected with pronase prepared or mechanically prepared
CCH1 cells consisting of equal numbers of viable cells (1 x 10°/ml).
Pronase prepared cells produced larger tumors with higher TAIg levels
(Fig. 34). Once again, the TAIg in both groups increased with age ana
size of tumors.
SUMMARY
The general pattern observed is that of an increase of in vivo
TAIg binding with age and size of CCH^ and T3 tumors of nontreated mice.
Although the levels of TAIg in CCKl and T3 tumors differ, their pattern
of variation with time and size of the tumors seem to be similar.
Uith cp treated mice a similar poative correlation of TAIg binding
with age and size of tumors is obtained. But while in nontreated mice
only large tumors tend to exhibit high levels of TAIg, in cp treated mice
the high levels are observed in small tumors. Moreover, the pattern of
variation of TAIg with time is different in CCHl and T3 tumors. Whereas
in CCHl tumors the TAIg increases with time, in T3 tumors it seems to fluctuate
■87-
Tumors produced by excised CCH1 cells e:xhibit higher levels of
TAIg than those produced by cultured CCI-l'i cells. In addition, the latter
seem to grow slower than excised CCH1 cells, resulting in smaller tumors.
In vivo TAIg binding seems to be dose dependent, with larger
doses resulting in higher binding.
Finally, tumors produced by mechanically prepared cells are smaller
in size and exhibit lower TAIg levels than those produced by pronase
prepared cells.
In conclusion, in vivo TAIg binding in nontreated mice appears
to be dose, cell-type and cell preparation mode dependent. Moreover,






















?IG 32 THE VARIATION OF TAIs BINDING WITH TIME IN CCHl FRESHLY EXCISED
AND CULTURED TUMOR BEARING NICE
8 n
Equal numbers of CBA mice were injected s.c. on Day 0 with 10 viable
freshly excised or cultured CCHl tumor cells. On days 19 and 25, the
4
amount of host Ig associated with 5 x 10 cells from individual
tumors was assessed by the indirect radio immune antiglobulin test.
Note that on both days, TAIg amounts are higher in tumors grown from
freshly excised tumor cells than tumors grown from cultured tumor
cells. In addition, there is a decrease of TAIg binding in both









FIG 33 THE EFFECT OF DOSE OH TAIri BINDING IN CCH.l TUMORS
Equal numbers of CBA mice were injected s.c. on Day 0 with 0.5 and
0
5 x 10 viable freshly excised CCHT tumor cells respectively. On
A
days 16 and 23, the amount of host Ig associated with 5 x 10 cells
from individual tumors was assessed by the indirect radio immune
antiglobulin test. It can be observed that on both days, tumors
produced by the larger dose of tumor cells exhibit higher amounts of
TAI.g than tumors produced by the smaller dose of tumor cells.
Moreover, both groups of tumors exhibit an. increase of TAIg binding






































FIG 34 LEFT: THE VARIATION OF TAIg BINDING WITH TIME IN CCH1 FRESHLY EXCISED
MECHANICALLY PREPARED AND PRONASE PREPARED TUMOR BEARING NIC!
Equal numbers of CBA mice were injected s.c. on Day 0 with 10 viable
freshly excised CCHl mechanically prepared or Pronase prepared tumor
cells. On days 15 and 20, the amount of host Ig associated with 5 x 10
ceils from individual tumors was assessed by the indirect radio immune
antiglobulin test. Note that on both days, TAIg amounts were higher
in tumors grown from pronase prepared cells than tumors grown from
mechanically prepared cells. In addition, both groups of tumors
chibit
RIGHT: THE VARIATION OF TAIg BINDING WITH SIZE IN THE CCHl FRESHLY
ex an increase of TAIg binding during the 3rd week of tumor growth.
EXCISED N5CIIAHICALLY PREPARED AND PEONAGE PREPARED TTT'OR BEARING NIC
Note that in both tumor groups, TAIg biinding significantly increases wiui-H infh^ <3 "i *7. Pi
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I E DEVELOPMENT OF THE DIRECT
RADIOIMMUNE ANTIGLOBULIN TEST
This section describes the experiments which were carried out to
determine the optimum conditions for the direct radioimmune antiglobulin
test (F.IAT) that was to be used for the reassessment of the results obtained
by the indirect RIAT and for additional tumor-associated immunoglobulin
(TAIg) studies. The standard method which was eventually adopted consisted
4 125 o
of incubating 5 x 10 cells with I-RAM Ig for 1 hour at 4 C, and then
washing the cells 4 times with 5% FCS PBS (further details in Materials
and Methods).
The various parameters studied in the development of the direct RIAT
included the following :
a. effect of tube precoating with FCS on the reduction of nonspecific
binding to plastic.
b. a study of the specificity of the RAM Ig •
c. effect of enzyme treatment on surface bound TAIg»
d. influence of reagent concentration on its binding to tumor cells .
e. effect of incubation temperature and time on the RAM Ig binding to
tumor cells .
f. effect of cell number on reagent binding.
g. nonspecific binding of the RAM Ig to dead tumor cells .
h. nonspecific binding to cells via the Fc-portion of the RAM Ig ,
The specific reasons behind these studies are mentioned in the
introduction to the development of the indirect RIAT.
The appreciable work carried out in this section by my colleague
James Merriman is thankfully acknowledged.
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EFFECT OF TUBE PRECOATING
In previous studies with the indirect RIAT, overnight precoating of
the tubes v/ith 5% FCS at 4°C was found to inhibit nonspecific binding to
plastic. In order to assess the effect of FCS on nonspecific binding in
the direct method, precoating with the following amounts and volumes of
FCS were compared : 0.1 ml neat, 1 ml neat, 4 ml neat, 4 ml 1:5, 4 ml 1:25,
and 4 ml 1:125. The concentration of RAM Ig was 4 jug/100 >al.
All the amounts and volumes of FCS studied showed a significant
reduction of nonspecific binding to plastic (Figure 35). It was therefore
decided to continue the standard, procedure of 5% FCS precoating overnight
at 4°C.
SPECIFICITY OF THE RAM Ig
The specificity of RAM Ig binding was initially tested on normal
spleen cells, normal thymus cells, cultured CCHl tumor cells and excised
CCh'l and CCH5 tumor cells. Two cell concentrations of 7 x 10G/ml and
5
7 x 10 /ml were used. As shown in Figure 36, the highest RAM Ig binding
was found to be on CCH5 tumor cells, followed by CCHl tumor cells and spleen
cells. The lower-binding of the reagent to the spleen cells may be partially
attributed to the smaller size of these cells compared to the tumor cells.
Only negligible RAH Ig binding to thymus cells and cultured CCHl tumor
cells was observed.
In a second experiment, spleen cells were used to assess the binding
of RAM Ig to surface bound immunoglobulins. Reagent concentrations of 1000,
G 5
500, 250 and 125 ng/0.1 ml were used on 1 x 10 and 1 x ICt cells. The
-90-
assay was carried out at incubation temperatures of 4 and 37°C. RAM I<?
binding to the spleen cells was found to var;r directly with cell and
reagent concentration (Fig. 37) and the reaction was observed to be
enhanced at 37°C.
In a third experiment CCH1 cultured tumor cells were incubated
with various dilutions of mouse serum (1:5, 1:10, 1:20, 1:40) for 1 hour
at 37°C. The sera were obtained from nontreated and C. parvurn treated
tumor bearing mice. The cells were then washed 3 times with 4 ml of
10% FCS-PBS and once with 4 ml complete RPiH, and recovered after each
wash by centrifugation at 283 g for 10 minutes. The cells were
12^ o
reincubated for a further hour with 50 jul of "I-RAM Ig at 37 C. The
cells were then washed 4 times with 4 ml 10% FCS-PBS, transferred to
new tubes and counted. A direct correlation of RAM Ig binding to the
cultured cells with serum and cell concentration was observed (Fig. 38).
Moreover, ceils incubated with sera obtained from C. parvum treated
tumor bearing mice exhibited higher binding of the RAM Ig.
EFFECT OF ENZYME TREATMENT
Six experiments were carried out in order to study the effect of
enzymes on surface bound TAIg. Similar to previous studies obtained with
the indirect method, all the experiments indicated a direct relationship
between loss of surface bound TAIg and the time and concentration of
enzyme treatment.
In the first experiment, mechanically prepared tumor cells were
compared with pronase prepared cells. The latter involved two 5 minute


























FIG 35 THE EFFECT OF PRECOATING THE TUBES WITH VARIOUS FCS CONCENTRATIONS
ON THE NONSPECIFIC BINDING OF REAGENTS TO PLASTIC
Tubes were precoated with PBS consisting of various FCS concentrations
overnight at 4°C. The solutions were then decanted and the direct
radio immune antiglobulin test carried out. It can be observed that
precoating the tubes with various FCS concentrations appreciably
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125,36 SPECIFICITY OF THE I-RAM Ig
In this experiment, the specificity of the RAM Ig to surface-bound
immunoglobulins x^as studied. The binding of the RAM Ig to freshly
excised tumor cells and spleen cells (positive cells) was compared
with its binding to cultured tumor cells and thymus cells (control
cells). Mote that a) the RAM Ig binds most to freshly excised tumor
cells and spleen cells; b) the binding to cultured tumor cells and
thymus cells hardly exceeds background levels c) the binding of
the reagent increases v/ith cell numbers.
-90c-
1 x 107/ml cells J~ # 37 C
1- O 4 C incubation
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FIG 37 SPECIFICITY OF THE I-RAM Ig AMD THE VARIATION OF ITS BINDING
WITH REAGENT CONCENTRATION AND CELL NUMBER
In this experiment, the specificity of the RAM Ig to surface bound
immunoglobulins on spleen cells was studied. Moreover, the
variation of reagent binding with its concentration, cell number,
and incubation temperature was examined. It can be observed that
at both cell numbers and incubation temperatures, RAM Ig binding to
the spleen cells varies positively with the reagent concentration.
Note that reagent binding to cells also varies positively with cell




























1:5 1:10 1:20 1:40 no serum Mouse serum
dilution
FIG 38 THE SPECIFICITY OF THE
125
I-RAM Ig AND THE VARIATION OF ITS
BINDING WITH MOUSE SERUM DILUTION AND TUMOR CELL NUMBER
In this experiment, the specificity of the RAM Ig to surface-
bound immunoglobulins was studied by examining its binding to
cultured tumor cells treated with various dilutions of mouse
sera. The latter were obtained from C.parvum treated or non-
treated CCHL. tumor bearing mice. It can be observed that RAM-Ig
binding to the cells varied positively with mouse serum concen¬
tration at both cell numbers. Note that a) reagent binding
increases with cell number and b) reagent binding to cells
treated with serum from C.oarvum treated mice is higher than its
binding to cells treated with serum from nontreated mice.
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Cell numbers of 2 x 10°, 106, 1CT, 104 and 103/0.1 ml were used. At all
cell concentrations, mechanically prepared cells exhibited a higher
amount of surface bound TAIg (Fig. 39). The RAM Ig binding to the cells
was found to be enhanced at 37°C.
The effect of prolonged enzyme treatment on TAIg was studied
in the second experiment. Periods of the enzyme treatment included
5, 30 and 60 minute incubations at 37°C. As shown in Figure 40, loss
of TAIg from tumor cell surface varied directly with time of enzyme
treatment. The RAM Ig binding to 'tumor cells was again found to be
enhanced at 37°C.
In the third experiment, pronase and/or collager.ase preparation
of tumor cells was compared with mechanical preparation. Enzyme
preparation of the cells involved the incubation of small tumor pieces
with 10 ml of enzyme for 15 minutes at 37°C, followed by decanting
the supernatant and reincubating the tumor with 10 ml of fresh enzyme
for 10 minutes. In one instance, pronase digested tumor was '/ashed
4 times with 25 ml of Dulbecco saline and incubated with 10 ml of
collagenase (conc. 0.1 mg/ml) for 10 minutes. Mechanical preparation
of the cells included a 15 minute stirring on ice or disruption of
the tumor pieces in a syringe. As can be observed from Figure 41,
enzyme treatment once again was found to remove surface bound TAIg.
However, the collagenase treatment was found to retain most of the TAIg.
In order to study the effect of the type of enzyme treatment,
the following enzymes were studied in the next experiment (conc.
0.1 mg/ml): trypsin., pronase and collagenase. The treatment included
a half hour incubation of the excised and cultured cells with the
respective enzymes at 37°C. The cell viability obtained with untreated
-92-
and trypsin, pronase and collagenase treatment was 20%, 63%, 71%
and 85% respectively. All enzyme treatments retained most of the
surface bound TAIg (Fig. 42). Binding of the RAM Ig to similarly
treated cultured cells remained the same and the viability of the cells
was not affected.
The above experiment was repeated with trypsin, pronase and
collagenase, yielding viabilities of 65, 100 and 25% respectively.
Once again the results showed a negligible loss of surface bound TAIg
(Fig. 43).
In the sixth experiment, the effect of enzyme concentration on
TAIg was studied. Pronase concentrations of 2.5, 1.25 0.5, 0.25 and 0.1
mg/ml were studied. As shown in Figure 44, loss of TAIg from the surface
of CCH1 tumor cells was found to vary directly with enzyme concentration.
IPIFLUENCE OF REAGENT CONCENTRATION
The results of most experiments showed a direct correlation between
PA1I Ig concentration and its binding to cells. Three experiments which
were particularly carried out to study the influence of reagent
concentrations will be described in this section.
In the first experiment, reagent concentrations of 5, 1, 0.2 and
0.04 jag/lOOjal v/ere studied and normal spleen ana thymus cells were included
in addition to CCHl tumor cells. RATI Ig binding to the cells was found to
vary directly with reagent concentration (Fig. 45). Moreover, at all
reagent concentrations, highest binding was always observed on CCHl.
tumor cells. Spleen cells exhibited lower RAM Ig binding whereas thymus
cells showed only negligible binding.
-92a-
FIG 39 A COMPARISON BETWEEN MECHANICALLY AND ENZYME PREPARED TUMOR CELLS
Mechanical preparations consisted of mincing the tumor with
scissors at 0-4°C. Enzyme preparation included 2 five minute
incubations with pronase at 37°C. It can be observed that
125
I—RAM Ig binding to mechanically prepared tumor cells is
usually higher than its binding to prona.se prepared tumor cells.
Note that reagent binding to cells varies positively with cell





















FIG 40 EFFECT OF ENZYME OH BOUND TUMOR ASSOCIATED IIE1UN0C-L03ULINS
The effect of pronase on tumor-associated immunoglobulins v/as
studied in the direct radio-immune antiglobulin test.
Enzyme treatment consisted of incubating freshly excised tumor
tissues with pronase for 5, 30 or 60 minutes. It can be observed
that the loss of tumor-associated Igs from the surface of tumor
cells increased with the enzyme incubation period. Note that
125
I—RAM Ig binding to cells varies positively with the incubation


































Syringe disruption Coliagenase Pronase Colla'genase +
pronase
'5%' rl% ' ' ' ' ' '753 100% 100%
FIC- 41 EFFECT OF ENZYME ON THE
125
I-RAH Ig BINDING TO TUMOR CELLS.
In this experiment the effect of DNAse, Collagenase and/or
pronase on the RAM Ig binding to tumor cells was studied.
The effect of DNAse was examined in order to determine whether
the reagent was binding to surface-bound DNA liberated from dead
cells. Moreover, coliagenase (0.1 mg/ml) treated cells were
compared with pronase (2.5 mg/ml) treated cells. It can be
observed that a) DNAse treatment did not reduce the binding of
RAM Ig to the cells; b) Pronase, whose concentration was higher ,
than that of collagenase, removed surface bound •tumor associated



















I-RAM Ig BINDING TO TUMOR CELLS
Enzyme
(0.1 mS/ml)
Freshly excised and cultured CCH1 tumor cells with trypsin,
pronase or collagenase (all at 0.1 mg/ml) were compared with
nontreated turner cells in the direct radio-immune antiglobulin
test. Enzyme treatment included half an hour incubation of the
tumor cells with the corresponding enzyme at 37°C. Control cells
were incubated at 4°C for half an hour. It can be observed that
surface bound tumor associated Igs were not effected by the low-
concentrated enzymes. Note that reagent binding to cultured tumor



















FIG 43 EFFECT OF ENZYME ON THE
trypsin pronase coilagenase Enzyme
(0.1 mg/ml)
125
I-RAM Ig BINDING TO TUMOR CELLS
Freshly excised and cultured CCHi tumor cells treated with trypsin,
pronase, or collagenase (all at 0.1 mg/ml) were compared with non-
treated tumor cells in the direct radio-immune antiglobulin test.
Enzyme treatment included half an hour incubation of the tumor cells
with the corresponding enzyme at 37°C. Control cells were incubated
at 4°C for half an hour. It can be observed that surface-bound
tumor associated Igs were not effected by the low-concentrated
enzymes. Note that reagent binding to cultured tumor cells did





































In this experiment, the CCH1 tumor was disaggregated mechanically
at 4°C or by incubation with various pronase concentrations in a
37°C water bath. The CCH1 cells were then washed and compared in
the direct radio-immune antiglobulin test. Note that loss of TAIgs
from the surface of the tumor cells varies positively with enzyme
concentration.
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RAM Is concentrations of 1, 2 and 4 jug/100 jul were studied in
the second experiment. Cells used included normal spleen cells, tissue
culture CCHl cells and excised CCH.1 cells. As observed in Figure 43,
reagent binding was found to vary directly with its concentration.
Finally, the effect of 2, 4 and 3 jug/100 jul concentrations of RAM
Ig on normal spleen cells, CCHl cultured and CCHL excised tumor cells was
studied. Reagent binding was once again found to be correlated with its
concentration (Fig. 47).
For more examples on the influence of reagent concentration see
Figures 37, 38, 48 and 51.
EFFECT OF INCUBATION TIHE AND TEMPERATURE
The standard incubation period and temperature used in our assay
was one hour at 4°C. However, to assess the effect of time and temperature
on RAH Ig binding to tumor cells, different incubation periods at 4°C and
37°C were investigated.
Incubation periods of 1, 2, 3 and 4 hours were studied in the first
experiment at temperatures of 4°C and 37°C. The RAH Ig concentrations used
included 1, 0.5 and 0.125 jug/100 Jul. As depicted in Figure 48, RATI Ig
binding to the tumor cells increased with time and the reaction was enhanced
at 37°C at the three reagent concentrations used. Horeover, as in previous
experiments, the binding was found to vary directly with reagent
coneentration.
In the second experiment, incubation periods of 1.5, 3,5 and 20 hours
were studied at 4°C and 37°C. Excised CCK1 and T3 tumor cells and normal
spleen cells were used. RAH Ig binding to the cells was once again found
to vary directly with time (Fig. 49). However, the difference in the binding
-94-
observed between incubations at 4°C and 37°C was found to decrease and,
in the case of T3 and spleen cells, was reversed at 20 hours. Excised
CCHl cells exhibited highest binding of the RAM Ig followed by T3 and
spleen cells.
In the third and final experiment, incubation periods of 1, 2
and 20 hours at 4°C were studied. Similar to the previous results,
RAM Ig binding to the cells was found to increase with time (Fig. 50).
For more examples of the effect of incubation temperature on RAM
Ig binding see Figures 37, 39 and 40.
EFFECT OF CELL CONCENTRATION
Most of the experiments carried out for the development of the
direct RIAT included a study of the effect of cell concentration on RAM
Ig binding. In all the experiments, reagent binding was found to vary
directly with cell concentration (see Figures 36, 37, 38, 39, 45, 51 and 52).
With the exception of Figure 51, all the figures represent a study of
cell concentration in conjunction with other parameters the details of
which are described in the respective sections. Figure 51 represents a
5 6 7
study in which RAM Ig binding to 5 x 10 , 5 x 10 and 1 x 10 cells/ml
was compared. The cells consisted of excised CCHl tumor cells, cultured
CCHl tumor cells and normal spleen cells. A direct relationship between
cell concentration and RAM Ig was again indicated. Moreover, the difference
between RAM Ig binding to excised CCHl cells and spleen cells was amplified
at higher cell concentrations probably due to the larger size of tumor
ceils.
-94a-
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FIG 45 DETSRMINATION OF THE OPTIMUM I-RAM I;~ CONCENTRATION IN THE
DIRECT RADIO IMI-IUN5 ANTIGLOBULIN TEST.
In this experiment, the effect of RAM Ig concentration on its
binding to cells was examined at 2 different numbers. Cells
studied included freshly excised CCH1 tumor cells, spleen cells,
and thymus cells. It can be observed that the binding of RAM Ig
to the cells varies positively with its concentration. Note that
a) RAM Ig binding is highest in CCH1 tumor cells; b) reagent
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FIG 46 DETERMINATION OF THE OPTIMUM I-RAM Ig CONCENTRATION IN THE
DIRECT RADIO IMMUNE ANTIGLOBULIN TEST.
In this experiment, the effect of RAM Ig concentration on its
binding to cells was examined. Cells studied included freshly
excised and cultured CCHl tumor cells, and spleen cells. It can
be observed that RAM Ig binding to the cells varies positively
with its concentration. Note that a) RAM Ig binding is highest
in freshly excised CCHl cells; b) reagent binding to cultured






















I-RAM Ig - CONCENTRATION IN THE
DIRECT RADIO IMMUNE ANTIGLOBULIN TEST.
In this experiment, the effect of RAM Ig concentration on its
binding to cells was examined. Cells studied included freshly
excised and cultured CCHi tumor cells, and spleen cells. It
can be observed that RAM Ig binding to the cells varies positively
with its concentration. Note that a) RAM Ig binding is highest
in freshly excised CCHi cells; b) reagent binding to cultured
tumor cells does not exceed background levels
-94d-
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FIG 48- DETERMINATION OF THE OPTIMUM INCUBATION TIME IN THE DIRECT
RADIO IMMUNE ANTIGLOBULIN TEST
In this experiment, the effect of incubation time on reagent
binding to freshly excised CCK1 tumor cells was examined at 2
different incubation temperatures. Three different reagent
concentrations were used. It can be observed that at both
incubation temperatures, RAM Ig binding to tumor cells gradually
increased with incubation time. Note that reagent binding to the
























■FIG 49 DETERMINATION OF THE OPTIMUM INCUBATION TIME IN THE DIRECT
RADIO IMMUNE ANTIGLOBULIN TEST.
20 Time
(hours)
In this experiment, the effect of incubation time on reagent
binding to freshly excised CCII1, T3, and spleen cells was examined
at 2 different incubation temperatures. It can be observed that at
both incubation temperatures, RAM Ig binding to the cells increased
with incubation time. Note that a)RAM Ig binding is highest in CCHI
tumor cells; b)the differences observed at the 2 incubation temperature
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FIG 50 - DETERMINATION OF THE OPTIMUM INCUBATION TIME IN THE DIRECT
■RADIO IMMUNE ANTIGLOBULIN TEST
In this experiment, the effect of incubation time on reagent
binding to freshly excised CCH1 tumor cells was examined. It
can be observed that RAM Ig binding to the tumor cells gradually





FIG-51 DETERMINATION OF THE OPTIMUM CELL NUMBER IT THE DIRECT RADIO
■ IMMUNE ANTIGLOBULIN TEST
In this experiment, the effect of cell number on reagent binding
to freshly excised and cultured CCH1 tumor cells, and spleen cells
was studied. It can be observed that RAM Ig binding to the cells
varies positively with cell number. Note that RAM Ig binding is
highest in freshly excised CCKl cells.
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ASSESSMENT OF NRIgG 3INDIITG
Some of the PAK Ig nonspecific binding observed to turn.or cells
could have been due to NRS. In order to find out whether NRIgG binds
to tumor cells, immune and nonimmune RIgG were compared. Immune RIgG
comprised an acid eluted RAM Ig (see Materials and Methods) and nonimmune
RIgG included a NH^SO^ precipitate of NRS consecutively passed through
a DEAE column. Reagent concentrations of 1000, 200, 40 and S ng/0.1 ml
were used, and as can be observed from Figure 52, immune RAM Ig exhibited
a much higher binding to the tumor cells than NRIgG.
In another experiment, immune RAM Ig .and NRIgG were compared on
mechanically and enzyme prepared cells, where again the former was found
to bind much more excessively to the cells (see Figure 41).
NONSPECIFIC BUSING TO DEAD CELLS
One experiment was carried out in order to determine the RAM Ig
binding to dead cells. Non treated CCH1 cultured cells (viability 100%)
were compared with CCHl cultured cells incubated at 48°C for 2 hours
(viability 30%). No significant difference was observed between dead and
live cells in their RAM Ig binding (Figure 53).
A STUDY OF F(ab)^ BINDING
In order to determine whether normal immunoglobulins bind to
/
the tumor cells through their Fc-portion, binding of NRIgG and its F(ab)
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derivative to the cells was compared. The F(ala)0 fraction was prepared
by pepsin digestion of the NRIgG followed by the recovering of the F(ab)
on G150 sephadex column. Both reagents were absorbed with CCK1 tumor
culture cells and adjusted to the same concentration. As observed in
Figure 54, binding of the NRIgG to the excised CCH'l cells was found to
7
decrease upon cleavage of its Fc portion, appreciably so at 10 cells/ml
6 5
but less significantly at 10 and 10 cells/ml. Since our RIAT assays
5
employ 10 cells/ml, the RAM Ig binding to cells through its Fc portion
may be insignificant.
SUMMARY
The optimal conditions for the direct RIAT were found to be almost
identical to those of the indirect RIAT. The RAM Ig binding to the tumor
cells proved to be directly correlated -with reagent concentration, incubation
time and temperature and cell number.
Precoating studies showed 5% FCS to be a suitable inhibitor of non
specific binding of the RAM Ig to the plastic.
Enzyme studies indicated that minute amounts of trypsin, pronase
or collagenase were sufficient to yield highly viable cells without
removing the surface bound TAIg.
RAM Ig binding to the tumor cells was found to be specific: binding
was restricted to excised tumor cells, normal spleen cells and cultured
tumor cells treated with serum from tumor-bearing mice; normal thymus
cells and cultured tumor cells did not bind the RAM Ig; immune RAM IgG
binding to tumor cells appreciably exceeded that of nonimmune NRIgG; and
RAM Ig did not bind more to dead cultured tumor cells as compared to live
cells.
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Finally, immunoglobulin binding to tumor cells via their Fc
portion was found to be insignificant at the cell number used in our
assay.
The following conditions were adopted for the application of
the direct RIAT :
a. an overnight precoating of the tubes at 4°C with 4 ml of 5% FCS PBS
per tube
4
b. a cell number of 5 x 10 '/1G0 jdl
c. a RAM Ig concentration of 4 jug/100 jul
o
d. an incubation period and temperature of 1 hour and 4 C respectively
(or on ice)
e. washing the cells with 5% FCS PBS
A temperature of 4°C instead of 37°C was chosen for the incubation
period in order to maintain the conditions used in the indirect RIAT.
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FIG 52 NONSPECIFIC BINDING OF NRIgG TO TUMOR CELLS IN THE DIRECT
RADIO IMMUNE ANTIGLOBULIN TEST.
In this experiment, the nonspecific binding of NRIgG to freshly
excised CCHL tumor cells was assessed at various reagent concentrations
It can be observed that at all the reagent concentrations used, RAM Ig
binding to tumor cells appreciably exceeded that of NRIgG binding.








FIG 53 -THE EFFECT OF DEAD CELLS ON REAGENT BINDING IN THE DIRECT RADIO
IMMUNE ANTIGLOBULIN TEST.
In this experiment, cultured CCHL tumor cells were divided into
2 tubes, one of which was incubated in a 48°C water bath for 2
hours, while the other was left at 4°C for 2 hrs. The viability
of-the cells incubated at 48°C dropped from 100% to 30%. The live
and dead cells were compared in the direct radio immune antiglobulin
test. Note that there is no difference in RAM Ig binding bet-ween























FIG 54 ASSESSMENT OF REAGENT BINDING TO TUMOR CELLS THROUGH THEIR
FC—PORTION IN THE DIRECT RADIO IMMUNE ANTIGLOBULIN TEST.
In this experiment, the binding of NRIgG to freshly excised
and cultured CCH.1 tumor cells was compared with the binding of
its F(ab^) derivative at varxus cell numbers. It can be observed
that NRIgG binds more to the freshly excised tumor cells than its
F(ab^)0 derivative. However, the observed difference decreases
at lower cell numbers. Note that a similar difference in binding
is not observed in cultured tumor cells. While this result may
suggest that reagents could nonspecifically bind to infiltrating
host cells via their Fc-portion, such binding would be insignificant
at the cell number used in the standard direct radio immune anti
globulin test (i.e. 5 x 10 cells/ml).
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APPLICATION OF THE DIRECT RIAT
The direct radioimmune antiglobulin test (RIAT) was used to repeat
experiments carried out by the indirect RIAT and to perform additional
experiments. Consistent results were obtained regarding the in vivo
binding of immunoglobulins to T3 and CCH1 tumor cells, to tumors produced
by excised and cultured tumor cells, and to tumors in C.narvum treated
and nontreated mice. The TAIg levels were again found to be dose dependent
and the amount tended to vary directly with size and age of tumor. Horover,
in order to determine whether the results in different mice could be
reproduced in the same mouse, comparative studies were also carried out
on opposite limbs of the same mouse.
THE RESPONSE TO CChTl AND T3 TUMORS IN DIFFERENT I TICS
An experiment was carried out in which the variation of in vivo
bound TAIg with age and size of CCHl and T3 tumors grown in different
mice was simultaneously studied. As can be observed in Figures 55 and 55
the in vivo bound TAIg was found to increase with the age and size of
both types of tumors. Moreover, CCHl tumor cells always exhibited higher
amounts of TAIg than T3 tumor cells. The reasons behind the decrease in




































FIG 55 THE \ARIATI0N OF TAIg BINDING WITH TIME IN CCH1-AND T3 TUT.'ORS
g
CBA mice were injected s.c. on Day 0 with 10 viable CCHl or
T3 tumor cells. At various times thereafter, the amount of
4
host Ig associated with the surface of 5 x 10 cells from individual
tumors was assessed by the direct radio immune antiglobulin test.
It can be observed that TAIg binding increases with time in both
CCHl and T3 tumors. Note that TAIg is consistently less on T3
tumor cells than CCHl cells.
-98b-
14 16 18 20 22 24 26 28 30 32
Size (mm)
FIG 56 ■ THE VARIATION OF TAIg BINDING 171TH TUMOR SIZE IN CCF1 AND T3 TUMORS
- ^3 .. . .
0
CBA mice were injected s.c. on Day 0 with 10 viable CCHl or T3
tumor cells. The figure depicts tumor size and the amount of host
4
Ig associated with the surface of 5 x 10 cells from the corresponding
tumor in the experiment carried out on CCH'l and T3 tumor bearing
mice (see Figure 55). It can be observed that there is a positive
correlation between TAIg binding and tumor size in both CCHl g^d
T3 tumors (For a similar' assessment of TAIg binding with CCHl






THE RESPONSE TO CCHl TUMORS IN C.PARVUI-I TREATED AMD NONTREATED MICE
The effect of C. parvum on tumor growth and in vivo bound TAIg
was studied. C, parvum treatment included an ip injection of 0.2 ml
(1.4 mg) C. parvum on the third day following the injection of tumor
cells. As observed with the indirect RIAT, tumor growth inhibition
in C. parvum treated mice was again found to be correlated with higher
in vivo bound TAIg in the tumors (Figures 57 and 58). Moreover, in
treated and nontreated mice, in vivo bound TAIg increased with the age
of the tumors and, in nontreated mice only, with the size of the tumors.
However, as in the previous experiment, a. decrease in TAIg was noted
on day 18.
THE RESPONSE TO EXCISED AND CULTURED CCHl TUMOR CELLS
The response to excised and cultured CCH^ tumors was studied in
one experiment. Unlike the other experiments in which tumor cells were
prepared mechanically, the tumor cells in this experiment were prepared
by incubating tumor tissues in 5 mis pronase (0.1 mg/ml) at 37°C for V2
an hour. Tumors grown from freshly excised tumor cells were found to bind
higher TAIg in vivo than those grown from cultured tumor cells (Fig. 59).
THE RESPONSE TO CCHl INJECTED INTO OPPOSITE LIMBS IN THE SAME HOUSE
In order to determine whether the effects observed in different mice




































FIG 57 THE VARIATION OF TAIg BINDING WITH TILEE IN C.PARVUIJ TREATED AMD
NONTREATED CCH1 TUMOR BEARING MICE
CBA mice were injected s.c. on Day 0 with 10 viable CCK1 tumor
cells. On Day 3, half of the mice were injected in with 1.4 mg
of C.parvum. At various times thereafter, the amount of host Ig
4
associated with the surface of 5 x 10 cells from individual tumors
was assessed by the direct radio immune antiglobulin test. It can
be observed that TAIg binding increases with time in both C.parvum
treated and nontreated tumor bearing mice. Note that C.parvum































FIG 58 THE RELATIONSHIP OF TAI^ BINDING TO TUMOR SIZE IN C.PARVUM
TREATED AND HONTRSATSD CCH1 TUMOR BEARING MICE
CBA mice were injected s.c. on Day 0 with 10^ viable CCH1 tumor
cells. On day 3, half of the mice were injected ip with 1.4 mg
of C,parvum. The figure depicts tumor size and the amount of host
4
Ig associated with the surface of 5 x 10 cells from the corresponding
tumor in the experiment carried out on C.parvum treated and non-
treated tumor bearing mice (see Figure 57). While the number of
tumors is too small for significant observations on the relationship
of TAIg with tumor size, it can be noted that the smaller tumors



















FIG 59 THE RESPONSE TO FRESHLY EXCISED AND CULTURED CCHl TUMOR CELLS
CBA mice were injected s.c. on Day 0 with 10^ viable freshly
excised or cultured tumor cells. On day 24, the amount of host
4
Ig associated with 5 x 10 cells from the individual tumors was
assessed by the direct radio immune antiglobulin test. Note
that tumors grown from freshly excised tumor cells exhibit
higher TAIg than tumors grown from cultured tumor cells.
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mice were studied in 2 experiments.
Prior to comparative studies between CCKl and other types of tumors
in the same mouse, CCH^- tumors grown on opposite limbs were compared in
order to insure that in vivo TAIg binding was eo.ual on both limbs. 1 x 10
CCRl cells were subcutaneously injected into each hind limb of 10 mice.
Five mice were sacrificed on days 16 and 20 by ether inhalation, and their
tumors excised and studied. On both days, no significant difference in
in vivo bound TAIg or size between tumors grown on opposite limbs of the
mice was observed (Figs. 60 and 61). A slight increase of in vivo bound
TAIg with time was noted on all the tumors studied. Similar results were
obtained with the other experiment.
THE RESPONSE TO CCHl AKD T3 TUMORS III THE SAME HOUSE
In vivo bound TAIg in CCKl and T3 tumors grown on opposite limbs
of the same mouse was compared in three experiments. CCHl tumor ceils
consistently showed higher in vivo bound TAIg than T3 tumor cells. Although
the tumors studied were approximate!;/ of the same age (15-17 days), the
mean TAIg amounts bound varied between the experiments owing to the
125
different I-RAH Ig reagents used in each experiment.
In the first experiment, 17 day old CCKl and T3 tumors were studied.
CCKl tumors showed a mean TAIg amount of 3.2 ng and a mean size of 18.6 mm
compared to 0,98 ng and 22.7 mm respectively in T3 tumors (Fig. 52a).
In the second experiment, 16 day old tumors were compared. CCHl
tumors once again showed a higher mean TAIg amount of 11.5 ng relative to
2.4 ng in T3 tumors (Fig. 62b).
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Day 15 tumors were studied in the third experiment.
Similar to the previous two experiments, CCH1 tumors exhibited
higher TAIg levels than T3 tumors (Fig. 62c).
THE RESPONSE TO FRESHLY EXCISED AND CULTURED CCHl TUMORS IN THE
SALE HOUSE
The response to freshly excised and cultured CCKl tumor cells
were also compared by injecting these preparations into opposite
6
limbs of the same mouse. In 10 mice, 1 x 10 excised CCHl cells and
6 .
1 x 10 cultured CCHl cells were injected into each of their hind right
and left limbs respectively. On days IS and 19, 5 mice were sacrificed
and their tumors studied. On both days, excised CCHl cells showed higher
in vivo TAIg binding than cultured CCH.l cells, and they were found to
produce larger tumors (Fig. 63). Moreover, TAIg binding on both types
of tumors was found to increase with time.
THE RESPONSE TO DIFFERENT DOSES OF CCHl TUMOR CELLS IN THE SALE MOUSE
Four experiments were carried out to study the response to
different doses of CCHl tumor cells in the same mouse. Unlike the
results obtained with similar studies in different mice where higher
doses of tumor cells were found to produce higher in vivo TAIg binding
(see 'application of the indirect RIAT' ), conflicting results './ere
obtained with experiments in the same mouse, where once the lover dose
was found to produce the higher TAIg binding.
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Ten mice in the first experiment were injected with 5 x 10°
5
and 0.5 x 10 CCHl tumor cells into their hind right and left limbs
respectively. Tumors produced by the higher dose of tumor cells
exhibited higher in vivo bound TAIg on day 17 and were larger (Figs. 54
and 65). By day 21, however, the TAIg gap between the 2 groups had
appreciably decreased. Moreover, contrary to the general trend obtained
in previous experiments, the TAIg binding was found to decrease with time
in this experiment.
In a similar study in another experiment, tumors induced
by different doses of tumor cells (5 versus 0.5 x 10 cells) in the sane
mouse were compared on day 20. As on day 22 in the previous experiment,
no significant difference in TAIg binding was observed between the 2
groups (Fig. 66a). Tumors produced by the larger dose, however, were
once again larger.
Contrary to the first experiment, the results of the third
experiment showed higher in vivo TAIg binding on tumors produced by
the lower dose of tumor cells (1 versus 0.1 x 10^ cells) (Fig. 66b).
Once again, however, the higher dose produced larger tumors.
Although no significant difference was obtained between the 2
groups in the fourth experiment, tumors produced by the higher dose






















FIG 60 COMPARISON OF THE AMOUNT OF Ig BOUND TO CCHl TUMORS OBTAINED
FROM CONTRALATERAL SITES
CBA mice were injected s.c. in contralateral sites on Day 0 with
10^ viable CCHl tumor ceils. On days 16 and 20, the amount of host
4
Ig associated with 5 x 10 cells from individual tumors was assessed
by the direct radio immune antiglobulin test. Note that no
significant difference in TAIg was obtained between tumors grown on

















FIG 61 ■ COMPARISON OF THE SIZE OF CCIil TUIIORS OBTAIKED FROM CONTRALATERAL
■SITES
6
CBA mice were injected s.c. in contralateral sites on Day 0 with 10
viable CCH1 tumor cells. The figure depicts the sizes of the tumors
on Days 16 and 20, Note that on either day, there is no






















Day 16 Day 15
FIG 62 COMPARISON OF THE AMOUNT OF Ig BOUND TO CCH1 OR T3 TUMORS
OBTAINED FROM CONTRALATERAL SITES.
CBA mice were injected s.c in contralateral sites on Day 0 with
6 i
10 viable CCHX or T3 tumor cells. About two weeks later, the
tumors were excised and the amount of host Ig associated with
A
5 x 10 cells from individual tumors was assessed by the direct
radio immune antiglobulin test. The figure represents the results
of 3 separate experiments. Note that in all 3 experiments, CCK1
tumors exhibit appreciably higher TAIg than T3 tumors.
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FIG 63 COMPARISON OF THE ALIOUNT OF Ig BOUND TO TUMORS GROWN FROM FRESHLY
EXCISED Aid CULTURED CCIij TUMOR CELLS ON CONTRALATERAL SITES
CBA mice were injected s.c. in contralateral sites on Day 0 with
0
10 viable freshly excised or cultured CCHl tumor cells. On days
A
16 and 19, the amount of host xg associated with 5 x 10 cells
from individual tumors was assessed by the direct radio immune
antiglobulin test. It can be observed that tumors grown from
freshly excised tumor cells exhibited appreciably higher TAIg
than tumors grown from cultured tumor cells. Note that TAIg


















Day 17 Day 21
■FIG 64 THE EFFECT OF TUMOR CELL DOSE ON TAIg BINDING
CBA mice were injected s.c. in contralateral sites on Day 0 with
5
5 or 0.5 x 10 viable CCHl tumor cells. On days 17 and 21, the
4
amount of host Ig associated with 5 x 10 cells from the individual
tumors was assessed by the direct radio immune antiglobulin test.
Note that on day 17, tumors produced by the higher dose of tumor
cells exhibited higher TAIg amounts than tumors produced by the
lower dose of tumor cells. However, this difference was no longer

















FIG 65 THE EFFECT OF TUMOR CELL DOSE OH TUMOR SIZE
CBA mice were injected s.c. in contralateral sites on Day 0 with
5
5 or 0.5 x 10 viable CCHl tumor cells. The figure depicts the
sizes of the tumors on Days 17 and 21. Note that on both days,
tumors produced by higher dose of tumor cells were larger in size



















Day 20 Day 17 Day 18
FIG 65 THE EFFECT OF TUMOR CELL DOSE ON TAIg BINDING
CBA mice were injected s.c. in contralateral sites on Day 0 with
different doses of viable CGHI tumor cells. Two to three weeks
4
later, the amount of host Ig associated with 5 x 10 cells from
individual tumors was assessed by the direct radio immune anti¬
globulin test. The figure represents the results of 3 separate
experiments.
a) Comparison between tumors produced by 5 or 0.5 x 10~ CCHl tumor
cells. Note that there is no significant difference between the
two groups. This result is similar to the observation made on
Day 20 of tumor growth in Figure 64.
b) and c) Comparisons between tumors
tumor cells. Note that there is no
tumors produced by different doses
0
produced by 1 or 0,1 x 10 CCHi
significant difference between the
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ADDITIONAL C.PARVUM STUDIES
a) THE RESPONSE TO CCK1 l/ITH AMD WITHOUT SC C. PARVUS TREATMENT
C. parvum studies were expanded to include tumors grown in
the same mouse. The right limbs of the mice were subcutaneously injected
with 0.2 ml (1.4 mg) C. parvum three days after the tumor injection, while
the left limbs were not treated. As observed in Figure 67a, no significant
difference in TAIg binding was observed between the 2 groups on days 17
and 21. Moreover, no inhibition of tumor growth was observed in C. parvum
treated mice.
b) THE RESPONSE TO CCHl WITH Ml? WITHOUT INTRATUMOR C. PARVUM IN TH3
SAME MOUSE
In order to study the effect of intratumor C. ffarvum treatment on
in vivo TAIg binding, tumors growing in the left limb of the mice were
injected with 0.2 ml (1.4 mg) C. parvum on day 8 following tumor injection,
while tumors growing on the right limb were not treated. Once again, no
significant difference was found between the 2 groups on days 18 and 22




Results obtained with the direct RIAT were similar to the results
exhibited by the indirect RIAT. CCHl tumors showed higher in vivo bound
TAIg than T3 tumors; excised tumor cells were found to bind higher in
vivo TAIg than cultured tumor cells; and mice receiving ip C. narvum
treatment exhibited higher in vivo bound TAIg on their tumors than non-
treated mice.
New comparative experiments conducted in the same mouse reaffirmed
the results obtained in different mice. CCHl tumors were found to bind
more in vivo TAIg than T3 'tumors. Excised CCHl tumor cells and larger
CCHl tumors in general, were found to bind higher in vivo TAIg than
cultured CCHl tumor ceils and smaller CCHl tumors respectively. However,
SC or intratumor C. parvum treatment on days 3 and 8 respectively following
tumor cell injection, was found not to influence tumor growth or the in


















FIG 67 THE EFFECT OF LOCAL C.PARVUH TREATMENT ON TAIg BINDING
CBA mice were injected s.c. in contralateral sites on Day 0 with
106 viable CCHl tumor cells. Tumors growing on one siiewere then
treated with C.parvum, while tumors growing on the other sites were
not treated. On various days thereafter, the amount of host Ig
4
associated with 5 x 10 cells from individual tumors was assessed
by the direct radio immune antiglobulin test. The figure represents
the results of 2 experiments.
a) the right limbs of the mice were injected s.c. v/ith 1.4 mg of
C.parvum on day 3. It can be observed that no significant
difference in TAIg binding was obtained between C.oarvum treated
and nontreated mice on days 17 and 21.
b) tumors growing on the left limbs of the mice were injected with
1.4 mg of C.parvum on day 3. No significant difference in TAIg
binding between C.parvum treated or nontreated tumors was obtained
on days 13 and 22. Note that in both gropps TAIg binding increased
with time.
No inhibition of tumor growth by C.parvum was observed in either experiment.
I M I' U NOSUPPRESSIVE STUDIES
Immunosuppressive e:cperiments were carried out in order to find
out some of the mechanisms that might be involved in the in vivo binding
of TAIgs. Nude mice and B mice were studied in order to determine the
significance of T cells in the in vivo binding of TAIgs. The importance
of macrophages in TAIg binding was investigated through the treatment of
mice by gold salts. In addition, the effects of sublethal whole body
irradiation on TAIgs was studied.
B mice consisted of thymectomized and X-irradiated mice. They were
thymectomized at the age of 4-6 weeks, followed ten days later by whole body
irradiation (850 rads) with thorax shielding. The mice were then allowed
to recover 'over a period of several weeks. Controls included non-treated
and sham thymectomized mice. T cell deprivation was assessed by visual
examination for the absence of the thymus and by antibody response to SRBC.
The right limbs of the mice were injected SC with 1 x 10° tumor cells around
the age of twelve weeks.
Two experimentsv/ere carried out on B mice. In the first experiment,
tumor growth and TAIg binding was examined on days 17 and 26 post tumor
cell injection. Although tumors grown in normal mice v/ere larger on day 17,
no significant difference was observed in TAIg binding between normal and
B mice on days 17 and 26 of tumor growth (Table 4). However, the significanc
of this experiment was limited by 2 criteria. Firstly, sham thymectomized
mice were not tested; and secondly, the normal mice had been preinjected
with CCH1 cultured tumor cells iv 11 days prior to the SC injection of the
tumor cells.
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Sham thymect'omized mice were included in the second experiment.
On day 15 after the tumor cell injection, the tumors were excised and
their TAIg content assessed. As can be observed from Table no
significant difference in TAIg levels was obtained between T-cell deficient
and normal mice. However, sham thymectomized and thymectomized mice
showed higher average levels of TAIgs ±1 their tumors than nontreated mice.
This could suggest that inflammatory reactions to the surgery may have led
to the enhancement of antibody synthesis, some of which may then have non-
specifically bound to the tumors.
Nude mice and their littermates were obtained from Moredun Institute,
Edinburgh, and maintained in germ free conditions. Control mice included
12 week old C3A mice. The right limbs of the mice were injected with
6
1 x 10 tumor cells. The tumors were measured and excised on days 17 and 22,
and the amount of TAIg present was assessed. Table 5 indicates that no
significant difference in tumor growth or in vivo TAIg binding was obtained
between the nude and CBA mice. The tumors did not grow in the littermates,
which were not of CBA origin.
In order to study the effect of gold salt administration on TAIg
binding, mice were injected 8 times intra-peritoneally with 1 mg sodium
aurothiomalate. Gold-salt treatment has been suspected to effect macrophage
function (James et. al. 1976). The treatment began on day 2 after the SC
5 i
injection of 1 x 10 tumor cells per mouse, and continued at 2-3 day
intervals (3 times a week). Tumors were measured and excised on day 24,
and their TAIg content determined. Gold salt treatment was found to have
no effect on tumor growth or in vivo binding of TAIg (Table 6).
Likewise, subjecting the mice to 400 rads whole body irradiation
24 hours before the injection of tumor cells had no major effect on TAIg
binding (Table ^). However, the difference observed on day 21 approached
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significance, especially when the increase of tumor size in irradiated nice
was considered.
SUBCLASS STUDIES
Preliminary class and subclass studies were carried out in order
to determine the quality of TAIg bound in tumors obtained from CP treated
and nontreated mice. The indirect tubd RAIT was applied in these studies.
Briefly, the tumor cells were incubated with rabbit anti-mouse IgG1, IgG2a,
IgG2b, IgG3, IgM, or IgA for 1 hr on ice. After a few washes, the cells
were incubated with "'^-'I-Swine anti-rabbit Ig for 1 hr on ice and then washed
and counted.
In the two experiments that were carried out, CCH1 tumor cells
were found to possess small quantities of all the classes and subclasses
of the Igs tested (Table 8). Moreover, tumor cells from CP treated mice
were found to have higher amounts of the Igs than tumor cells from non-
treated mice, especially IgA, IgG2b, and IgG3.
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TABLE 5 TUMOR—ASSOCIATED Ig LEVELS AMD TUMOR SIZE IN NUDE MICE









normal 4.7 - 1.7 13.3 - 0.9 6.5 - 3.1 13.5 - 3.5
nude 5.7 - 2.3 13.6 - 2.5 6.3 - 2.5 13.8 - 1.7
+ Refers to the day tumor was removed
X Each group contains 3-4 mice.
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TABLE S TUMOR—ASSOCIATED Ig LEVELS AND TUT-IOR









"lone 12.5 - 5.2 I-IC\J*+1CO•COC\J
Gold-salt 9.5 - 2.1 23 - 1.8
+ Refers to the day tumor was removed
X Treated mice were injected with sodium
aurothiomalate (lmg) ip 8x, beginning on
day 2 after s.c. injection of CCHi tumor
cells. The mice underwent an ip injection
every 3 days.
* Each group contains 4 mice.
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TABLE 7 TUKOR—ASSOCIATED Ig LEVELS AND TUIIOR SIZE IN IRRADIATED I-UCE
+x
Treatment
















Irradiation 6.9 - 2.9 14.9 - 2.0 6.5 - 3.2 16.9 - 0.3
* Refers to the day tumor was removed
+ Treated mice were irradiated (whole body, 400 rad) 24 hrs before
the s.c. injection of CCHi tumor cells.
X Each group contains 3 - 4 mice
Note that although irradiation does not effect Ig levels on day 17,
it appears to inhibit the Ig level on day 21.
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DISCUSSION
1. SUMMARY OF THE RESULTS
a. The development of the direct and indirect RIAT : The initial studies
on the development of the isotopic antiglobulin test were carried out
by the plate method. Preliminary results suggested the relevance of the
indirect plate method for the semiquantitative assessment of in vivo
bound TAIgs in freshly excised mechanically prepared tumor cells. It
was observed that the sensitivity of the technique was diminished by
non-specific binding of reagents to plastic and the binding of normal
rabbit serum to tumor cells. The latter was suspected to be due to the
presence of Fc-receptor bearing host cells in the tumor. The non-specific
binding to plastic was inhibited by precoating the plates with 5% FCS-
o
PBS overnight at 4 C.
The sensitivity of the indirect RIAT was improved by the use of the
tube method. This method permitted the use of larger volumes of washing media
and facilitated the technique. Studies for optimal assay conditions indicated
that the binding of the radio—iodinated antiglobulin reagent varied positively
with reagent concentration, cell number, and incubation period. Further
studies with the direct RIAT confirmed these results and the specificity
of the method. The reagent was found to specifically bind to freshly
excised tumor cells and spleen cells. Moreover, the binding of the reagent
to tumor cells and host cells via their Fc-portion was found to be insig¬
nificant at the cell number used in our assay.
Enzyme studies with the direct and indirect RIAT demonstrated that
the loss of TAIg from the surface of tumor cells increased with increasing
enzyme concentration and incubation time. However, incubation of tumor
tissues for half an hour at 37 C with an enzyme concentration of 0.1 mg/ml
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was found to yield sufficient number of viable cells without the
removal of surface-bound TAIg.
b. The application of the direct and indirect RIAT : The RIA.T was
applied to the study of in vivo bound TAIgs and its variation with the
age and size of "tumors, the type of tumors, and the dose of tumor cells
injected. The influence of non-specific immunostimulation and immuno¬
suppression on the in vivo binding of TAIg were also examined. The
indirect RIAT was used for the preliminary studies of TAIg. CCH1 tumors
were found to contain higher amounts of TAIg than the less immunogenic
T3 tumors. Similarly, "tumors produced by freshly excised CCH1 cells
were found to have more in vivo bound TAIg than tumors produced by
cultured CCH1 tumor cells. Pronase prepared freshly excised tumor cells
were demonstrated to produce tumors of higher TAIg amounts than tumors
produced by mechanically prepared freshly excised tumor cells.
In general, the amount of in vivo bound TAIg was found to increase
with the age and size of all types of tumors that were investigated.
Moreover, larger doses of CCKl tumor cells were shown to produce larger
tumors which possessed higher amounts of TAIg than tumors produced by
lower doses of CCKl tumor cells. However, the positive relationship
between in vivo bound TAIg and size of tumors was not absolute. Small
tumors whose growth were inhibited by the administration of C.parvum
were found to contain higher amounts of TAIg than the larger non-inhibited
tumors.
Studies with the direct RIAT confirmed the above observations
obtained by the indirect RIAT. Moreover, similar comparative studies
were carried out on opposite limbs of the same mouse. As previously noted,
CCHl tumors were found to bind higher ar.iou.nts of TAIg than T3 tumors. In
addition, freshly excised CCHl tumor cells and larger CCHl tumors were
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found in general to bind more TAIg than cultured tumor cells and
smaller tumors respectively. SC cr intratumor C. parvum treatment
on days 3 and 8 respectively after tumor cell injection was not
found to influence 'tumor growth or the in vivo binding of TAIg.
Preliminary immunoglobulin class and subclass studies with the
I
indirect RIAT on CCHl tumor cells indicated that in vivo bound TAIg
was comprised of IgGl, IgG2a, IgG2b, IgG3, IgA and IgM. Moreover,
tumors obtained from C.parvum treated mice were shown to contain
significantly higher amounts of IgA, IgG3 and IgG2b. Parallel studies
on CCHl tumor extracts showed that tumors from C.parvum treated mice
contained higher levels of IgA, IgGl and IgM than tumors from nontreated
mice.
T-cell deprivation was not found to influence the in vivo binding
of TAIg. Tumors grown in thymectomized mice or nude mice were found to
possess similar amounts of TAIg to tumors grown in normal mice. In
addition, gold salt administration did not inhibit the binding of TAIg
in CCHl tumors. Likewise, whole body irradiation was not found to
influence appreciably the in vivo binding of TAIg. However, tumors
assessed on day 21 after tumor cell injection were observed to have
lower TAIg than tumors obtained from non irradiated mice, although
tliis was not significant. (For more information on these mechanism
studies, refer to section 5 of discussion).
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2. RELEVANCE OF THE RADIO IMMUNE ANTIGLOBULIN TEST TO THE STUDY
OF TUITOR—ASSPCIATED IISIUNOGLOBULINS, AND ITS POTENTIAL
The radio immune antiglobulin test (RIAT) has been extensively
investigated in order to ascertain its validity in studying cell-bound
immunoglobulin. It has been primarily employed in measuring the in vitro
binding by lymphoid cells and tumor cells of immunoglobulins from
preparations believed to contain antibody. Our aim was to study Ig
bound in vivo to the tumor by applying the RIAT on mechanically prepared
tumor cells. The use of enzymes to obtain tumor cells was avoided as
they were known to remove cell-surface bound proteins (Hynes, 1976).
The indirect RIAT which was used in our studies was based on an
assay introduced by Harder and McKhann (1S68). Similar to our studies,
these authors and others (Sparks et, al. 1969) found that the uptake
of the iodinated Ig was proportional to antibody concentration. The
nonspecific binding which they observed was attributed to both radio-
iodinatea Ig ana the test serum. Goldstein et. al. (1973) were able
to detect by the RIAT non-cytolytic antibodies directed against cell
surface antigens. Burdick et. al. (1973) obtained similar results
with the RIAT demonstrating an almost linear relationship of the anti¬
globulin and test serum uptake with their corresponding concentrations.
James et. al. (1977a) used the indirect RIAT to studjr anti-tumor anti¬
bodies in the sera of tumor bearing mice. Nits et. al. (1974) used
a direct RIAT to study in vivo bound TAIgs in ascitic tumors.
Other investigations have employed iodinated staphylococcal
protein A in the indirect RIAT. Protein A has been found to react with
specifically bound mouse IgG, 2a, 2b, and 3; and human IgG 1, 2 and 4
(Kronvall et. al., 1970). Brown et. al. (1977) used staphylococcal
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protein A in order to study serum Igs produced against different tumors.
As with the previous RIATs, the uptake of serum Ig was found to decrease
with higher dilutions, but was still detectable at a dilution of 1/1600.
When compared to the isotopic antiglobulin assay, the protein A method
was found to be more sensitive. However, the former retained the
advantage of detecting classes of Ig other than IgG.
While "the RIAT has been widely used in the study of TAIg in ascitic
tumors (Witz et. al. 1974; Dorval et. al. 1976; Braslav/sky et. al. 1976a;
Bras lav/sky et. al. 1976b and Moav et. al. 1978), its application to the
study of TAIgs in solid tumors has been very limited. One of the main
reasons behind this has been the difficulty of obtaining single cell
suspensions of solid tumors without the use of enzymes. In our studies,
the tumor cells were prepared mechanically either by gentle teasing or
stirring of the tumor tissue, or by incubating > ':he latter in collagenase
(0.1 mg/ml) at 37°C . Cell surface proteins on tumor cells prepared by
either method, have been found to be qualitatively the sane (Guy et. al. 1977).
Although the cells prepared mechanically had low viability, the shape
of the cells appeared intact, and the binding of the iodinated antiglobulin
to the tumor cells was found to bear no relationship to their viability.
Enzyme studies by both the direct and indirect RIAT established
that the loss of TAIg from the surface of freshly excised tumor cells
was directly related to enzyme concentration and its time of incubation
period. Although enzyme concentrations of 0.1 mg/ml achieved higher
cell viabilities than the mechanical cell preparation, TAIg amounts on
tumor cells prepared by either method were very similar.
Some of the factors which might have interfered with the
sensitivity of both the direct and indirect RIAT include the following:
elution of TAIg; binding of reagents to plastic; loss of cells during
the assay; and binding of the reagents to Fc-receptors on tumor and/or
host cells. As previously mentioned (see 'Results' section), the effect
of these factors wasminimized by various means. The elution of TAIg
from the surface of tumor cells was avoided by performing the assay on
ice or at 4°C; The nonspecific binding of the reagents to plastic was
inhibited by precoating the tubes with 5-10 % FCS-P3S overnight at 4°C.,
The loss of cells was diminished by increasing the centrifugation time
of each wash from three to five minutes, and by carrying out the assay in
tubes instead of plates. Finally, 'while the binding of reagents to Fc
receptors on the cells was found to occur at high cell concentrations,
a similar binding of the reagents to Fc-receptors at the cell number
used in our assay was found to be less significant.
As previously noted, our results also showed that reagent binding
varied positively with reagent concentration, cell number, incubation
time, and incubation temperature. Although the increase in temperature
may have led to a limited elution of TAIgs from the surface of tumor
cells, the results suggest that the latter must have been compensated
for by increased binding of reagents to the TAIg on the cells due to
higher kinetic energy at higher temperatures. However, an incubation
temperature of 4°C was maintained in the direct RIAT in order to facilitate
the comparison of its application with that of the indirect RIAT.
Specificity studies by the direct RIAT demonstrated that reagent binding
was restricted to freshly excised tumor cells, spleen cells, and cultured
cells treated with anti-tumor antibodies. Thymus cells and cultured
tumor cells did not bind the antiglobulin reagent.
It would appear, therefore, that the RIAT is relevant for the
quantitative study of TAIgs. While the direct RIAT seems to be more
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sensitive than the indirect RIAT, the specificity, of both methods could
be considerably improved by cell-separation techniques. The latter would
involve the separation of host T-cells, 3 cells, macrophages, -and dead
cells from the freshly excised tumor cells. In addition, the specificity
of the RIAT might also be further enhanced by multiple absorption of the
reagents with cultured tumor cells and thymus cells. Finally, preliminary
class and subclass studies have indicated that the indirect RIAT could
also be suitable for qualitative studies of TAIgs.
V/ith the improved assay conditions which are outlined above, the
prospects for the use ox the RIAT in tumor immunology research appear to
be good. Radio iodinated immunoglobulins or Staphylococcus aureus
protein A have been shown to be sensitive enough to detect in vivo
variation of TAIgs in tumors and the rebinding of eluted antibodies to
cultured tumor cells. (V/itz et. al. , 1974; Dorval et. al. , 1976;
Braslawsky et. al., 1976b; V/itz, 1977; Moav et. al,, 1973 and Ehriich
and V/itz, 1979).
Similar to our findings, variability in the in vivo TAIg binding
between different tumors of the same group of mice has been observed
(Dorval et. al., 1976). Moreover, this variability was found in the latter
study and in some of our experiments to increase with the age of the tumors.
Therefore, the observed variability among tumors of the same group seems
to be due to different patterns of tumor progression in these tumors rather
than being due to a defect in the RIA.T. For example, different degrees of
angiogenesis in different tumors within the same group could lead to
variable TAIg binding. A study of the correlation between vascularization
and TAIg binding should clarify this point.
The RIAT nay also be exempt from another disadvantage that might
be attributed to it; namely, the non specific binding of normal sera to
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the cells. There is little doubt that the nonspecific binding of
normal sera, and especially normal rabbit serum could be due to
infiltrating Fc-receptor bearing host cells. (Szynaniec and James 1975;
and I'/itz, 1977). The latter nonspecific binding can be diminished by
the removal of Fc-receptor host cells, moreover, such sera might
bind to plastic thus decreasing the sensitivity of the RIAT. The use
of siliconized glass tubes might improve the sensitivity of the RIAT.
Compared to other assay systems for TAIgs, such as immunofluor-
esence and haenadsorption, the RIAT appears to be a/ell suited for the
quantitative and qualitative study of TAIgs. It is objective, sensitive
and economical.
3. .RELATIONSHIP OF THE IM-IUI'TOC-EICSCITY AND DOSE OF TUIIOR C5LIS TO TITS
IN VIVO BINDING OF TAIg
•
The results showed a general tendency of the in vivo TAIg binding
in tumors to vary positively with the immunogenioity of the tumor cells
and their dose. CCKL tumor cells were found to produce tumors of higher
TAIg content than T3 tumor cells. Freshly excised CCKl tumor cells and
pronase prepared tumor cells were found to bind higher TAIg in vivo
than cultured CCKl tumor cells and mechanically prepared tumor cells
respectively. In addition, larger doses of CCHl tumor cells were shown
to produce larger tumors containing higher amounts of TAIgs.
The higher in vivo binding of TAIg by CCHl tumor cells compared
to T3 tumor cells could be due to the higher immunogenicity of the CCHL
cells (James et. al. 1973). This hypothesis is particularly plausible
if it is assumed that the majority of the TAIgs are anti-tumor antibodies.
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On the other hand, if the TAIgs include nonspecific antibodies,
then the lower in vivo binding of TAIg by T3 tumor cells may be due
to its more rapid growth. In other words, it may be possible that those
nonspecific antibodies aire 'diluted' in the larger T3 tumors. The latter
could also effect the binding of anti-tumor antibodies. Another reason
for the lower amount of TAIg inT3 tumors could be due to the greater
shedding of antigens by such tumors. This can be examined by assays
for immune complexes in the sera of T3 tumor bearing mice. Such immune-
complexes have been found to contribute to tumor growth by interrupting
the anti-tumor immune response (Price and Robins, 1973).
A further reason for the lower TAIg binding by T3 tumor cells could
be due to the production of proteolytic enzymes by these cells. Such
enzymes may cleave the Fc portion of surface bound immunoglobulins
(Keisari and Uitz, 1976). In addition, since a constant number of
cells were used in the RIAT, the decreased presence of TAIg on T3 tumor
cells could be due to their slightly smaller size compared to CCKl tumor
cells. However, the latter hypothesis is unlikely -especially that similar
differences were noted in tumor cells of comparative sizes grown in vivo
(i.e. CCH1 freshly excised vs cultued tumor cells). Finally, the observed
differences between CCKl and T3 tumor cells may be due to the influx
of different types and numbers of host cells into the tumors (Pross and
Xerbel, 1976), which may bind TAIg through their Fc-receptors (see also
the addendum).
In an examination of the Ig subclass content in CCIil and T3
tumor extracts, the latter were shown to have significantly lower levels
of Igi'l and igA (James et. al. , 1979). This was further demonstrated in
another experiment where T3 tumors were shown to contain significantly
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lower levels of surface bound IgM. These observations could imply-
that the more immunogenic CCHl tumor cells may induce complement
binding antibodies which may inhibit their growth compared to T3
tumo^ cells. However, this has to be confirmed by further experiments
on the sera of tumor bearing mice and their freshly excised turner cells
and tumor cell extracts. The differences of IgA binding between CCHl and
T3 tumors could be due to differences in the influx of polymorphonucleo-
cytes which may possess receptors for the Fc-portion of IgA (Van Epps
et, al«, 1978). However, preliminary studies of host cell content in
our tumors showed no significant differences between CCHl and T3 tumors in
the influx of PMN (see addendum).
Likewise, there could be many reasons to explain the higher in vivo
binding of TAIg by CCHl freshly excised tumor cells compared to cultured
tumor cells. For example, freshly excised tumor cells may be more immuno¬
genic than cultured tumor cells by the virtue of in vivo immunoselection.
Fcr the immunostimulation theory would predict that only the relatively
immunogenic tumor cells would escape the immune response and propagate.
Thus, freshly excised tumor cells may consist of a uniform population
of tumor cells of high immunogenicity, while cultured tumor cells, which
would have been multiplying in vitro for some time, could consist of
a heterogenous population of cells of varying immunogen4city. Since,
according to the immunostimulation theory again, higher immunogenicity
may be correlated with enhanced tumor growth, then this could explain
the faster growth of freshly excised CCHL tumor cells and their greater
binding of TAIg.
However, a more convincing hypothesis for the observed difference
between cultured CCH1 tumor cells and their freshly excised counterpart
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may be based upon the host cell content of the latter. Freshly
excised turner cells may contain plasma cells which could continue to
produce anti-tumor antibodies when transplanted with the tumor cells.
Moreover, freshly excised tumor cells may contain sensitized T-cells
which could induce the influx of PMN by liberating lymphokines. A
similar influx of antibodies and plasma cells could also be enhanced
by macrophages which may facilitate tumor antigen processing. Moreover,
another reason for the increased binding of TAIg by freshly excised
tumor cells could be due to antigenic changes produced by the enzyme
pronase. Enzymatic dissociation has been found to enhance the tumori-
genicity of preneoplastic nodule lines (Medina et. al., 1978).
Quantitative differences of in vivo bound TAIg were also observed
between freshly excised tumor cells prepared in different ways. Freshly
excised pronase prepared CCHi tumor cells produced larger tumors
containing higher in vivo bound TAIg than freshly excised mechanically
prepared tumor cells.
Pronase preparation of tumor cells could have resulted in the
following: the emergence of new antigenic sites; the production of
more viable cells; the elimination of certain types of host cells; and/
or the removal of surface bound TAIgs. These factors could have acted
synergistically to enhance the influx of TAIgs into the tumors. However,
the largest contribution of the enhanced immunogenicity of pronase
prepared tumor cells could have come from the emergence of new antigenic
sites (Bekesi and Holland, 1976; and Medina et. al., 1978), and the
uncovering of old antigenic sites by the removal of surface-bound Igs.
In contrast, the antigenic sites on mechanically prepared tumor cells
would have remained covered by TAIgs, which could have diminished the
immunogenicity of these cells. Such in vivo antigenic modulation has
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been observed (Jacobson et. al., 1978). Moreover, although pronase
and mechanically prepared tumor cells had an equal number of viable tumor
cells, mechanically prepared cells were contaminated by a large
number of dead cells, amongst which may have been dead host cells.
Therefore, the lower number of viable host cells in the mechanically
prepared cells may have hindered the influx of TAIg compared with
pronase prepared cells.
The results in general indicated that the in vivo binding of
TAIgs was dose dependent. This could imply a positive correlation
between antigenicity and the inducement of TAIgs. Moreover, since
larger doses of freshly excised tumor cells may contain a higher number
of host cells, the observed difference between the different doses
could be due to the host cell content of each dose of tumor cells.
This can be tested by comparing different doses of cultured CCHi tumor
cells.
4. IN VIVO KINETICS OF TAI^
Studies with ascitic tumors have shown that the in vivo binding
of TAIg increases with age of the tumors. Witz et. al. (1974) demonstrated
that the in vivo binding of TAIg by various ascitic tumors increased on
day 10 of tumor growth. Even though TAIg binding as measured by a
direct RIAT was shown to remain constant until day 9, it was argued
that TAIg binding was in fact increasing throughout this period. This
was because, for example, the number of cells used in order to measure
0
the TAIg on days 7 and 9 was 25 x 10 cells, while the total number of
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tumor cells in the mouse had in fact increased from 290 to 550 x 10
cells from day 7 to 9. In other words, if TAIg binding to the whole
tumor was indeed constant, then the amount of TAIg bound to 25 x 106
cells would have been expected to decrease from day 7 to day 9 due to
the 'dilution' of TAIg by the size increase of the tumors. Therefore,
there was a steady increase of TAIg binding with the age and size of
the tumors. It was postulated by the authors that the latter paralleled
the time-dependent increase in antibody synthesis following an immuno¬
genic stimulus.
Likewise, Braslawsky et. al. (1976b) showed that the in vivo
binding of TAIg by SEYF-a tumor cells increased during the first two
weeks of tumor growth. These TAIgs were found to consist of complement
dependent cytotoxic anti-tumor antibodies. Although the amount of TAIg
in the tumor remained high during the third week of tumor growth, the
anti-tumor antibodies were found to lose their cytotoxicity. The reason
for this was shown to be due to cell-surface bound immune-complexes, which
were present in close proximity to the anti-tumor antibodies.
Similar results were obtained on in vivo propagated SEV/A, Ta3/St
and YAC ascitic tumors (Dorval et. al., 1976). After an initial lag period,
the in vivo binding of TAIg was found to increase considerably during the
second week of tumor growth, reaching a plateau immediately prior to
death of the mice. Witz and Moav (1978) demonstrated that IgG eluates
from 11-15 day old SEYF-a tumor cells possessed the highest specific
cytotoxic activity. This cytotoxic activity was found to decrease after
the second week of tumor propagation, similar to a previous observation
(Braslawsky et. al. 1976b).
A purpose of this study was to assess the variation of in vivo
TAIg binding with the age and size of solid tumors. The studies were
carried out on tumors produced by freshly excised CCHL and T3 tumor
cells, and by cultured CCHl and T3 tumor cells. While a general pattern
of an increase in TAIg binding with age and size of CCHl tumors was
obtained, a similar pattern was not clearly observed with T3 tumors.
In 7 out of 8 experiments on CCH1 tumors, the in vivo TAIg binding was
found to increase during the third week of tumor growth. Whereas in
only 1 out of 4 experiments on T3 tumors the TAIg was shown to increase
during the third week of tumor growth. However, when the overall data
on TAIg was plotted against time, both CCHl and T3 tumors exhibited a
fluctuating pattern (see Figures 23 and 28). It was therefore postulated
that the latter may have represented a rythmic shedding of immune complexes
in vivo. This hypothesis was tested by the direct method, where the
variation of TAIg binding with time in CCHl and T3 tumors was studied every
three days, from day 15 to day 30. Apart from an initial decrease of in vivo
TAIg binding on day 18, both tumors showed a continuous increase of TAIg
with time (see Figure 55). Similar to the above studies on ascitic tumors,
the in vivo kinetics of TAIgs in solid tumors also appeared to parallel
a time dependent increase in antibody synthesis following an immunogenic
stimulus. The decrease of TAIg on day 18 could be due to the increase
of tumor size without a similar increase in antibody production. However,
this decline does not appear to last long, as antibody production and its
binding to the enlarging tumor seems to increase from day 21. Alternatively,
the decrease of TAIg on day 18 may represent shedding of immune-complexes
from the surface of the tumor cells. Although in this case the shedding
of immune-complexes would be expected to continue throughout tumor growth,
the loss of TAIgs would appear to be rapidly made up by day 21 by the
continuing synthesis of antibodies.
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The results also indicated a general tendency of the TAIgs
to increase with the size of tumors. Although this may have merely
reflected the above mentioned increase of antibody synthesis with
time, it may also have been due to increased angiogenesis in tumors
with size (Folkman, 1978). Increased angiogenesis would be expected
to increase the influx of anti-tumor antibodies and plasma cells into
the tumors.
In conclusion, these findings suggest that antibody synthesis
increases with time and that these antibodies bind to unoccupied antigens
on old tumor cells and to the antigens on new cells produced by the
rapidly propagating tumor» The specific and nonspecific binding of
immunoglobulins may be enhanced by the increasing size and angiogenesis
of the tumors. However, the in vivo kinetics of TAIgs remain complex
and as discussed in section 6(c) a lot remains to be done in order to
determine the nature of the TAIgs bound to tumors.
5. INFLUENCE OF C.PARVUFI ON THE INVITO BINDING OF TAIgs
C.garvum has been found to influence the humoral response in
tumor bearing mice. James et. al. (1976) showed that the ip or sc
administration of C.parvum led to increases in certain immunoglobulin
levels and to the development of antibodies reacting with syngeneic and
allogeneic tumor cells. The administration of gold salts was found to
inhibit the observed effect of C.parvum, indicating therefore the
importance of macrophages and PMN in the in vivo mechanisms of C.parvum
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induced immune response. In another study, antibodies produced by
C. parvum treatment were found to be extremely heterogeneous, some
of which also reacted with syngeneic embryonic fibroblasts, and adult
syngeneic kidney and spleen cells (James, et. al., 1977a).
Ip or iv administration of C. parvum was also found to induce
increases in IgM in homozygous nude mice (nu nu), and IgM, IgGl, IgG21
and 2b in heterozygous nude mice (nu +) (James et. al., 1977b). Moreover,
the ip administration of C,parvum was shown to increase anti-tumor
antibodies too, though significantly so only in nu + mice. These results
implied that the in vivo mechanisms of C.parvum induced immune response
were partly T-independent.
Enhancement of antibody production has also been observed in
tumor-bearing mice treated with other adjuvants like BCG. Complement-
dependent cytotoxic anti-tumor antibodies were among the antibodies
induced by BCG treatment (Boyle et:. al. 1976). Macrophages, as well as
T-cells, were also shown to be involved in the in vivo mechanisms of
bCG induced immune response. Non-adherent cells in the presence of
tuberculin antigen, were found to cause the aggregation of cultured
macrophage monolayers derived from BCG-sensitized mice (Preston et. al.,
1977). In another study, MER was found to affect primarily the non¬
adherent cell population (Kedar et. al., 1978).
In our studies too, the administration of C.parvum was found to
produce higher in vivo binding of TAIg both in CCHl and T3 tumors. InCCHl
tumors, the smaller C.parvum treated tumors were shown to possess
higher amounts of in vivo bound TAIgs than the larger nontreated tumors.
This was in contrast to the other findings which indicated that larger
tumors usually tended to contain higher amounts of TAIgs. One of the
reasons behind the latter could be due to the influx of different classes
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and subclasses of antibodies, the possible in vivo mechanisms of
which are expounded in section 6. Other reasons for the higher
binding of TAIg in C.parvum treated tumors include the increased
influx of macrophages, plasma cells, B cells and T cells into these
tumors (see addendum). As mentioned above, C.parvum treatment has
been suspected to enhance the activity of macrophages and T cells
(James et. al. 1976), and their infiltration into tumors. It can
therefore be speculated that the increased infiltration of macrophages
and T cells would precipitate the increased influx of plasma cells
and B cells, which in turn would raise the amount of TAIg bound by both
tumor cells and host cells. Our results also indicated that the observed
effect of C.parvum was dependent on the route and time of injection,
for C. parvum injection sc or into the tumor on days 3 and 8 respectively
was not found to inhibit tumor growth or enhance TAIg binding.
Different patterns in the variation of TAIg binding with time was
obtained in C.parvum treated CCH1 and T3 tumors. While in vivo TAIg
binding was found to increase with time in C.parvum treated CCHL tumors,
it was found to fluctuate in G.parvum treated T3 tumors. This result
suggests that the inhibition of tumor growth by C.parvum treatment could
be brought about by various means depending on the type of the tumor.
For example, while certain TAIgs may be important in the growth inhibition
of C.parvum treated CCH1, they may be less significant in C.parvum treated
T3 tumors. The possible in vivo mechanisms of the C.parvum effects in
CCH'l and T3 tumors is elaborated further in the following section.
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6. MECHANISMS OF IN VIVO TAIg BINDING
a. The effect of T-cell deprivation
B mice and nude mice were used in order to study the effect of
T-cell deprivation on the in vivo TAIg binding. Tumors were produced
by injecting 1 x 10 CCHl tumors cells into the right limbs of mice.
In the first experiment, tumors grown in CBA normal and B mice
were studied on days 17 and 26. Although tumor growth was found to be
slightly inhibited in B mice on day 17, no significant difference was
observed in the amounts of TAIg bound on days 17 and 26 (Table 4).
It should be mentioned, however, that sham thymectomized mice were not
used in this study. Furthermore, the normal mice had been injected with
CCHl tumor cells iv 11 days prior to the SC injection of tumor cells.
Similar results were obtained in the second experiment where
sham thymectomized mice were included. 15 day old tumors were excised
and their TAIg content assessed. As can be seen from Table 4, in vivo
TAIg binding was not found to be significantly effected by T-cell
deprivation.
Additional studies in nude mice confirmed the results obtained
in the above experiment. No significant difference in TAIg binding
between normal and nude mice was observed on days 17 and 21 of tumor
growth (Table 5 ).. The tumors did not grow in the nude mice littermates.
It would therefore seem from these results that the in vivo
binding of TAIgs may be T-independent.
b. The effect of gold salt treatment
Tumors grown in normal and gold-salt treated mice were compared
for their in vivo TAIg binding. Treated mice were injected with 1 mg
sodium auriothiomalate 3 times beginning on day 2 after the So injection
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of 1 x 10^ CCHl tumor cells. As observed in Table §, no difference
was noted between gold-salt treated mice and non-treated mice. Since
gold salts usually effect macrophages and PMN, this result would suggest
therefore that the in vivo binding of TAIgs is independent of these cells.
c. The effect of sublethal irradiation
Mice were X irradiated (400 rads) 24 hrs before the SC injection
6 4
of 1 x 10 CCH-1- tumor cells. On day 17 of tumor growth, no significant
difference in tumor size or TAIg binding was observed between normal
and irradiated mice (Table 7). in contrast, on day 21, tumors grown
in irradiated mice were found to have lower amounts of TAIg than tumors
grown in normal mice. This was observed in spite of the fact that tumors
in irradiated mice had increased in their size between days 17 and 21.
Therefore, the difference observed on day 21 approached significance,
especially when the increase of tumor size in irradiated mice was
considered. This may have indicated a quantitatively decreasedresponse
of antibodies in irradiated mice. Moreover, since the tumors in the
latter experiment were assessed on days 17 and 21, the results do not
rule out the possibility of significant TAIg differences in younger
tumors. Further studies are required in order to determine whether
the in vivo TAIg binding is radiation sensitive. Our results were at
variance with those obtained by Witz (1974) whose experiments suggested
that TAIg binding by ascitic tumor cells was radiation sensitive. This
discrepancy may have been due to the fact that the TAIgs in his experiments
were assessed in younger tumors aged 5, 7 and 9 days. It would be of
interest to find the relationship between sublethal irradiation, which
effects T-suppressor cells, and the in vivo binding of TAIgs in solid
tumors.
d. The effect of immunostimulation
This was studied by the ip administration of C.parvum (CP).
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As mentioned previously, CP treatment was found to inhibit tumor
growth and increase the quantitative binding of TAIg. Moreover,
parallel studies on immunoglobulin class and subclass binding in
tumor extracts showed CP treated tumors to possess significantly
higher levels of IgA, as well as more IgM and IgGl (Table £).
Similarly, two qualitative studies on surfaces-bound TAIgs in CP
treated and nontreated tumors showed the former to possess higher
levels of the immunoglobulin classes and subclasses tested (Table 9 ).
Moreover, these differences were significant for IgA, IgG2b, and IgG3.
It would seem, therefore, that CP administration enhances the
in vivo binding of most immunoglobulins to the tumor cells. Since a
similar observation has been made on the humoral immune response in CP
treated tumor-bearing mice, where a significant increase of IgG2b were
noted, then our results could indicate that the elevated binding of
TAIgs is a reflection of the elevated humoral response.
At present, the relationship of this increased humoral response
and elevated TAIg binding to tumor growth inhibition in CP treated mice
can only be speculative. Among the mechanisms that can be envisaged may
be the cytolysis of tumor cells by complement-binding immunoglobulins
such as IgG and IgM (this hypothesis is especially supported by recent
results indicating that IgGl can fix complement (Ey, 1979); the
destruction of tumor cells by activated macrophages, which can be
enhanced by opsonization; and enhanced T cell activity caused by antigen
processing in activated macrophages. CP administration could also
assist certain TAIgs to compete with immune-complexes for binding to
host cells and tumor cells (Braslawsky et. al. 1976c).
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e. The nature of TAIgs
There are indications that TAIgs consist of antitumor antibodies
and natural antibodies (Uitz 1977). These TAIgs would be expected to
bind to both tumor cells and host cells within the tumor. Antitumor
antibodies would bind to tumor cells through their Fab portion, while
natural antibodies, as well as the anti-tumor antibodies, could bind
to host cells through their Fc-portion. Moreover, TAIgs may represent
humoral antibodies or antibodies that are produced locally (Roberts
et. al. 1973). In either case, the nature of TAIgs and the extent of
their association with the different cells within the tumor remains
to be determined.
Many strains of mice have been found to possess circulating anti¬
viral antibodies (Ihle and Hanna, 1977). Therefore, it was conceivable
that TAIg detected in this study may consist of nonspecifically bound
anti-viral antibodies. However, the sera of CBA mice used in our
department have recently been shown to be devoid of such anti-viral
antibodies (James et. al. 1978). This may have been due to the fact that
the 10-12 week old mice routinely used in our studies were not yet
expressing endogenous viral antigens. Tumor cell or C.parvum injections
did not elicit antiviral responses. Moreover, there was no evidence of
virus or virus-like particles in our cultured tumor cell lines when
examined by electron-microscopy, nucleic acid incorporation studies, reverse
transcriptase assays, or fluorescent studies with antisera to RD 114,
MLV and anti-AKR P30 (James-et. al. 1978). Therefore, it is unlikely
that anti-viral antibodies constitute a part of the TAIgs detected in
this study.
The fact that the in vivo binding of TAIgs depended an the immuno-
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genicity of the 'tumor would tend to suggest that they consisted of
antitumor antibodies. On the other hand, TAIgs may have been immuno¬
globulins hound merely to infiltrating host cells, for host cell
infiltration has been also shown to depend on the immunogenicity of
tumors: Eccles et« al. (1976) showed that the more immunogenic HSBPA
tumors possessed significantly more monocytes than the less immunogenic
MC3 tumors. Both of the latter tumors had been chemically induced.
The issue may only be resolved when appropriate cell separation methods
are carried out. Moreover, it has recently been shown that some strains
of mice possess IgA and IgM autoanti-IgG antibodies (VanSnick and Masson,
1980). It can therefore be speculated that some of the TAIgs may be
auto-anti Ig antibodies. This may explain the predominance of IgA in
CCHl tumors and needs to be investigated.
Two main effects can be envisaged regarding the role of TAIgs
in vivo. These TAIgs can be tumor growth enhancers and/or tumor
growth inhibitors. They could enhance tumor growth through immune-
complexes which bind to immuno-competent host cells. Moreover, non-
complement fixing antibodies which bind to tumor cells could prevent
host cells from recognizing the tumor cell-surface antigens. On the
other hand, the TAIgs could inhibit tumor growth through complement
cytotoxicity and/or antibody-dependent cell cytotoxicity. Tumor cells
have been shown to possess complement components ontheir surfaces,
the activation of which may lead to chemotaxis of B cells, neutrophils,
monocytes, and macrophages; as well as to increased vascular permeability.
Moreover, TAIgs may facilitate macrophage binding to tumor cells.
Both of these contradictory effects of TAIgs could be operating
simultaneously and the eventual outcome of tumor growth may depend on
the nature of the TAIgs involved. Among the immunoglobulins whose levels
were increased by CP administration were IgM and IgGl, IgG2b, and IgG3,
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all cf which bind complement. Although this is only a minor step
towards correlating the role of TAIgs with its type, it gives credence
to the attempts that are being made to determine the nature of TAIgs.
In conclusion, for a better understanding of the quantitative
and qualitative assessments of TAIgs that were made in this study,
the association of TAIgs with infiltrating host cells in CP treated
and nontreated CCHl and T3 tumors should be determined, and the
specificity and nature of immunoglobulins eluted from the tumor
cells should be studied.
7. PROSPECTS OF TAIgs IN CANCER
As mentioned in the Introduction, TAIgs can be practically
applied in tumor immunogiagnosis and immunotherapy. Although a lot
remains to be done for the isolation and purification of anti-tumor
antibodies, their significance in immunodiagnosis can be in little
doubt. Anti-tumor antibodies, eluted from the surface of human tumor
13!L 125
cells, can be concentrated, labelled with I or I and reinjected
into the patient to screen for occult metastatic sites. Moreover,
anti-tumor antibodies thus eluted can be used for detecting soluble
antigens inthe sera of cancer patients and normal people alike. They
can also be used in Histology for determining tumor cells in a tissue
specimen with the immunofluorescence microscppe. However, Fc-receptors
on infiltrating host cells in the latter tissue should be blocked by
aggregated IgG prior to the addition of the anti-tumor antibodies.
Similar important applications of TAIgs can be envisaged for
tumor immunotherapy. Eluted anti-tumor antibodies can be conjugated
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to chemotherapeutic drugs in order to guide the latter to tuner cells.
This would help avoid the side effects which these drugs incur upon the
patient. Moreover, cytotoxic anti-tumor antibodies can be separated
from non-cytotoxic blocking antibodies and reinjected regularly to
post-operative patients in order to minimize metastatic spread.
It was found in this study that C.parvum (CP) administration
increases the in vivo binding of TAIgs. Therefore, cancer patients
can be injected with CP and serum samples, rich in anti-tumor antibodies,
later obtained from them. Cytotoxic anti-tumor antibodies isolated
from these sera and stored can then be used to inhibit metastatic
spread inthe patient after surgery.
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ADDENDUM
Recent results obtained from studies on TAIgs that are
continuing in our department are reported in this section. These
include an assessment of the host cell content of tumors, a study
of the nature of TAIgs, and determination of the characteristics
of eluted TAIgs.
Preliminary studies on the host cell content of CCHl tumors
have shown that infiltrating host cells comprise 27-34% of the cells
in tumors aged 14-23 days. Fc-receptor bearing cells were found to
be the most prominent host cells, including lymphocytes, macrophages
and PMN. A similar pattern of host cells in tumors obtained from CP
treated mice was observed. However, infiltrating host cells in the
latter were found to comprise 32-45% of the cells in tumors aged
18-35 days. Most of this increase in host cell content was found to
be due to increased infiltration by Fc-receptor bearing cells and
macrophages.
Infiltrating host cells in T3 tumors were found to comprise
20-37% of the cells in tumors aged 8-23 days. In contrast to CCHl
tumors, host cell content in T3 tumors was found to be evenly.
distributed betweeri Fc-receptor bearing cells, lymphocytes and PMN.
The macrophage content was consistently low. In general, CP treatment
was not found to appreciably enhance host cell infiltration in T3 tumors.
However, in one experiment on 18 day old tumors, CP treatment was found
to appreciably increase host cell infiltration. Most of this increase
in host cell content was observed to be due to increased infiltration
by Fc-receptor bearing cells, lymphocytes and PMN. An increased influx
of macrophages was also noted.
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An attempt to determine the nature of TAIgs was made by
pre-injecting the mice with SRBC. Since the CCBl tumors contained
a high proportion of Fc-receptor bearing cells, it was expected
that these cells may bind circulating anti-SRBC. Indeed, the
results of 2 experiments showed that anti-SRBC antibodies comprised
a part of TAIgs. For tumor cells obtained from mice which had been
preinjected with SRBC were found to form significantly more rosettes
with SRBC than tumor cells obtained from non-pretreated mice. Moreover,
a similar observation was made with spleen cells from tumor-bearer
or normal mice that had been pretreated with SRBC. These results
suggested that some of the TAIgs may represent nonspecifically bound
Igs to Fc-receptors on host and/or tumor cells. They may also represent
Igs present on infiltrating sensitized lymphocytes and/or plasma cells.
Present studies on TAIgs also include the elution of these Igs
and the determination of their characteristics. TAIgs are eluted by
treatment of the tumor cells v/ith acid citrate buffer or PBS. Preliminary
125
studies with I-labelled eluates have shown them to be heterogenous in
nature. Although specific antibodies may be amongst the eluates,
attempts to elute appreciable amounts of these specific antibodies
have been unsuccessful so far. However, it is interesting to note that
a major component in the eluate has been found to be a high molecular
weight glycoportein. This component (33K) has been found in eluates from
both freshly excised and cultured CCH-L tumor cells. PAGE/SDS gel studies
of extracts of tumors prelabelled by the lacto-peroxidase technique
suggested that the 33K component was not well exposed on the surface of
the intact tumor cells, for it was absent in such preparations.
Additional studies indicated that the 33K component was in the form of
a single polypeptide chain. Investigations are continuing on this compo¬
nent, especially in order to determine whether it represents an Fc-receptor.
PAGE - SDS GEL ANALYSIS OF ACID CITRATE ELUATE
FROM CULTURED CCHI TUMOUR
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